75 years of patient care
research
prevention
education
making cancer history
Mission
The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

Vision
We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science. We are Making Cancer History®.

Core values
Caring
By our words and actions, we create a caring environment for everyone.

Integrity
We work together to merit the trust of our colleagues and those we serve.

Discovery
We embrace creativity and seek new knowledge.
Wheeler Williams’ “Wave of Life” was the centerpiece of the fountain located in front of MD Anderson’s Houston Main Building (formerly the Prudential Building) until 2012. The sculpture can still be seen outside the Dan L. Duncan Building.

2 A message from MD Anderson Cancer Center: Opportunity and the evolution of cancer care
4 MD Anderson’s role in establishing the three pillars of modern cancer care
8 The history of Making Cancer History®
12 75 years of progress: A determined, patient effort
24 75 years of discovery: Pursuing the answer to cancer
36 The Shared Governance Committee
37 Administration
38 Faculty leadership
42 Our partners in Making Cancer History
67 Financial and statistical data
In its 75-year history, MD Anderson has experienced many changes on its way to becoming the premier cancer hospital in the nation.

From March 1, 1944, when The University of Texas’ M.D. Anderson Hospital for Cancer Research admitted its first patient, a 57-year-old man with lymphoma, to last year when The University of Texas MD Anderson Cancer Center served close to 135,000 patients, the institution has never slowed in its drive to advance cancer medicine through its patient care, research, prevention and education initiatives.

Much of that success is due to the bold, brilliant and dedicated faculty members and staff who have never stopped learning, evolving and bringing new approaches to the understanding and treatment of cancer. The MD Anderson team is committed to defeating cancer because it’s one of humanity’s most important pursuits.

Cancer also evolves. It changes to become resistant to medication. It’s also determined, evasive, extremely complex and, in its way, intelligent.

But our intelligence and ability to adapt to change is far greater. And in evolution and transition, there is opportunity.

As an institution, MD Anderson is evolving and changing with the current health care environment. This time of transformation has made us stronger, and in the past year we’ve continued to make significant progress toward our goal of ending cancer.

Through strong strategic alliances, MD Anderson has created the nation’s leading drug discovery infrastructure, which has led to new therapies and numerous clinical trials for patients failing the current standard of care. The program has yielded major contracts with biopharmaceutical companies, enabled transformative agreements, catalyzed significant funding channels and created new companies that will advance our knowledge and provide long-term sources of revenue to support our mission. You’ll read stories about such groundbreaking work in drug development in the pages of the annual report.

We continue an unprecedented effort to more rapidly convert scientific discoveries into lifesaving advances through our Moon Shots Program™. Launched in 2012 with six Moon Shots™, the program has expanded to 13 multidisciplinary teams of cancer experts collaborating and innovating to stop close to 20 types of the disease, which collectively account for 63% of cancer deaths annually. Of course, MD Anderson addresses all forms of cancer in its broad research portfolio and vast clinical enterprise.

Through the Moon Shots’ APOLLO (Adaptive Patient-Oriented Longitudinal Learning and Optimization) platform, high-quality biopsies and blood samples are being collected from patients before, during and after treatment. Deep genomic and immune profile analysis of these longitudinally collected samples provides a “moving picture” of cancer’s adaptability and enables our researchers to understand why some cancers respond to or resist certain treatments such as immunotherapy. APOLLO provides an opportunity to learn from every patient and have every patient benefit from research. It is true precision medicine.

Over the next two years, such penetrating analysis will be conducted in thousands of tumor biopsies in more than 2,000 patients enrolled in 28 clinical trials for a number of cancers. The development of “liquid biopsies” holds the potential to replace tumor biopsies with blood-based profiling, providing a less invasive way to detect certain tumor mutations or changes in the immune cells that can point toward the best therapy for a specific person. A multi-year partnership recently was announced to make comprehensive liquid biopsy technology the standard of care in cancer treatment.
His commitment to forward-looking cancer prevention is found in the DNA of other institutional tobacco-control policies such as the EndTobacco program and tobacco-free hiring policy. MD Anderson's expertise and leadership in prevention set an important example for the entire University of Texas System and helped pave the way for the system's Eliminate Tobacco Use initiative. Because of that initiative, all 14 UT System institutions will be tobacco-free by June 1.

In September, nearly 54 years to the day after President John F. Kennedy inspired the nation to lead the world in innovation and space exploration with his “We choose to go the moon” speech at Rice University, Vice President Joe Biden shared a deeply personal message about his family’s battle with cancer and their experience with the brilliant team of physicians and nurses at MD Anderson. He also emphasized ideas critical to both the Moon Shots Program and the national Cancer Moonshot initiative — increased collaboration, the importance of sharing data and the need for better access to clinical trials.

The vice president returned a few months later to join more than 2,000 guests, including dignitaries from around the world such as former President George H.W. Bush — a past Board of Visitors chair — at a stellar gala honoring MD Anderson’s 75th anniversary. During the celebration, the creation of the Beau Biden Chair for Brain Cancer Research was officially announced. It was part of an exciting week of events that raised close to $15 million to support our cancer-fighting efforts.

It’s philanthropic support such as this that makes our mission possible. Without your commitment, the institution wouldn’t be able to test the limits with high-impact, high-reward research projects. We couldn’t take aim at major breakthroughs in patient care and hope to dramatically reduce mortality and suffering sooner through the Moon Shots Program and its platforms.

Without you, we wouldn’t be the No. 1 cancer hospital in the nation and the most impactful cancer institution in the world as we look back over 75 years of Making Cancer History.
When the MD Anderson Cancer Center opened its doors to patients in 1944, the standard method for removing tumors was surgery.

Then came radiation treatment, its use accelerated by Drs. Gilbert Fletcher and Leonard Grimmett, pioneers in the field and MD Anderson faculty members, who designed the first affordable radiotherapy machine. Approved by the U.S. Atomic Commission in 1950, the cobalt-60 unit proved to be a more effective source of radiotherapy than existing machines and quickly became used around the world.

The methods and machines that deliver radiation therapy have steadily improved since — and MD Anderson led the way. From the use of the betatron in the mid-1950s, to high-voltage linear accelerators (also developed by Fletcher) and the development of interventional radiology in the 1970s, to fractionated radiotherapy and intraoperative radiotherapy in the 1980s, in addition to many other breakthroughs, such as the combination of radiation and surgery or chemotherapy, MD Anderson was on the leading edge of what is known as the second pillar of cancer treatment.

In the decades that followed, more effective, targeted and personalized approaches to treating cancer were developed and emerged as major pillars of modern cancer treatment. These include combination chemotherapy, in which multiple anticancer drugs are given simultaneously; targeted therapy, which uses drugs or other substances to more precisely identify and kill cancer cells without harming surrounding healthy tissue; and immunotherapy, an approach that enlists the body’s own immune system to fight cancer.

As with radiotherapy, MD Anderson has been at the forefront of creating, improving and implementing these new treatments.

Three of the institution’s trailblazers, in particular, are among the physicians and researchers throughout the world who have discovered new approaches that would forever change the way cancer care is delivered.
Chemotherapy

Emil J Freireich, M.D., clinical professor of Leukemia

When Emil J Freireich, M.D., arrived at the National Cancer Institute (NCI) in 1955 to head its leukemia program, the disease was a virtual death sentence. Newly diagnosed patients soon died, usually from massive hemorrhaging or infections. “Back then, the treatment for acute leukemia was very primitive,” says Freireich. “Chemotherapy drugs had recently become available, but patients died before the drugs had a chance to work.”

To buy time for patients while the drugs killed cancer cells, Freireich knew he needed to halt the non-stop bleeding that is the hallmark of leukemia.

He conducted studies that revealed patients’ bleeding was caused by an insufficient number of platelets — the tiny, colorless discs that circulate in blood and promote clotting. Further studies by Freireich showed that platelets needed to be obtained from freshly donated blood.

“Platelets in blood only last 48 hours,” he explains. “At the time, blood bank protocol specified that the oldest blood on the shelf be used first. So the platelets patients were getting didn’t work — they had already expired.”

These findings inspired Freireich to help invent a machine to separate blood into three components: plasma, red blood cells and white blood cells. Separating the blood into parts let patients get only the specific part of the blood they needed to combat infections, control hemorrhaging and help manage other complications of cancer and its treatment. Later models are used around the world today.

With bleeding as a cause of death essentially eliminated, Freireich, who was assigned to the pediatric leukemia ward, turned his attention to curing children.

Another difficult-to-treat disease, tuberculosis, recently had been cured by administering three drugs simultaneously. When given separately, they didn’t work.

Freireich believed this approach might work for leukemia as well. So he began combining chemotherapy drugs instead of giving them one at a time.

First he administered two of the highly toxic drugs, then three. With each addition, children became sicker from the drugs’ side effects. Some almost died. When he upped the ante to four drugs in a 1961 trial, an outcry arose from the medical establishment. Freireich’s toxic cocktail would kill the children, they said. Instead, 90% went into remission immediately.

Once children were in remission, Freireich continued their four-drug regimen for a full year to kill any residual cancer cells. That exact strategy, called early intensification, is still used today, and the cure rate for childhood leukemia is 92%.

“The disease recurs in some patients, but not many,” Freireich says. “Most are cured for the duration of their lifetime. Their survival rates are the same as for people who hadn’t had leukemia.”

He next applied this approach to Hodgkin’s disease, also rendering it curable in many cases.

Combination chemotherapy is now a standard treatment for a wide range of cancers, including breast, bone and testicular, and has been credited with saving millions of lives worldwide.

In 1965, Freireich and his NCI friend and collaborator Tom Frei, M.D., were recruited by MD Anderson to launch a chemotherapy program. Until then, the cancer center had treated patients with surgery and radiation. The two doctors formed the Department of Developmental Therapeutics and hired brilliant young scientists who developed drug combinations that cured various cancers based on the same methods used to treat childhood leukemia. Today, nearly all successful chemotherapy regimens use this approach of administering multiple drugs simultaneously.
Targeted Therapy

John Mendelsohn, M.D., professor of Genomic Medicine and director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy

While the 1970s and ’80s continued to see progress arising from innovations in surgery, radiation and chemotherapy, as well as bone marrow transplantation, the late 1990s ushered in the era of targeted therapies — drugs and other agents like antibodies that interfere with specific molecules found inside of and on the surface of cancer cells, effectively blocking the disease’s growth.

Unlike chemotherapy’s random blast, which kills both healthy and cancerous cells, targeted therapies, also called precision medicine, act like a sniper shot aimed precisely at the growth signal in malignant tumors. Targeted therapies usually are not cures, but they stop tumors from growing and spreading, which is significant because it’s a tumor’s ability to reproduce and metastasize throughout the body that makes it deadly. By stopping cancer growth, targeted therapies often work in combination with other treatments, such as surgery, chemotherapy or radiation, to effectively remove, shrink or destroy tumors.

The advent of targeted therapy saw the creation of precision drugs by scientists worldwide, including rituximab (Rituxan), which targets certain forms of lymphoma and leukemia; imatinib (Gleevec), for the treatment of certain leukemias, skin cancers, and stomach and digestive system cancers; and trastuzumab (Herceptin), which targets the product of a gene in breast cancers.

One of the very first targeted drugs, cetuximab (Erbitux) was born from research conducted by John Mendelsohn, M.D., and Gordon Sato, Ph.D., while they were faculty members at the University of California, San Diego. Mendelsohn would later become president of MD Anderson, which under his leadership in the early 2000s, became the leading clinical trial site for smart drugs that target cancers at the molecular level. Today, Erbitux is used for colon, pancreatic, head and neck, and lung cancers.

Simply put, here’s how it works: Many cancer cells have receptors called epidermal growth factor receptors (EGFR) on their surfaces. A protein produced naturally in the body called epidermal growth factor (EGF) attaches to these receptors. This triggers the cancer cell to grow and divide into more cancer cells. Erbitux works by attaching itself to the EGF receptors and turning them off by preventing them from binding to EGF.

Mendelsohn likens the process to “putting chewing gum in a car’s ignition to prevent the key from turning on the engine.”

For this discovery, he and Sato are widely acknowledged as the physician-scientists who shaped the landscape for today’s research into targeted therapies.

Mendelsohn says he had the privilege of benefiting from the influence of a number of physicians and mentors early in his career, including James D. Watson, Ph.D., who won the Nobel Prize in Medicine for identifying the structure of DNA. While working toward his bachelor’s degree at Harvard College, Mendelsohn became the first undergraduate student in Watson’s lab.

“The field of molecular biology was in its infancy, ready to explode,” he recalls. “I was introduced into rigorous experimental science and new technologies in a superb scientific environment.”

The past several decades have witnessed a quantum leap in understanding the genetic and molecular causes of cancer, Mendelsohn says, and the pace of drug discoveries is increasing as more abnormal molecular signals and pathways are discovered.

“It’s an exhilarating time to be part of the growing rise of precision medicine,” he says.

Mendelsohn stepped down in 2011 after 15 years of leadership as MD Anderson’s president. He remains on faculty as a professor of Genomic Medicine and director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. The institute focuses on targeting the abnormal genes and products of genes that cause cancer, tailoring specific treatments for individual patients.

“I remain committed to doing what I can to translate the many new scientific discoveries about cancer into better treatments that ease the burden of cancer on our patients today and in future generations.”

Targeted therapies usually are not cures, but they stop tumors from growing and spreading, which is significant, because it’s a tumor’s ability to reproduce and metastasize throughout the body that makes it deadly.
Immunotherapy

Jim Allison, Ph.D., chair of Immunology

For more than 100 years, scientists and physicians found tantalizing hints that our immune system is capable of detecting, destroying, remembering and permanently stifling cancer, as it does viral or bacterial infections.

In 1891, surgeon William Coley began treating patients with a mixture of bacteria and bacterial fragments called Coley’s Toxins. Coley cured a few patients, but the treatment failed for most and was completely unpredictable. By the early 1900s, it was superseded by radiation, a new therapy with more consistent results.

German scientist and 1908 Nobel Laureate Paul Ehrlich, M.D., proposed that the immune system routinely suppresses tumor formation, a hotly contested hypothesis for decades.

A trickle of immune-related cancer therapies emerged. These included the tuberculosis vaccine Bacillus Calmette-Guérin for non-invasive bladder cancer; an immune signaling molecule, interleukin-2, a harsh drug that helps a small percentage of melanoma patients; and a host of therapeutic vaccines designed to stimulate an immune attack on cancer, which largely failed.

Basic science breaks through

A combination of curiosity-driven basic science research and an intimate familiarity with the personal tragedy of cancer helped Jim Allison, Ph.D., chair of Immunology, lay the foundation for immunotherapy to emerge as the next pillar of cancer treatment.

“I’ve always wanted to know how things work,” Allison says. “I became fascinated with the immune system as an undergraduate, and eventually settled on studying T cells — these remarkable cells that travel all over our bodies detecting and destroying infections and abnormal cells, usually without harming normal cells.”

As a young scientist, he immersed himself and his lab in understanding the basic biology of T cells, first at MD Anderson’s Science Park-Research Division in Smithville, Texas, and later at the University of California, Berkeley.

Allison helped identify a brake on the immune system, an off-switch on T cells that for decades eluded investigators trying to develop immune treatments.

German scientist and 1908 Nobel Laureate Paul Ehrlich, M.D., proposed that the immune system routinely suppresses tumor formation, a hotly contested hypothesis for decades.

Treating T cells, not cancer

Allison’s key insight was to block the brake with an antibody, freeing T cells to attack cancer.

“I didn’t set out in my research to treat cancer, but it was in the back of my mind,” Allison says. “My mother died of lymphoma when I was 11, and she suffered greatly from the effects of chemotherapy and radiation. An uncle died of prostate cancer, and another of lung cancer.”

His drug treated the immune system, not the cancer, with powerful results in mice.

Given the past failures of immune-based therapies, it took Allison years to persuade a small biotech company to develop the treatment for people. Ipilimumab, a drug developed from his research, became the first ever to extend the survival of patients with late-stage melanoma.

His efforts cleared the way, both scientifically and commercially, for a new class of drugs.

Today, immune checkpoint blockade drugs are approved for late-stage lung, kidney, bladder, head and neck cancers, melanoma and Hodgkin lymphoma; with 15 to 30% of patients responding. Allison’s drug, known commercially as Yervoy, has been in the clinic the longest, and research shows that approximately 22% of late-stage patients live for 10 years or longer — previously unprecedented results.

Hundreds of clinical trials are expanding the reach of these drugs to other cancers and to earlier stages of disease. The answer to higher response rates and longer survival in more cancers, Allison says, is more science.

As executive director of the immunotherapy platform of MD Anderson’s Moon Shots Program™, Allison and colleagues seek to identify new checkpoints to block, and new immune-stimulating molecules to activate and protect.

Examination of tumors before, during and after treatment has provided a scientific basis for drug combinations that might make immunotherapy work for prostate, colorectal and other common cancers.

And scientists have developed and are testing new therapies that expand a patient’s own T cells in the lab or genetically modify them to attack specific targets before infusing them back into patients.

“Cancer immunotherapy is still in its early stages, but as science progresses and clinical research grows, we’ll be able to talk about curing or greatly extending the lives of more cancer patients,” Allison says.
The history of making cancer history

At MD Anderson, everything revolves around patients, which is why it’s been ranked the nation’s top cancer hospital for nine of the past 10 years. The institution has changed the world by turning research discoveries into life-saving care. Through its Moon Shots Program®, these breakthroughs are being converted into clinical advances more quickly than ever. Here are some of the highlights of what’s been accomplished over the past 75 years.

1941

The Texas Legislature votes to establish a state cancer hospital devoted to research and treatment. It’s placed under the jurisdiction of The University of Texas and its Board of Regents.

1944

M. D. Anderson Hospital for Cancer Research is dedicated on February 17. On March 1, the hospital, with fewer than 25 full-time employees, takes in its first patient in a makeshift clinic at the Baker Estate. Admission is limited to indigent Texas residents without treatment facilities in their home communities, though staff seek to make the hospital available to all Texans as quickly as possible.

1946

Physician R. Lee Clark, M.D., is appointed director and surgeon-in-chief. Clark immediately begins planning for permanent facilities.

1949

English physicist Leonard Grimmett, M.D. (bottom row, middle) arrives to work with French-born physician Gilbert Fletcher, M.D. Within months, they design a 1,000-Curie cobalt-60 unit that will revolutionize radiation therapy.

1950

The U.S. Atomic Energy Commission approves Fletcher (second from left) and Grimmett’s original concept for the cobalt-60 unit. The machines deliver more effective, less expensive radiation therapy and will eventually be used in nearly all of the world’s hospitals.

1954

Forty-six patients from the Baker Estate are moved to the new hospital in the Texas Medical Center. The 320,000 square-foot facility has 310 beds and is hailed as the most modern hospital in the nation.
1958
Emil J Freireich, M.D., designs the continuous-flow blood cell separator, which greatly improves the process of removing white blood cells from donor blood. The technique will later be adapted for both immunotherapy and bone marrow transplantation. Soon after, Freireich, a legendary figure in oncology, joins MD Anderson.

1960
A landmark study shows the effectiveness of mammography in detecting early breast cancers, paving the way for routine use of screening mammograms for women throughout the world.

1964
Wataru Sutow, M.D., greatly improves survival rates for children with Wilms’ tumor by introducing the first successful chemotherapy to treat the inoperable kidney cancer.

1966
Microscopes such as this one were used in the study of tumor virology, a field that has led to breakthrough discoveries and a better understanding of cancer over the years. These discoveries have resulted in improved treatments and ways to prevent many forms of the disease.

1967
The effects of hyperbaric oxygen therapy are tested on mice in the Department of Experimental Radiotherapy.

1968
The National Cancer Institute (NCI) selects MD Anderson to become the headquarters for a new program designed to make sure radiation dosimetry is uniform at all institutions participating in NCI-cooperative clinical trials. The Radiological Physics Center establishes MD Anderson as a primary radiation physics resource for hospitals throughout the U.S.

1971
President Richard Nixon declares war on cancer by signing the National Cancer Act, which appropriates millions of dollars to cancer research. The majority of funds are designated for NCI-recognized “comprehensive cancer centers,” of which MD Anderson is one of the first three.
1973
Isaiah Fidler, D.V.M., Ph.D., finds that cancerous tumors are composed of many distinct cell types. Fidler proposes and confirms that metastasis is a non-random event unique to specific cell types within a tumor environment, a breakthrough that will transform the study of tumors, drug development and targeted cancer treatments. He will bring his research to MD Anderson and continue on as one of the foremost experts on cancer metastasis.

1976
MD Anderson demonstrates in clinical studies that “lumpectomy” followed by radiation therapy for breast cancer can be as effective as radical surgical mastectomy. The new procedure becomes a worldwide standard and replaces the highly invasive and widely practiced radical mastectomy.

1978
MD Anderson physicians collaborate with the IBM Corporation to develop and introduce a simplified blood-cell separator for practical use in small hospitals. The machine revolutionizes the availability and use of blood component therapy throughout the U.S.

1981
With a $2.8 million grant from the National Cancer Institute, installation of the country’s first medical cyclotron begins.

1985
Gabriel Lopez-Berestein, M.D., develops an antifungal, liposomal-encapsulated agent for the treatment of potentially life-threatening systemic fungal infections, common among patients with reduced immunity due to chemotherapy. Lopez-Berestein’s development is an incredible advancement, as regular antibiotics have proven too toxic for cancer patients to withstand.

1986
A team directed by Waun Ki Hong, M.D., proves the effectiveness of chemoprevention by showing that synthetic vitamin A can significantly reduce the incidence of second primary tumors in head and neck cancer patients.

1988
MD Anderson becomes the first hospital in the country to open an operating room that includes a linear accelerator to treat tumors with electron beam radiotherapy during surgery.
The National Institutes of Health gives MD Anderson approval to conduct gene therapy trials for patients with lung cancer. MD Anderson doctors use gene therapy for ovarian and breast cancer patients, and within six years, the techniques will be applied to multiple types of cancer.

1995
The Texas Legislature approves Senate Bill 192, allowing patients to refer themselves to MD Anderson. In addition to self-referral, the measure helps the institution become more competitive in the area of managed care.

1992
The National Institutes of Health gives MD Anderson approval to conduct gene therapy trials for patients with lung cancer. MD Anderson doctors use gene therapy for ovarian and breast cancer patients, and within six years, the techniques will be applied to multiple types of cancer.

1994
Scientists at MD Anderson invent the concept of varying the intensity of radiation beams, leading to the revolutionary development of intensity-modulated radiation therapy, in which radiation doses are tightly conformed in three dimensions to the shape of the tumor.

2005
MD Anderson pioneers the first pencil beam scanning capability in the nation’s most advanced proton therapy facility. The precise treatment builds upon proton therapy, which uses protons to deliver radiation directly to a tumor, leaving surrounding healthy tissue unharmed.

2006
A team of MD Anderson researchers demonstrates the effectiveness of two new drugs, dasatinib and nilotinib, in Gleevec-resistant chronic myelocytic leukemia, leading to FDA approval.

2009
An experimental drug developed at MD Anderson is able to starve human neuroblastoma cells by shutting down their energy source. The drug, 3-BrOP, is found to reduce tumor growth by more than 75% as a single agent. Pre-clinically, this drug has proven effective against other cancers, including glioblastoma, colon cancer, lymphoma and acute leukemia.

2013
Juan Fueyo, M.D., and Candelaria Gomez-Manzano, M.D., create an experimental therapy that genetically modifies the adenovirus that causes the common cold, transforming it into a cancer-seeking missile that attacks brain tumors.

2012
Jim Allison, Ph.D., a pioneer in the innovative field of immunotherapy, joins MD Anderson to lead critical immunology research and work with the Moon Shots Program™. Allison’s groundbreaking discoveries have led the way for oncologists to unleash the immune system to attack cancer.

2000
The institution’s first international partnership, MD Anderson Madrid, opens, giving patients access to many MD Anderson clinical trials closer to home, and allowing specialists at each center to exchange expertise in clinical care and basic science research.
During a routine checkup, Kylie Delaney's pediatrician noticed an unusual mass in her middle ear that turned out to be an extremely rare bone tumor called an osteoblastoma. Her parents brought the 8-year-old to MD Anderson, whose cancer experts are renowned for treating rare and uncommon forms of the disease. Surgeons Paul Gidley, M.D., and Franco DeMonte, M.D., successfully removed the entire tumor. Read Kylie's story on Page 21.

photo by Wyatt McSpadden
For 75 years, one determined patient effort to end cancer

Seven-five years. Think about it. That’s 900 months. 27,375 days. 657,000 hours. That’s a lot of time committed to treating, researching, studying and learning about one thing: cancer.

Since 1941, MD Anderson has attracted many of the brightest minds in medicine to Houston, where they’ve changed the world and the way cancer is treated through innovation, creativity and breakthroughs. They’ve developed and put into practice leading-edge technologies. Their commitment has resulted in improved outcomes and a steady rise in survival rates for cancer patients around the world.

That tradition of discovery continues in 2017, and will carry the institution through the years to come as the advances of today lay the foundation for the cancer care of tomorrow.

And care is the operative word, because in addition to discovery and integrity, it’s one of the three keystones of what has been — and will be — built at MD Anderson.
Rosa Hwang, M.D., associate professor of Breast Surgical Oncology
photo by Wyatt McSpadden
Treatment puts the freeze on breast cancer

By Ronda Wendler

When Jo Ann West learned she had early-stage breast cancer, her doctor suggested an inventive new treatment that involves no major surgery, no chemotherapy and no radiation.

The simple outpatient procedure, called cryoablation, “deep-freezes” tumors, killing cancer cells on the spot. Recovery is measured in minutes instead of months.

“It sounded like science fiction to me, but I thought, ‘why not try it?’” says West, 79. “It sure beat the alternatives.”

The retired elementary school teacher said yes, and was placed in a clinical trial designed to determine cryoablation’s effectiveness.

The study took place at 19 cancer centers across the country, including MD Anderson.

“Cryoablation has been used for years to successfully treat benign breast tumors called fibroadenomas, as well as other cancers such as prostate and kidney,” says Rosa Hwang, M.D., associate professor of Breast Surgical Oncology and principal investigator of MD Anderson’s trial site. “It worked for other cancers, so we thought, ‘let’s try it on breast cancer.’”

How it works

To perform the procedure, doctors use ultrasound imaging to guide a thin, needle-like device through the skin and into the breast tumor, where it blasts liquid nitrogen to freeze and destroy the cancerous tissue.

“Everyone in the treatment room, including the patient, watches the action in real time on the ultrasound screen,” Hwang says. “An ice ball forms around the tumor and freezes it from the inside out. It’s visually impressive.”

The regimen includes a 6- to 8-minute freeze at temperatures 40 degrees below zero or colder, followed by a 10-minute thaw, then another 6- to 8-minute freeze. Doctors then remove the probe, place a Band-Aid over the tiny incision, and the patient goes home.

The entire procedure takes less than half an hour. There’s no hospitalization, no sedation, no scarring and no pain.

“I’ve prescribed pain pills but no one fills their prescriptions,” Hwang says. “They simply don’t need to.”

Recovery is instantaneous, she says. Some women have even walked out of the hospital and gone shopping or to a restaurant.

After cryoablation, patients are seen for follow-ups, including mammograms, every six months for the first five years, then annually after that. Some may be followed more frequently, depending on their individual health.

Promising results

In the multicenter trial, cryoablation was performed on women with early-stage breast cancer whose tumors were 2 centimeters or smaller.

“Before and after” MRI images were taken so doctors could examine each patient’s tumor to confirm it had been fully frozen.

Several weeks after cryoablation, the women’s now-dead tumors were surgically removed and examined so doctors could confirm that all cancer cells were killed.

The results: At all 19 cancer centers, cryoablation killed 92% of cancers — meaning no remaining cancer was found — and 100% of tumors smaller than 1 centimeter. In the MD Anderson trial, 100% of all tumors were killed.

“This is a huge advance for women,” Hwang says. “I think it could be the wave of the future.”

Boosting an immune response

Besides the advantages of no pain, no downtime and no scarring, there’s another potential perk with this technique: It appears to stimulate an anti-cancer immune response, Hwang says.

“We think that cryoablation causes tumor cells to burst and release their cancer genetic material into the body,” Hwang explains. “The patient’s immune system ramps up to attack this flood of cancer.”

Immune cells, researchers believe, will attack the primary cancer, as well as cancer cells that have spread to other areas in the body. And because the immune system “remembers” the cancer cells, it will annihilate any cancer that attempts to recur.

Researchers have confirmed this revved-up immune response in mice, and they’re preparing to test it on people.

“Only time and further research will uncover the full benefits of cryoablation for breast cancer,” Hwang says. “But right now the potential looks promising.”
Study draws attention to what could be a costly trend in treatment

By Laura Sussman

When Caroline Wetherall of Kentucky was diagnosed with early-stage breast cancer at age 43, her doctors recommended a complete mastectomy.

Stunned by her diagnosis and her doctors’ aggressive recommendation, Wetherall returned to her hometown of Houston seeking a second opinion.

There, she met radiation oncologist Benjamin Smith, M.D., and was immediately relieved to learn her treatment could be limited to lumpectomy — surgery in which only the tumor and some surrounding tissue is removed — and three weeks of radiation.

“Personally, I couldn’t imagine having both of my breasts unnecessarily removed at such a young age if I didn’t have to,” Wetherall says.

Women with early-stage breast cancer have a number of treatment options, including lumpectomy plus whole breast radiation, lumpectomy plus brachytherapy, in which tiny radioactive seeds are implanted to destroy cancer cells, mastectomy alone, mastectomy plus reconstruction, and, in older women, lumpectomy alone.

These therapies offer equal survival profiles, explains Smith, an associate professor of Radiation Oncology, but differ greatly in terms of what patients endure.

“We haven’t had a nuanced understanding of the pros and cons of these different treatment approaches,” says Smith. “That is, until now.

In a study published in the Journal of the National Cancer Institute, Smith and colleagues found that mastectomy followed by reconstruction had the highest rate of complications and complication-related costs for women with early-stage disease, regardless of their age.

“There’s been little data to understand the differences in complications, and even less data to understand the difference in cost between those options,” says Smith. “Quantifying this information is helpful both for patients making treatment decisions and for payers.”

The rate of mastectomy plus reconstruction has continued to rise across the country over the past decade as reconstruction has become more widely accessible. This study is the first to quantify the harm associated with this trend, Smith points out.

In conducting the study, researchers analyzed data from more than 100,000 early-stage breast cancer patients who were split into two age groups – younger than 65 and 66 and older. Data was collected from Medicare and other insurance claim databases.

In both age groups, the risk of complications in patients undergoing mastectomy and reconstruction was almost twice that of patients undergoing lumpectomy and radiation. The most common problems were infections, fluid buildup, breast pain, blood clots, implant removal or graft failure.

Mastectomy and reconstruction was the most expensive therapy. The total cost within two years of diagnosis in the younger population was about $88,000, which was $22,000 more expensive than lumpectomy followed by radiation. In the older population, lumpectomy with brachytherapy was most expensive, at approximately $38,000. Mastectomy and reconstruction was around $36,000, while lumpectomy with radiation was $34,000.

Smith says he found the results shocking, especially the fact that, on average, insurance companies pay roughly $10,000 in the two years following diagnosis to deal with complications experienced by patients who chose mastectomy and reconstruction.

“For the first time, we show that while the patient is undergoing more surgery, she is also taking on a considerable amount of risk with regard to what could happen,” Smith says. “If the patient can have a lumpectomy and radiation, it may be a smoother course than going through a mastectomy, reconstruction and, potentially, other surgeries.”

He stresses decisions shouldn’t be based solely on cost, but instead on what’s personally best for each patient.

“Many women with early-stage breast cancer differ in their family histories, genetic profiles and experiences and situations,” he says.

Wetherall says she’s relieved to have been offered lumpectomy with radiation.

“The ‘less-is-more’ option was the right decision for me.”
Partnerships expand MD Anderson’s reach from coast to coast

MD Anderson’s four newest partnerships are providing adult cancer patients in California, Texas and New Jersey with access to the most advanced oncology care in the country.

In November, MD Anderson and The University of Texas Health Science Center at San Antonio announced an affiliation that will provide care for patients in 38 South Texas counties. Through this agreement, the Cancer Therapy & Research Center of the UT Health Science Center will be known as UT Health San Antonio MD Anderson Cancer Center when it opens this year. At the new center, patients will have access to MD Anderson’s treatment protocols, standards of care, extensive clinical trials and translational research.

“Beyond all these obvious advantages is that we will be able to offer our region the very best care close to home,” says UT Health Science Center President William Henrich, M.D.

Leveraging the UT System’s strengths

In another move toward collaboration across the UT System, MD Anderson and The University of Texas Health Science Center at Tyler announced a partnership in December that will provide care for patients in northeast Texas and the surrounding region. Through this agreement, UT Health Northeast’s Cancer Treatment and Prevention Center will be known as UT Health Northeast MD Anderson Cancer Center when it officially launches in late 2017.

The new cancer center will be fully integrated with MD Anderson in Houston, which means Tyler patients will have access to the same high level of cancer care and clinical trials as those in Houston.

UT Health Northeast MD Anderson will practice multidisciplinary care based on MD Anderson’s model, and physicians in Tyler will collaborate with MD Anderson faculty members on clinical discussions and tumor boards to make recommendations for individual patients.

“This partnership will help reduce cancer rates in our region, where citizens are among the unhealthiest in the state due to lack of access to care,” says Kirk Calhoun, M.D., president of UT Health Northeast.

The agreements between MD Anderson, UT Health San Antonio and UT Health Northeast support the vision of UT System Chancellor William McRaven to create a “quantum leap” by building collaborative teams of UT System institutions based on the respective strengths and expertise of the institutions within the UT System.

Growing in the Garden State

In April, MD Anderson and Summit Medical Group, the largest and oldest physician-owned multispecialty practice in New Jersey, announced they would join together to form the Summit Medical Group MD Anderson Cancer Center, bringing world-class cancer services to patients in northern New Jersey and the surrounding area. MD Anderson first brought its top-ranked cancer care to the state in 2013, when it partnered with Cooper University Health Care to create MD Anderson Cancer Center at Cooper in Camden, New Jersey. Summit Medical Group is an extension of MD Anderson at Cooper. MD Anderson’s partnership with Summit is the first time the cancer center has partnered with a physician-owned-and-governed multispecialty group.

Better care for Southern California

In August, MD Anderson and San Diego-based Scripps Health agreed to an affiliation that creates Scripps MD Anderson Cancer Center. The center provides care to patients in eight Southern California counties, from Santa Barbara to the U.S.-Mexico border.

“This new alliance gives Southern Californians easy access to MD Anderson’s proven, research-based approach to cancer care,” says Scripps Health President and CEO Chris Van Gorder. “Our partnership builds on Scripps’ history of providing exceptional cancer care to our region and allows us to offer the best cancer treatment available anywhere.”

Physicians and administrators from MD Anderson and Scripps together oversee patient care and research at Scripps MD Anderson, where patients have access to comprehensive cancer care, including medical, radiation and surgical oncology; pathology; laboratory and diagnostic imaging; and other clinical and support services.

These most recent partnerships make Scripps MD Anderson, UT Health San Antonio MD Anderson and UT Health Northeast MD Anderson part of MD Anderson Cancer Network, a global collaborative network of hospitals and health care systems dedicated to MD Anderson’s mission to end cancer.
Tonya Edwards helps patients deal with pain caused by their disease and treatment. photo by Wyatt McSpadden
One nurse’s prescription for curbing pain pill addiction
By Ronda Wendler

Ask Tonya Edwards how frequently she encounters cancer patients addicted to prescription painkillers, and she offers a weary reply. “Every day,” she sighs.

Edwards is a nurse in MD Anderson’s Supportive Care Center, where health care providers help patients deal with pain caused not only by their disease, but also their treatment.

“Not everyone with cancer will have pain, but more than half will,” Edwards says. “Our mission is to lessen their suffering.”

Prescription opioids, with brand names such as Vicodin, Oxycontin, Percocet and Fentanyl, have long proven superior to other drugs for easing cancer-related discomfort.

“These drugs interact with receptors in the brain to produce a powerful, pain-numbing effect,” says Eduardo Bruera, M.D., chair of Palliative Care and Rehabilitation Medicine. “They also make some patients feel happy, relaxed, even euphoric.”

Such soothing and pleasurable effects can lead to addiction. Most people won’t run into trouble when taking opioids prescribed for pain, but some will.

“One in five people have a larger than average number of opioid receptors in the brain,” Bruera explains. “These are the individuals who are predisposed to getting hooked.”

Opioid epidemic
The lure of addiction is the driving force behind an opioid epidemic that began slowly in the late 1990s and today has burgeoned into a public health crisis. Overdoses of prescription painkillers and the illegal opioid heroin are killing more than 27,000 people a year.

“No one is immune,” Bruera says. “Emergency rooms across the country are treating young and old, professional and blue-collar, urban and rural, all races and backgrounds. The problem is seen everywhere, Bruera says, including MD Anderson.

“Opioids are essential to controlling cancer pain,” he says, “but those who fail to take the drugs strictly as prescribed may find themselves dealing with cancer and addiction.”

First responder
As a nurse, Edwards is on the front lines of the addiction crisis. She’s first to see patients who show up unannounced, demanding, cajoling or asking politely for more medication.

Some claim their pills have been lost or stolen, while others say they’ve run out of pills early, with no explanation. Then there are the “doctor shoppers” who seek opioids from multiple MD Anderson doctors in the hospital’s various departments. A few go so far as to visit emergency rooms at other hospitals.

“They use excuses — whiplash, back pain, toothache — anything they can think of, to get the drugs,” Edwards says.

A quick check of MD Anderson’s computerized patient records and Texas’ statewide drug dispensing registry reveals who’s been making the rounds in search of prescriptions.

Over time, Edwards has learned to sense when she’s being “gamed,” but she doesn’t judge. Her first concern always is for each patient’s safety.

“This is a chronic disease that patients didn’t choose,” she says. “No one wakes up one morning and says, ‘I want to get addicted to my opioid pills because it’ll be fun.’ This could happen to me, and it could happen to you.”

Extra attention
Realizing the magnitude of the problem, Edwards devised a plan to help patients at risk, with assistance from Bruera and Supportive Care Center colleagues.

Put simply, it works like this:

Every patient who’s newly admitted to the Palliative Care Center completes two written tests that reveal whether they’re susceptible to addiction and how much supervision they may need.

Those whose test scores raise a red flag for potential abuse are closely monitored by clinic staff. If their behavior suggests they’re already abusing drugs — for example, they ask for new prescriptions, claim their pills were lost, or request stronger opioids — they undergo a urine drug screen.

When drug misuse is detected, MD Anderson’s Opioid Safety Initiative squad pays the patient a visit. Team members include Edwards, as well as a doctor, patient advocate, pharmacist and psychologist. Only a handful of hospitals across the country have such a resource.

Compassionate care
“This isn’t about playing detective, spying on patients, or reprimanding them,” says Suresh Reddy, M.D., professor of Palliative Care and Rehabilitation Medicine. “The team’s sole purpose is to provide compassionate care to those who need our help and to see them safely through their cancer journey.”

Together, patients, their families and team members agree upon a plan of action that includes rules, boundaries and interventions.

Almost always, the plan calls for more frequent clinic visits — perhaps twice a week instead of twice a month — to ensure opioids are being taken as prescribed. Patients meet regularly with an addiction counselor. Those on stronger pain pills are transitioned to weaker ones and offered other forms of pain management.

Claims of lost or stolen medication must be backed up by a police report before a new prescription can be written.

And to prepare for a “worst-case” scenario, patients’ family members are provided with Narcan, a prescription nasal spray that blocks the effects of opioids and reverses an overdose.

All these measures can help, Edwards says, but patient cooperation is key.

“Our message to patients is, ‘We’ll control your pain. It’s up to you to control your behavior.’”

The program launched a year ago and is working, says Edwards, who for her efforts won this year’s Brown Foundation Award for Excellence in Oncology Nursing. The award is MD Anderson’s highest nursing honor.

“Most patients do much better when they understand that certain behaviors are required,” she says. “A little extra attention makes a big difference.”
Leukemia was no match for her donor sister and a ‘reduced-intensity’ stem cell transplant

By Ron Gilmore

When Cinda Matthews began working as a speech therapist in the 1960s at the Houston Speech and Hearing Center on the campus of the Texas Medical Center, there were more trees than buildings.

Little did Matthews know that years later, her life would depend on MD Anderson Cancer Center, only blocks from where she worked. That life-altering revelation came in 2003, when Matthews was diagnosed with chronic myelomonocytic leukemia (CMML), a blood cancer that at the time had an average survival rate of two to five years.

“I was totally surprised and upset with the initial diagnosis,” Matthews says. “I’d always been healthy. I was told that chemotherapy might put my disease in remission, but it wouldn’t last. My only hope for long-term remission was a stem cell transplant.”

Although Matthews wasn’t considered young enough for a full stem cell transplant, and she happily donated stem cells to help her sibling battle cancer.

The transplant kept Matthews in remission for 18 months, but her cancer came back. Her sister donated a second time in 2006, and Matthews’ remission has lasted ever since.

“After each transplant, I was hospitalized for four weeks, then I had home care,” she says. “Since my second transplant, I see my doctor monthly and after each visit I receive five booster shots of azacitidine, an anticancer chemotherapy drug. It’s obviously been and will continue to be a long process, but the entire treatment has not been painful and I continue to live my life fully.”

After her second transplant, Matthews decided to join the ranks of the volunteers who spent time with her during treatment. “I enjoyed visiting with the volunteers and appreciated their work during both of my long-term stays,” she says. “I’m so grateful for my treatment at MD Anderson and wanted to give to others something of what had been given to me.”

As a volunteer, Matthews is especially touched by young mothers and fathers who undergo treatment and have to leave young children at home, often far away.

“They tell me they just want to survive to see their children grow up,” she says. “Seeing my grandchildren develop and grow was very important to me, so I can only imagine what a parent must feel.”

Today, Matthews, 74, enjoys time with her six grandchildren, husband, three daughters and friends.

“I learned from this experience that many things happen in life beyond our control,” she says, “and that caring, smart doctors and nurses, as well as loving family and friends, can make all the difference. The disease as well as the treatment process has caused me to appreciate my many blessings. It’s deepened and strengthened my faith and my relationships.”
Routine pediatric exam uncovers extremely rare tumor
By India Ogazi

Like many parents, San Antonio residents Richard and Heather Delaney almost skipped their daughter Kylie’s annual checkup. The 8-year-old seemed healthy and wasn’t due for immunizations. But Heather decided to keep the appointment anyway.

“Looking back, I’m so glad I did,” she says.

During Kylie’s checkup, the pediatrician noticed an unusual mass in the girl’s middle ear and referred her to a nearby hospital for further testing.

The result? Kylie was diagnosed with a rare, noncancerous bone tumor called an osteoblastoma. These tumors usually develop in the bones of the spine, legs, hands and feet. But Kylie’s tumor was located in her temporal bone, which encloses the ear.

“Only 35 cases of this tumor type have ever been documented, and Kylie is one of the youngest patients ever,” says Paul Gidley, M.D., a neurotologist and skull base tumor surgeon at MD Anderson.

The Delaneys, doctors themselves, selected Gidley to perform their daughter’s surgery.

“After speaking with the skull base tumor experts at MD Anderson, we knew this was the place for Kylie,” Heather says. “And, when we came to stay in the MD Anderson Rotary House Hotel, everyone was so nice — it just felt right.”

“Plus, it was so close to San Antonio, which made it very convenient for us,” adds Richard.

Before surgery, the couple met with Gidley and neurosurgeon Franco DeMonte, M.D., co-director of the Skull Base Tumor Program. The doctors would work together to remove the portion of the tumor near Kylie’s brain.

“They were thorough, knowledgeable and answered all of our questions,” Richard says. “As a physician, I really appreciated that.”

Before surgery, Heather shaved Kylie’s favorite stuffed animal — a kitten — to match Kylie’s pre-surgical haircut. Gidley and DeMonte successfully removed Kylie’s entire tumor, and the only remnant of her disease is mild hearing loss.

“I’m so grateful we took Kylie for her checkup,” says her mom. “If we had waited one more year, the tumor could have grown into her brain.”

Gidley also points to the important role Kylie’s annual exam played in the discovery of her tumor.

“The fact that her pediatrician completed a thorough checkup and recognized the abnormality makes her the hero in this story,” Gidley says.
Cancer Prevention: How a division came together

By Clayton Boldt, Ph.D.

The commitment to ending cancer through prevention isn’t new for MD Anderson, but it has evolved over time.

The institution’s Division of Cancer Prevention and Population Sciences began as a fledgling program with just 35 faculty and staff members in 1979. Today it’s one of the largest and most respected prevention programs in the nation.

Over the past four decades, the division’s success and growth required strong institutional dedication and just the right catalyst to get things started.

That initial push came from Charles LeMaistre, M.D., the second president of MD Anderson.

“Dr. LeMaistre possessed a longtime interest in cancer prevention,” says Bernard Levin, M.D., the first vice president and head of the division. “He really believed this was an important new direction for the institution. It would never have happened without him.”

LeMaistre bolstered the existing cancer prevention program by raising it to new prominence and formally creating the Division of Cancer Prevention. He envisioned recruiting a multidisciplinary group with an initial focus on tobacco, says Levin.

However, LeMaistre’s efforts were not met without controversy. Levin, who’s now retired and living in New York, recalls opposition from senior scientists and clinicians who either did not understand the vision or thought resources were better used elsewhere.

Nevertheless, with LeMaistre’s support, Levin was able to turn the dream into reality. He recruited leading faculty in the field of prevention, which helped MD Anderson build a strong reputation in the cancer prevention community.

“These were really first-rate people,” Levin says. “The prominence of these individuals at a national level helped establish this as an effort of high quality. It was pulling its own weight in every sense.”

For 13 years, Levin oversaw expansion of research and clinical services, new departments and even a new division name. When he retired, he transferred the reigns to current vice president and division head, Ernest Hawk, M.D., who he describes as “the clear choice.”

Hawk focused first on clarifying the division’s four mission-oriented domains — research; clinical care; education, training and mentoring; and cancer control — all with a focus on translating research into services that benefit individuals, future generations, and the community at large. This required better communication across departments and establishing a clear vision for progress in each of these domains, he says.

“The vision was much aligned with the institution’s vision to be a change agent in cancer prevention,” says Hawk. “It was all about making science relevant to the clinic and the patients we serve as well as to the broader public.”

Hawk’s vision was aided by “transformative” philanthropic gifts, which established the Duncan Family Institute for Cancer Prevention and Risk Assessment and the Lyda Hill Cancer Prevention Clinic.

Now with more than 500 faculty and staff, the division continues to provide high-quality care to patients and to help implement and disseminate evidence-based actions in public policy, public and professional education, and community-based services.

When it was created in 1979, the Division of Cancer Prevention, which is now known as the Division of Cancer Prevention and Population Sciences, was focused on three main areas: Preventive Epidemiology, to identify markers of risk; Health Maintenance, to detect and remove cancers early; and Health Education, to disseminate information on the causes of cancer and lifestyle changes to health professionals and the public. Much has changed in the past 40 years. Here’s a look at some of the highlights:

1978
The Texas Legislature appropriates $160,810 for “prevention” at MD Anderson.

1979
The Division of Cancer Prevention is created on Sept. 1, 1979, with a staff of 35 (including faculty). It was formalized as an integral part of the institution’s mission in 1980.

The Department of Cancer Prevention and Control — the division’s only department — oversees four main programs: Clinical Epidemiology, Nutrition, Community Oncology and Behavioral Research.

All prevention activities are placed under the direction of the VP for Academic Affairs.

The division expands to two departments, Cancer Prevention and Control and Patient Studies. Its programs include Clinical Epidemiology, Nutrition Research and Application, Behavioral Research, Prevention Clinic, Professional Education, Outreach Activities and the Cancer Prevention and Detection Program.

1986
Bernard Levin, M.D., is named ad interim vice president of Cancer Prevention.

1988
The Department of Behavioral Science is created.
Responding to a growing need to better understand and demonstrate the value of all aspects of cancer care, Hawk led the creation of the Department of Health Services Research. The department’s goal is to study health care delivery and its outcomes, so that safety, timeliness, effectiveness, efficiency and equity of care will be better measured and promoted. Researchers use a patient-centered approach that addresses each person’s cultural, socioeconomic and medical needs. Research focuses on healthy individuals, those currently battling cancer, and those who have completed cancer treatment.

The cancer prevention and control platform, part of MD Anderson’s Moon Shots Program, is committed to extending prevention efforts beyond MD Anderson’s walls, particularly for the uninsured and underserved.

“Serving those in greatest need is something I think everyone in our division is very passionate about, but it’s hard to reach all the places where it’s needed,” says Hawk. “So I think we’ve been creative in trying to study and serve those communities in a variety of ways.”

With a foundation in stellar research, Hawk looks forward to continued success for the division. As new discoveries clarify the connections between lifestyle factors and cancer risk, MD Anderson will continue to translate those discoveries into actionable interventions.

“It’s the greatest place in the world for these types of initiatives,” Hawk says.
“We have every opportunity in the world to find here in Houston the answer to the question of the cause and cure of cancer.”

— Dudley Woodward, chairman of The University of Texas System Board of Regents from 1944-55

Since day one, MD Anderson researchers have worked tirelessly to find an answer to cancer. In that time, they’ve made great progress in understanding the disease — how it adapts, survives and spreads. Three-quarters of a century later, the institution’s labs and research institutes continue to turn out discoveries and breakthroughs that lead to better and more effective treatments for cancer patients.

In many of today’s labs, experts from different fields who have a shared research vision are brought together in the same space to encourage collaboration, communication and creativity, which are vital to the rapid and dramatic reductions in death and suffering that are at the heart of the Moon Shots Program™.

MD Anderson doctors and researchers are building on the success of immune checkpoint blockade drugs, which are now approved for many late-stage cancers. They also are learning why these drugs don’t work for all patients. And through the Moon Shots™ platforms, new and innovative drugs and therapies are being developed to fight the disease.

And the research continues to pay off. Just as the amount of money invested in cancer research at MD Anderson has grown each year — from just over $15,000 in 1944, to more than $787.3 million in 2016 — the five-year survival rates for cancer patients have continued to rise.
Impressive results against BRCA-positive breast cancer show drug’s game-changing potential

By Scott Merville

After every breast cancer patient responded positively to a new targeted therapy in a first-of-its-kind clinical trial, MD Anderson researchers have quickly taken the next step toward potentially establishing a new standard of care.

After just two months of treatment with a drug called a PARP inhibitor, tumors in all 13 newly diagnosed breast cancer patients shrank significantly.

Tumors shrank anywhere from 30% to 98% with a median reduction of 88% in the 13 patients studied.

PARPs — short for Poly (ADP-ribose) polymerase — are proteins that can help different types of cells, including cancer cells, repair and survive damaged DNA. Inhibiting PARPs can keep cancer cells from surviving DNA damage and spreading.

“Acknowledging that this is a small study, I can’t think of any drug-based therapy that gives results this consistently strong in only two months,” says Jennifer Litton, M.D., associate professor of Breast Medical Oncology and leader of the study.

Litton originally expected the study would sign up 20 patients in two years. Instead, 13 enrolled in eight months, and the results were striking enough that the study was stopped in early 2016.

An extension of the study to enroll 20 more patients began in August, and is filling quickly.

The idea is to first give the PARP inhibitor talazoparib to newly diagnosed patients who also have BRCA mutations. BRCA-related cancers, including ovarian cancer, are thought to be vulnerable to PARP inhibitors. Currently, a chemotherapy combination followed by surgery is the frontline therapy.

In the initial trial, patients agreed to delay chemotherapy and first take talazoparib for two months, then proceed to chemotherapy and surgery. In the extension trial, patients are treated only with talazoparib before surgery.

None of the 13 patients had to withdraw from the first trial due to side effects, which were limited mainly to fatigue and low blood counts. Eight of the 13 had triple-negative disease — a difficult-to-treat breast cancer that doesn’t have the cancer-promoting HER2 protein or two hormones (estrogen and progesterone) that fuel breast cancer growth and can be targeted by anticancer drugs.

"After we saw the extensive clinical response, confirmed by ultrasound, and with a favorable toxicity profile, we really wanted to move forward into an extension to evaluate this drug as a single treatment," Litton says. "If the extension study produces similarly strong results, the next step would be to directly compare talazoparib to chemotherapy in the presurgical, curative setting."

Chemotherapy may even be delayed or replaced if the extension trial is similarly effective and shows less toxicity than the initial trial, she adds.

PARP inhibitors are approved by the Food and Drug Administration for advanced ovarian cancer, but are not yet approved for breast cancer.

The Moon Shots Program is paving the way to faster results

In addition to the trials above, Litton is principal investigator of an international clinical trial of talazoparib for patients with advanced or metastatic breast cancer who have been previously treated.

To more quickly offer talazoparib to newly diagnosed patients who have not undergone surgery, Litton proposed an investigator-initiated pilot study backed by MD Anderson’s Moon Shots Program™. The pharmaceutical company that owns the drug agreed to the study.

Litton noted that institutional support through the Moon Shots Program helped convince the company to provide the drug for her trials. Moon Shot™ backing decreased the time needed to launch the first trial by about two years, she estimates.

Extensive, unique biomarker research

The pilot and extension studies also tap Moon Shots Program resources for extensive biomarker evaluation, providing a unique opportunity for researchers and the drug company to better understand how the drug works and identify patients who will respond in advance.

Biopsies taken before and after PARP inhibition are evaluated for DNA and RNA changes, and proteomics (proteins) by Gordon Mills, M.D., Ph.D., chair and professor of Systems Biology.

Helen Piwnica-Worms, Ph.D., vice provost for science and professor of Experimental Radiation Oncology, and colleagues harvest tissue samples from patients’ tumors that can be transplanted into mice to further study how tumors respond to treatment.

"We will be able to learn a great deal," Litton says. "These models that are being built will be available for multiple investigators in the future to study and test other drugs and drug combinations."
BRCA1 and BRCA2 are tumor-suppressing genes and are found to have mutations in 5 to 10% of all breast cancer patients. BRCA-related cancers, including ovarian cancer, are thought to be vulnerable to PARP inhibitors.
For decades, combination chemotherapy has been the main treatment for patients with acute myeloid leukemia (AML) – an aggressive cancer of the blood and bone marrow.

“About 40 percent of younger patients survive long term, and for those over 65, survival drops to 10 percent,” says Marina Konopleva, M.D., Ph.D., professor of Leukemia. “There’s been no drug approved for the last 40 years for AML, and outcomes haven’t significantly improved with targeted therapies.”

Researchers at MD Anderson’s Institute for Applied Cancer Science (IACS) are hoping to put an end to that drought with a drug they developed to starve these malignant blood cells to death.

The initial Phase I clinical trial of the drug known as IACS-10759 opened for patients in October, a milestone for IACS, which acts as a biotech company embedded in a cancer center. The institute connects MD Anderson faculty with drug discovery and development expertise.

“We’re hopeful we’ll soon see in patients the promising response to IACS-10759 that we observed in preclinical models,” says Giulio Draetta, M.D., Ph.D., head of Therapeutics Development and director of IACS.

While researchers have found AML to be vulnerable, they’ve also discovered that subgroups of tumors in lymphoma, glioblastoma, melanoma, colorectal and pancreatic cancers harbor this weakness.

**Leukemia and Lymphoma Society funds innovative trial**

Konopleva and Naval Daver, M.D., assistant professor of Leukemia, lead the AML trial, which is funded by a $3.5 million investment from the Leukemia and Lymphoma Society under its Therapy Acceleration Program, part of an intensive campaign the society launched against AML in late 2016.

IACS aims to provide MD Anderson physicians and patients access to novel drugs tailored specifically to vulnerabilities found in tumors of unique groups of patients. These projects are based on findings coming from basic scientists at MD Anderson.

“The IACS model emphasizes the need for us to deeply understand the biological effects of drugs,” Draetta says. “We want to increase the precision with which we identify and develop new molecules, and to ask critical questions about the effects of any new drug within the most relevant contexts.”

**Putting cancer on a lethal diet**

Based on an approach discovered by the institute, IACS-10759 is designed to target a metabolic vulnerability of AML cells.

Most cells rely on two metabolic processes to survive. Cellular organelles called mitochondria use oxygen to convert energy stored in sugars, fatty acids and proteins into energy through a process called oxidative phosphorylation (OXPHOS). Cells also convert glucose to energy in the absence of oxygen through a less efficient process called glycolysis. IACS-10759 inhibits OXPHOS, thus one of two arms of metabolism that provide energy and building blocks to cancer cells.
Konopleva says her team’s research has shown that AML cells are highly dependent on these mitochondria-driven processes. “OXPHOS is how they survive, but no one has had a clinically viable inhibitor,” she says.

Enter IACS, where scientists, applying their drug development expertise and capacity for rapidly testing and understanding the mechanism of possible drugs in preclinical models, developed IACS-10759.

“Normal cells can get around OXPHOS inhibition by turning up glycolysis, but we’ve identified some cancers like AML that can’t do that enough to survive,” says Joseph Marszalek, Ph.D., head of Translational Biology for the Center for Co-Clinical Trials.

“We’re already working closely with several MD Anderson Cancer Moon Shots Program™ teams to develop IACS-10759 treatment for patients whose tumors rely on oxidative phosphorylation,” says IACS Executive Director Philip Jones, Ph.D.

Create, test, refine, test again

It’s taken a team of more than 25 people to successfully bring IACS-10759 into clinical trials. Emilia Di Francesco, Ph.D., associate director of Medicinal Chemistry at IACS, leads a group that crafts small-molecule drugs to efficiently hit targets in cancer cells while avoiding off-target effects.

Marszalek’s group puts those drugs to the test in cell lines and mouse models. What they discover about the drug’s efficacy and side effects is fed back to Di Francesco’s group, which fine-tunes the drug.

This intensive, reiterative process allowed them to analyze a series of molecules over 18 months before zeroing in on IACS-10759 for development.

“We needed to refine the drug for the clinic and build in all the properties to make it more effective in patients,” Di Francesco says.

Marszalek and Di Francesco say the collaborative nature of MD Anderson clinicians is invaluable. They connected with Konopleva, whose knowledge of AML and preclinical models was vital to developing IACS-10759 and has enabled the development of clinical assays to study the biology of OXPHOS inhibition in the ongoing clinical trial. Additionally, the institute has a pipeline of other experimental drugs working their way toward first-in-human use, with others expected to enter clinical trials in the next year.

“There’s no shortage of good ideas at a place like MD Anderson,” Jones says. “Identifying therapies that will be impactful for specific patient populations and moving those medicines into clinical trials at MD Anderson is our mission.”

AML FACTS

Acute myeloid leukemia occurs when the myeloid stem cells that usually become healthy versions of some types of white blood cells, platelets or red blood cells instead become immature versions of those cells.

The Leukemia and Lymphoma Society estimates there were 19,960 new cases of AML diagnosed in 2016, mostly in adults, and the disease caused some 10,430 deaths.

Konopleva says her team’s research has shown that AML cells are highly dependent on these mitochondria-driven processes. “OXPHOS is how they survive, but no one has had a clinically viable inhibitor,” she says.

Enter IACS, where scientists, applying their drug development expertise and capacity for rapidly testing and understanding the mechanism of possible drugs in preclinical models, developed IACS-10759.

“Normal cells can get around OXPHOS inhibition by turning up glycolysis, but we’ve identified some cancers like AML that can’t do that enough to survive,” says Joseph Marszalek, Ph.D., head of Translational Biology for the Center for Co-Clinical Trials.

“We’re already working closely with several MD Anderson Cancer Moon Shots Program™ teams to develop IACS-10759 treatment for patients whose tumors rely on oxidative phosphorylation,” says IACS Executive Director Philip Jones, Ph.D.

Create, test, refine, test again

It’s taken a team of more than 25 people to successfully bring IACS-10759 into clinical trials. Emilia Di Francesco, Ph.D., associate director of Medicinal Chemistry at IACS, leads a group that crafts small-molecule drugs to efficiently hit targets in cancer cells while avoiding off-target effects.

Marszalek’s group puts those drugs to the test in cell lines and mouse models. What they discover about the drug’s efficacy and side effects is fed back to Di Francesco’s group, which fine-tunes the drug.

This intensive, reiterative process allowed them to analyze a series of molecules over 18 months before zeroing in on IACS-10759 for development.

“We needed to refine the drug for the clinic and build in all the properties to make it more effective in patients,” Di Francesco says.

Marszalek and Di Francesco say the collaborative nature of MD Anderson clinicians is invaluable. They connected with Konopleva, whose knowledge of AML and preclinical models was vital to developing IACS-10759 and has enabled the development of clinical assays to study the biology of OXPHOS inhibition in the ongoing clinical trial. Additionally, the institute has a pipeline of other experimental drugs working their way toward first-in-human use, with others expected to enter clinical trials in the next year.

“There’s no shortage of good ideas at a place like MD Anderson,” Jones says. “Identifying therapies that will be impactful for specific patient populations and moving those medicines into clinical trials at MD Anderson is our mission.”

A clinical trial takes on a deadly blood cancer with an experimental drug

IACS-10759 was developed by the Institute for Applied Cancer Science, which was established in 2011 to develop new treatment options for cancer patients. IACS is a platform of the Moon Shots Program™ — the ambitious effort launched in 2012 to reduce cancer deaths by more rapidly developing and implementing advances in prevention, early detection and treatment based on scientific discoveries.

The trial will enroll up to 48 patients with relapsed or resistant AML.

Primary goals: Determine the safety and tolerability of the drug, establish a maximum tolerated dose and a recommended dose for a Phase II trial.

Secondary goals: Learn more about the drug’s pharmacokinetics and early indications of clinical impact, including overall response rates, duration of response, progression-free survival and overall survival.

The expansion phase allows for enrollment of 12 patients to receive the recommended Phase II dose.

Leukemia and Lymphoma Society funding also provides for analysis and development of biomarkers for the drug.
Breakthrough research leads to new hope for patients resistant to immunotherapy

By Leslie Loddeke

Stories of immunotherapy’s success against metastatic melanoma in patients such as former President Jimmy Carter are well publicized, but the treatment doesn’t work for everyone.

In fact, checkpoint blockade drugs such as pembrolizumab and nivolumab, which inhibit protein molecules on T cells that keep the immune system from attacking tumors, only work for about one-third of patients.

Why do some tumors respond to immunotherapy and others don’t? That’s a question MD Anderson’s Wei Yi Peng, M.D., Ph.D., and her team of investigators are getting closer to answering.

Peng, an assistant professor of Melanoma Medical Oncology, led a study that showed a link between the loss of a tumor-suppressor gene called PTEN and resistance to checkpoint inhibitor immunotherapy.

Patients with inactive PTEN had fewer T cells in their tumors, indicating that a lack of PTEN suppresses the immune response against melanoma. Patients with inactive PTEN also had worse outcomes when treated with checkpoint inhibitors compared to melanoma patients with intact PTEN.

These findings indicate PTEN loss may be an important biomarker to predict melanoma patients’ resistance to immunotherapy. The study also showed that treatment with an experimental drug that blocks a molecular pathway called PI3K improved the effectiveness of anti-PD-1 treatment in laboratory models of melanomas with loss of the PTEN gene.

“These results allowed us to devise a means of combating resistance to immunotherapy due to PTEN loss in melanoma patients,” Peng says.

Findings of the study, which was Cancer Discovery’s February 2016 cover story, have led to a Phase I and II clinical trial that will test a combination of immunotherapy and targeted therapy in patients with metastatic melanoma who lack the PTEN gene.

Hussein Tawbi, M.D., Ph.D., associate professor of Melanoma Medical Oncology, is leading the Phase I and II clinical trial of pembrolizumab, an FDA-approved anti-PD-1 antibody, and GSK2636771, a PI3K-beta inhibitor, in patients with metastatic melanoma who lack the PTEN gene.

The study represents the first clinical trial to test the effects of the PI3K-beta inhibitor in melanoma patients — and the first to test its effects in combination with immunotherapy in any cancer type.

“About one-third of melanoma patients respond to pembrolizumab, which means there are two-thirds of patients in whom we need to do better,” Tawbi says. “This trial is a very significant step in that direction.”

This research and trial capitalize on the skills of targeted therapy experts such as Michael Davies, M.D., Ph.D., deputy chair of Melanoma Medical Oncology and co-leader of the Melanoma Moon Shot®, and immune therapy experts like Peng and Patrick Hwu, M.D., chair of Melanoma Medical Oncology and head of Cancer Medicine. Davies and Hwu were co-senior authors on the article.

“This exciting clinical trial builds upon the collaborative research we have undertaken at MD Anderson to understand the interactions between oncogenic signaling pathways in cancer cells and the regulation of the anti-tumor immune response, based on our extensive expertise and resources in these two areas,” Davies says. “In addition to representing an important new clinical trial for patients with advanced melanoma, the results and translational research from this trial may have impact for the many other cancer types in which loss of PTEN occurs.”

How checkpoint blockade drugs work

PD-1 is a checkpoint protein on T cells — white blood cells that find and kill invaders — that acts as an “off switch” when it binds with the protein PD-L1 on healthy cells, protecting them from attack. However, PD-L1 can also be found on cancer cells, allowing them to prevent an immune response by joining with a T cell’s PD-1. Anti-PD-1 immunotherapies target the checkpoint and prevent it from binding with PD-L1 on a cancer cell, effectively turning “on” an immune attack against cancer.
Weiyi Peng, M.D., Ph.D., assistant professor of Melanoma Medical Oncology

photo by Wyatt McSpadden
Meet the visionary leader of Pediatrics who’s on a ‘research and destroy’ mission

By Katrina Burton

After his own diagnosis at age 13, Richard Gorlick, M.D., set out on a lifelong journey to end cancer in children.

Along the way, he has focused his clinical and research studies on sarcomas — tumors that grow in connective tissues including the bones, muscles, tendons and cartilage. These are the same tumors that interrupted his teenage years.

Now, the physician-scientist's journey has brought him to MD Anderson Cancer Center, where, as division head and chair of Pediatrics, he'll use his pediatric oncology expertise and experience as an educator, clinician, scientist and cancer survivor to help children, adolescents and young adults treated at MD Anderson Children's Cancer Hospital.

"Research, clinical care and education are all important priorities," says Gorlick. "Providing multi-disciplinary care, minimizing the burden to patients and families, and developing a global model for treating young cancer patients are all important to me."

Gorlick's MD Anderson laboratory focuses on targeted therapies, new drugs for childhood cancers, and understanding the mechanisms behind the development and progression of osteosarcoma, the most common form of childhood bone cancer.

Gorlick, whose research resulted in the establishment of the world’s largest osteosarcoma tissue bank, leads the Bone Tumor Disease Committee for the Children's Oncology Group, a collaborative clinical trials system and the largest organization focused exclusively on pediatric cancer research. He is drawing on that spirit of teamwork to forge collaborations with MD Anderson colleagues who've seen success using adult therapies such as immunotherapy and genetic profiling, which can ensure the right drugs get to the right patients.

"Therapies developed for adults don't become effective therapies for children as quickly as they should," says Gorlick. "Children aren't simply small adults, they are unique, and we must acknowledge and study their uniqueness. That includes pursuing funding to support childhood cancer research, which is often lacking.”
Better data — and more of it — translates to better care

“Cancers are exceptionally adaptive in the face of treatment pressure,” says Andrew Futreal, Ph.D., chair of Genomic Medicine and co-leader of MD Anderson’s Moon Shots Program™.

“We know a tumor after therapy is likely to be different than before, but we haven’t done a good job of tackling this from a research perspective until now.”

To understand how tumors evolve and resist treatment, Futreal is helping lead APOLLO, which stands for Adaptive Patient-Oriented Longitudinal Learning and Optimization. It’s a systematic approach that relies on taking blood samples and biopsies before, during and after treatment, and conducting deep molecular and immune analysis of those tumor samples to understand what causes them to respond to or resist a given treatment.

In the next two years, APOLLO is scheduled to conduct such analyses in 2,100 patients enrolled in 28 high-priority clinical trials for melanoma, multiple myeloma, glioblastoma, lymphoma, sarcoma, lung, breast, colorectal, pancreas and ovarian cancers, and cancers caused by the human papillomavirus.

Results of these analyses, plus clinical information, will be added to the Translational Research Accelerator (TRA), which is a big data platform that integrates longitudinal clinical and research data — the same sample tracked at different points in time — to support translational research throughout the institution. These enormous amounts of data are housed in data centers like the one pictured here.

Information from approximately 250,000 patients treated at MD Anderson since 2012, along with research data from Moon Shots™ platforms, has been loaded into the secure database. The TRA will provide researchers with an unprecedented capacity to more quickly and efficiently generate science-based inquiries in the pursuit of better cancer treatment.

“APOLLO, with its pipeline of comprehensive data feeding the Translational Research Accelerator, drives our vision of every patient contributing to, and potentially benefiting from, research,” says Futreal.

— Scott Merville

Enormous amounts of data that can benefit researchers in their pursuit of cancer breakthroughs are housed in MD Anderson data centers such as this one. photo by Nick de la Torre
MD Anderson’s ORBIT program may have an otherworldly name, but the Oncology Research for Biologics and Immunotherapy Translation unit was established and continues to thrive through purely Earth-bound partnerships that pair novel therapeutic targets discovered at MD Anderson with state-of-the-art pharmaceutical technologies for biologic drug development.

Since its inception in 2014, ORBIT’s primary mission has been to develop innovative monoclonal antibodies — “magic bullets” that first recognize specific target molecules on the surface of cancer cells, then zero in to kill the cells. ORBIT is one of the three drug development platforms that support MD Anderson’s Moon Shots Program™ and grew out of a $330 million alliance with GlaxoSmithKline to develop in the clinic an OX40 agonist antibody generated at MD Anderson. The OX40 mAb, now named GSK3174998, entered the clinic in late 2015 and is now in the advanced stage of a Phase I trial. ORBIT works closely with MD Anderson’s Strategic Industry Ventures (SIV) office to develop partnerships — primarily with biotech and pharmaceutical companies — in an effort to quickly develop new antibody-based cancer therapies that can be brought to clinical trials at an accelerated pace.

Today, ORBIT is comprised of a core group of 16 people led by Executive Director Carlo Toniatti, M.D., Ph.D., and Scientific Directors Jeffrey Molldrem, M.D., professor of Stem Cell Transplantation and Cellular Therapy, and Michael Curran, Ph.D., assistant professor of Immunology. The team works closely with colleagues in a number of MD Anderson’s clinical departments to fight melanoma, prostate, ovarian and hematologic cancers, among others.

Although ORBIT is focused on advancing novel therapeutics for several forms of cancer, the development of a novel antibody-based therapy for hematologic cancers has shown great promise and will enter Phase I trials early this year.

“Hematologic cancer is certainly a current area of interest for ORBIT in terms of novel mAb discovery,” says Toniatti. “However, we are agnostic about tumor type as far as we have good targets. The reason why we can be agnostic is that MD Anderson has experts in almost every type of cancer.”

One potential new therapy for leukemia is h8F4, a mAbs invented by Molldrem, which targets a specific peptide expressed on the surface of acute lymphoblastic leukemia. ORBIT accelerated its development by funding the start of the manufacturing process for the antibody, creating a detailed, three-year plan to bring the drug to clinic, and contacting potential pharmaceutical company partners.

As a result, in April 2015, MD Anderson signed an agreement with the international drug company Astellas Pharma Inc., to develop h8F4, which will enter the clinic in mid 2017.

“Current treatments for aggressive leukemias are often toxic,” says Molldrem. “We are developing a safer, more potent therapy for cancers with poor survival outcomes. We hope this important collaboration will allow us to deliver much-needed antibody-based treatment to patients’ bedsides more quickly.”

Collaboration with biotech and pharmaceutical companies is crucial given the high cost of drug development. In addition to h8F4, ORBIT has four immune checkpoint programs and one T cell receptor antibody antibody in various stages of development.
Graduate School emphasizes ‘core’ value for research students

By Gillian Kruse

The transition from undergraduate studies to graduate research can be daunting. But for first-year students at The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences (GSBS), the school’s Core Course is cushioning that bumpy ride.

“The Core Course helped me adjust to the life of a researcher in a big way,” says Kimiya Memarzadeh, a third-year graduate student in Neuroscience. “It really helped me become more analytical and not take things at face value.”

The GSBS premiered the course for incoming first-year students in the fall of 2014 to give them a foundation of science and research skills they’d need to succeed in their individual programs.

Previously, each of the 13 GSBS programs had its own curriculum and graduation requirements, with no course standardization and very little communication between programs. Dean Michelle Barton, Ph.D., knew a core course for every first-year student would help new students become acclimated to the many aspects of the academic biomedical research world.

“We develop the leaders of the future here,” she says. “In any field they enter — research, science policy, law, pharmaceuticals or biotechnology — it will be ingrained in them to use their leadership skills and work collaboratively.”

Starting from scratch

Based on input from all 13 GSBS programs, the course, titled Foundations of Biomedical Research, launched in January 2014 with 41 students enrolled. A different faculty member led each of the 15 weeks, with guest lecturers from various departments giving overviews of their areas. Wednesday mornings were reserved for biostatistics, since that had been identified as a weak area for young researchers.

There were no exams; instead students were evaluated on take-home exercises and group projects. By the time the course ended, students had interacted with more than 70 faculty members from different specialties.

“Because this was so different from anything we’d done before, we had to really come at this with an open mind,” Barton says.

The course evolved as students and instructors adjusted to the new format. Students gave feedback in weekly surveys on what worked and what didn’t, and their suggestions were included in the following week’s sessions.

The nontraditional structure also meant students were able to pick up some of the soft skills necessary for becoming successful scientists.

“I had to give a presentation to about 30 people in another course, which I normally would have found nerve-racking,” Memarzadeh says. “But because we’d received practice and tips on presentation skills each week in the core course, I was confident I’d deliver a solid presentation.”

Students also formed friendships that may someday further their careers.

“People often say that it’s not what you know, but who you know,” Memarzadeh notes. “I’ve formed relationships with fellow students and faculty members I wouldn’t have encountered otherwise. These people are my future mentors, collaborators and potential employers.”

This story originally appeared in Messenger, MD Anderson’s magazine for employees, volunteers, retirees and their families.
ADMINISTRATION

OFFICE OF THE PRESIDENT
Marshall E. Hicks, M.D.
President ad interim
Stephen Hahn, M.D.
Deputy President and Chief Operating Officer
Tadd Pullin
Senior Vice President, Institutional Advancement
Crista Latham
Vice President, Strategic Communications
Mark Moreno
Vice President, Governmental Relations
Patrick Mulvey
Vice President, Development

OFFICE OF THE PROVOST AND EXECUTIVE VICE PRESIDENT
Ethan Dmitrovsky, M.D.
Provost and Executive Vice President
Robert C. Bast Jr., M.D.
Vice President, Translational Research
Diane Bodurka, M.D.
Vice President, Medical Education
Oliver Bogler, Ph.D.
Senior Vice President, Academic Affairs
Aman Buzdar, M.D.
Vice President, Clinical Research Administration
Maureen Cagley
Vice President, Academic Operations
Ernest Hawk, M.D.
Vice President, Cancer Prevention
Mien-Chie Hung, Ph.D.
Vice President, Basic Science
Helen Piwnica-Worms, Ph.D.
Vice Provost, Science
George Wilding, M.D.
Vice Provost, Clinical and Interdisciplinary Research

OFFICE OF ADMINISTRATION
Dan Fontaine, J.D.
Executive Vice President, Administration and Chief Financial Officer ad interim
Chris Belmont
Vice President and Chief Information Officer
Brad Gibson
Vice President, Revenue Cycle and Treasurer
Amy Hay
Vice President, Business Development
Steven Haydon, J.D.
Vice President and Chief Legal Officer
Rebecca Kaul
Vice President and Chief Innovation Officer
Allyson Kinzel, J.D.
Vice President and Chief Compliance Officer
Sherri Magnus
Vice President and Chief Audit Officer
Chris McKee
Vice President, Business Operations
Spencer Moore
Vice President and Chief Facilities Officer
Ferran Prat, Ph.D., J.D.
Vice President, Strategic Industry Ventures
Margaret Row, M.D.
Vice President, Operations, MD Anderson Cancer Network®
Shibu Varghese
Vice President, Human Resources

OFFICE OF THE EXECUTIVE VICE PRESIDENT AND PHYSICIAN-IN-CHIEF
Thomas Buchholz, M.D.
Executive Vice President and Physician-in-Chief
Robert Brigham
Senior Vice President, Hospital and Clinics
John Bingham
Vice President, Performance Improvement and Chief Quality Officer
Lewis Foxhall, M.D.
Vice President, Health Policy
Joel Lajeunesse
Vice President, Pharmacy
Paul Mansfield, M.D.
Vice President, Acute Care Services
Alma Rodriguez, M.D.
Vice President, Medical Affairs
Frank Tortorella, J.D.
Vice President, Clinical Support Services

37
DIVISION OF ANESTHESIOLOGY, CRITICAL CARE AND PAIN MEDICINE

DIVISION HEAD
Carin Hagberg, M.D.

DEPARTMENT OF ANESTHESIOLOGY AND PERIOPERATIVE MEDICINE
PROFESSOR AND CHAIR
Tom F. Rahafs, M.D.

DEPARTMENT OF CRITICAL CARE AND RESPIRATORY CARE
PROFESSOR AND CHAIR
Kristen J. Price, M.D.

DEPARTMENT OF PAIN MEDICINE
PROFESSOR AND CHAIR
Salahadin Abdi, M.D., Ph.D.

DIVISION OF CANCER MEDICINE

DIVISION HEAD
Patrick Hwu, M.D.

DEPARTMENT OF BREAST MEDICAL ONCOLOGY
PROFESSOR AND CHAIR
Debasish Tripathy, M.D.

DEPARTMENT OF EXPERIMENTAL THERAPEUTICS
PROFESSOR AND CHAIR AD INTERIM
Varsha V. Gandhi, Ph.D.

DEPARTMENT OF GENERAL ONCOLOGY
PROFESSOR AND CHAIR
Alyssa Rieber, M.D.

DEPARTMENT OF GENITOURINARY MEDICAL ONCOLOGY
PROFESSOR AND CHAIR
Christopher J. Logothetis, M.D.

DEPARTMENT OF GASTROINTESTINAL MEDICAL ONCOLOGY
PROFESSOR AND CHAIR
James C. Yao, M.D.

DEPARTMENT OF INVESTIGATIONAL CANCER THERAPEUTICS
PROFESSOR AND CHAIR
Funda Meric-Bernstam, M.D.

DEPARTMENT OF LEUKEMIA
PROFESSOR AND CHAIR
Hagop M. Kantarjian, M.D.

DEPARTMENT OF LYMPHOMA/MYELOMA
PROFESSOR AND CHAIR AD INTERIM
Robert Orlowiski, M.D., Ph.D.

DEPARTMENT OF MELANOMA MEDICAL ONCOLOGY
PROFESSOR AND CHAIR
Patrick Hwu, M.D.

DIVISION OF CANCER PREVENTION AND POPULATION SCIENCES

VICE PRESIDENT AND DIVISION HEAD
Ernest Hawk, M.D., M.P.H.

DEPARTMENT OF BEHAVIORAL SCIENCE
PROFESSOR AND CHAIR
Paul M. Cinciripini, Ph.D.

DEPARTMENT OF CLINICAL CANCER PREVENTION
PROFESSOR AND CHAIR
Powel H. Brown, M.D., Ph.D.

DEPARTMENT OF EPIDEMIOLOGY
PROFESSOR AND CHAIR AD INTERIM
Sanjay Shete, Ph.D.

DEPARTMENT OF HEALTH DISPARITIES RESEARCH
PROFESSOR AND CHAIR AD INTERIM
Sharon Hermes Giordano, M.D., M.P.H.

DEPARTMENT OF HEALTH SERVICES RESEARCH
PROFESSOR AND CHAIR
Sharon Hermes Giordano, M.D., M.P.H.
DIVISION HEAD
Marshall E. Hicks, M.D.

DIVISION OF INTERNAL MEDICINE

DIVISION HEAD
David Tweardy, M.D.

DEPARTMENT OF CANCER SYSTEMS IMAGING
PROFESSOR AND CHAIR
David Piwnica-Worms, M.D., Ph.D.

DEPARTMENT OF DIAGNOSTIC RADIOLOGY
PROFESSOR AND CHAIR
Wei Tse Yang, M.D.

DEPARTMENT OF IMAGING PHYSICS
PROFESSOR AND CHAIR
John D. Hazle, Ph.D.

DEPARTMENT OF INTERVENTIONAL RADIOLOGY
PROFESSOR AND CHAIR AD INTERIM
Sanjay Gupta, M.D.

DEPARTMENT OF NUCLEAR MEDICINE
PROFESSOR AND CHAIR
Horner A. Macapinlac, M.D.

DEPARTMENT OF GASTROENTEROLOGY, HEPATOLOGY AND INFECTIOUS DISEASES
PROFESSOR AND CHAIR AD INTERIM
John R. Stroehlein, M.D.

DEPARTMENT OF GENERAL INTERNAL MEDICINE
PROFESSOR AND CHAIR
Carmelita P. Escalante, M.D.

DEPARTMENT OF INFECTIOUS DISEASES, INFECTION CONTROL AND EMPLOYEE HEALTH
PROFESSOR AND CHAIR
Issam I. Raad, M.D.

DEPARTMENT OF PSYCHIATRY
PROFESSOR AND CHAIR
Alan D. Valentine, M.D.

DEPARTMENT OF PULMONARY MEDICINE
PROFESSOR AND CHAIR
Burton F. Dickey, M.D.

DEPARTMENT OF SYMPTOM RESEARCH
PROFESSOR AND CHAIR AD INTERIM
Annemieke Kavelaars, Ph.D., M.S.

DEPARTMENT OF DIAGNOSTIC IMAGING

DIVISION HEAD
Richard Gorlick, M.D.

DEPARTMENT OF EXPERIMENTAL RADIATION ONCOLOGY
PROFESSOR AND CHAIR
Junjie Chen, Ph.D.

DIVISION OF PATHOLOGY AND LABORATORY MEDICINE

DIVISION HEAD
Stanley R. Hamilton, M.D.

DEPARTMENT OF PATHOLOGY
PROFESSOR AND CHAIR
Victor Gerardo Prieto, M.D., Ph.D.

DEPARTMENT OF TRANSLATIONAL MOLECULAR PATHOLOGY
PROFESSOR AND CHAIR
Ignacio Ivan Wistuba, M.D.

DIVISION OF PEDIATRICS

DIVISION HEAD
Richard Gorlick, M.D.

DEPARTMENT OF EXPERIMENTAL RADIATION ONCOLOGY
PROFESSOR AND CHAIR
Junjie Chen, Ph.D.

DIVISION OF RADIATION ONCOLOGY

DIVISION HEAD
Stephen Hahn, M.D.

DEPARTMENT OF RADIATION ONCOLOGY
PROFESSOR AND CHAIR
Stephen Hahn, M.D.

DEPARTMENT OF RADIATION PHYSICS
PROFESSOR AND CHAIR AD INTERIM
Mary Martel, Ph.D.
DIVISION OF SURGERY

DIVISION HEAD
Stephen Swisher, M.D.

DEPARTMENT OF BREAST SURGICAL ONCOLOGY
PROFESSOR AND CHAIR
Kelly K. Hunt, M.D.

DEPARTMENT OF GYNECOLOGIC ONCOLOGY AND REPRODUCTIVE MEDICINE
PROFESSOR AND CHAIR
Karen H. Lu, M.D.

DEPARTMENT OF HEAD AND NECK SURGERY
PROFESSOR AND CHAIR
Randal S. Weber, M.D.

PROFESSOR AND CHAIR
Raymond E. Sawaya, M.D.

PROFESSOR AND CHAIR
Valerae O. Lewis, M.D.

PROFESSOR AND CHAIR
Charles E Butler, M.D.

PROFESSOR AND CHAIR
Jeffrey E. Lee, M.D.

PROFESSOR AND CHAIR
ARA A. VAPORCIYAN, M.D.

PROFESSOR AND CHAIR
Colin P. Dinney, M.D.

EXTERNAL ADVISORY BOARD

MD Anderson’s External Advisory Board is comprised of highly regarded scientific advisors who consult with MD Anderson faculty leaders on research programs and initiatives.

Carolyn “Bo” R. Aldigé
Prevent Cancer Foundation

David B. Allison, Ph.D.
University of Alabama at Birmingham

Frederick Appelbaum, M.D.
Fred Hutchinson Cancer Research Center

Monica Bertagnolli, M.D.
Dana-Farber Cancer Institute

Brigham and Women's Hospital
Elizabeth Blackburn, Ph.D.

Salk Institute
Paul A. Bunn, Jr., M.D.

University of Colorado Cancer Center
Steven K. Clinton, M.D., Ph.D.

The Ohio State University
Graham A. Colditz, M.D., Dr.P.H.

Washington University School of Medicine
Nancy E. Davidson, M.D.

Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center

University of Washington, Fred Hutchinson Cancer Research Center

Keith T. Flaherty, M.D.
Massachusetts General Hospital

Judy E. Garber, M.D., M.P.H.
Dana-Farber Cancer Institute

Levi A. Garravay, M.D., Ph.D.
Eli Lilly and Company

Gad Getz, Ph.D.
Broad Institute

Lauren E. Hackett, M.P.A.
Vanderbilt-Ingram Cancer Center

Dorothy Hatakami, Ph.D.
University of Minnesota

Lee J. Helman, M.D.
Clinical Research Center for Cancer Research, National Institutes of Health

Lydia Kavraki, Ph.D.
Rice University

Quynh-Thu Le, M.D.
Stanford School of Medicine

David N. Louis, M.D.
Harvard Medical School

Tak Wah Mak, Ph.D.
University of Toronto

Elaine Mardis, Ph.D.
The Ohio State University

Monica Morrow, M.D., F.A.C.S.
Memorial Sloan Kettering Cancer Center

Harold Moses, M.D.
Vanderbilt-Ingram Cancer Center

William G. Nelson, M.D., Ph.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Giovanni Parmigiani, Ph.D.
Harvard School of Public Health

Dana-Farber Cancer Institute

Antoni Ribas, M.D., Ph.D.
UCLA Jonsson Comprehensive Cancer Center

Robert Schreiber, Ph.D.
Washington University School of Medicine

Department of Pathology and Immunology

Norman E. “Ned” Sharpless, M.D.
Lineberger Comprehensive Cancer Center, University of North Carolina

Yang Shi, Ph.D.
Boston Children's Hospital

Ellen Sigal, Ph.D.
Friends of Cancer Research

David R. Spriggs, M.D.
Memorial Sloan Kettering Cancer Center

Craig B. Thompson, M.D.
Memorial Sloan Kettering Cancer Center

Daniel Von Hoff, M.D., F.A.C.P.
TGen

Ralph Weissleder, M.D., Ph.D.
Massachusetts General Hospital

Harvard Medical School
RESEARCH DEPARTMENTS
Helen Pivnica-Worms, Ph.D.
Vice provost for science

DEPARTMENT OF BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
PROFESSOR AND CHAIR
John N. Weinstein, M.D., Ph.D.

DEPARTMENT OF BIOSTATISTICS
PROFESSOR AND CHAIR
Kim-Anh Do, Ph.D.

DEPARTMENT OF CANCER BIOLOGY
PROFESSOR AND CHAIR
Raghu Kalluri, M.D., Ph.D.

DEPARTMENT OF EPIGENETICS AND MOLECULAR CARCINOGENESIS
PROFESSOR AND CHAIR
Sharon R Dent, Ph.D.

DEPARTMENT OF GENETICS
PROFESSOR AND CHAIR
Guillermina Lozano, Ph.D.

DEPARTMENT OF IMMUNOLOGY
PROFESSOR AND CHAIR
James P. Allison, Ph.D.

DEPARTMENT OF MOLECULAR AND CELLULAR ONCOLOGY
PROFESSOR AND CHAIR
Mien-Chie Hung, Ph.D.

DEPARTMENT OF SYSTEMS BIOLOGY
PROFESSOR AND CHAIR
Gordon B. Mills, M.D., Ph.D.

DEPARTMENT OF VETERINARY MEDICINE AND SURGERY
PROFESSOR AND CHAIR
Peggy T. Tinkey, D.V.M.

DEPARTMENT OF VETERINARY SCIENCES
PROFESSOR AND CHAIR
Christian Abee, D.V.M.

SCHOOL OF HEALTH PROFESSIONS
PROFESSOR AND DEAN
Shirley Richmond, Ed.D.
MD Anderson Cancer Center Board of Visitors

The MD Anderson Cancer Center Board of Visitors is an appointed board of people committed to helping MD Anderson achieve its mission of eliminating cancer. Board programs emphasize private fund development, public relations and outreach on behalf of the institution.

**Officers**
- **Chair**
  - Mr. James J. Mulva
  - Mrs. Marsha Shields
  - The Honorable Donald L. Evans
  - Mr. Melvyn N. Klein
- **Chair Elect**
  - Mr. Richard C. Adkerson
  - Dr. Durga D. Agrawal
  - Mrs. Peggy Brunet Ahuja
  - Mr. Mark W. Albers
  - Mr. John D. Alexander, Jr.
  - Mr. Stanford J. Alexander
  - Mrs. Judy Ley Allen
  - Mrs. Nita Ambani
  - Mr. Richard H. Anderson*
  - Mr. Barry G. Andrews
  - Mr. Glynn Andrews
  - Mr. Matthew Anthony
  - Mr. James B. Archer*
  - Mr. Andrew M. Baker
- **Immediate Past Chair**
  - The Honorable James A. Baker, III
  - Mr. Lee Barberito
  - Mr. John W. Barnhill, Jr.
  - Mr. Michael G. Bartolotta
  - Mr. Lawrence E. Bathgate II
  - Mr. Alan R. Batkin*
  - Mr. David J. Beck
  - Mr. Paul E. Becala
  - Mr. Brent Alan Benoit
  - Mr. G. Alex Bernhardt, Sr.
  - Mrs. Sally B. Berry
  - Mr. Kelli L. Blanton
  - Mrs. Patricia Bodin
  - Mr. Giorgio Borlenghi
  - Dr. W. E. Bosarge, Jr.
  - Mr. Joel Brochstein
  - Mr. Robert T. Brockman
  - Mr. Kyle C. Brooks
  - Mr. J. Robert Brown
  - Mr. I. Jon Brumlney
  - Mrs. Barbara Bush
  - The Honorable George H. W. Bush
  - Mr. William R. Bush
  - Mr. Charles Butt
  - Pastor Kirbyjon H. Caldwell
  - Mr. Rick J. Calhoon
  - Mr. Clarence P. Cazalot, Jr.
  - Mr. Michael J. Cerno
  - Mr. Albert Y. Chao
  - Mr. Tony Chase
  - Ms. Lois Chiles
  - Mr. Arthur Ciocca
  - Mrs. Cindy Citrone
  - Mr. David A. Cockrell
  - Mr. Ernest H. Cockrell
  - Mr. Ted Collins, Jr.
  - Mr. Gus H. Comiskey Jr.
  - The Honorable Peter R. Coneway
  - Mrs. Anne P. Connally
  - Mr. John B. Connally III
  - Mr. Rufus Cormier, Jr.
  - Mrs. Shirley Coskey
  - Mr. Edwin L. Cox
  - Mrs. Nadine Craddick
  - Mrs. Cheryl Creuzot
  - Mrs. Rose S. Cullen
  - Mr. William M. Daley*
  - Mr. Christopher Damico*
  - Mr. James D. Dannenbaum
  - Mr. Doug Deason*
  - Mr. Alfred L. Deaton III
  - Mrs. Myrna J. Deckert
  - Mrs. Linnet F. Deily
  - Mrs. Patricia Hamilton Dewhurst
  - Mr. Jerry Dickman
  - Mr. Ben A. Donnell
  - Mr. William J. Doré, Sr.
  - Mr. Walter W. Driver, Jr.
  - Mrs. Jan E. Duncan
  - Mr. John H. Duncan, Sr.
  - Mr. Raymond A. Eckstein, Jr.
  - Mr. Jay S. Eisenberg
  - Mrs. Elizabeth G. Epley
  - Dr. Susan Zane Epstein*
  - Mrs. Christine Gaylord Everest
  - Mr. James H. Everest
  - Mr. Gregg H. Falgout
  - Mr. G. Steven Farris
  - Mr. Stephen L. Feinberg
  - Mr. Alan D. Feld
  - Mr. Dillon J. Ferguson
  - Mr. Jason B. Few
  - Mr. George A. Finley III
  - Mr. William B. Finneran
  - Mrs. Alejandra De la Vega Foster
  - Mrs. Patsy S. Fourticq
  - Mr. Steve L. Fox
  - Mr. Michael E. Frazier

*New members*
Mr. James L. Gallogly
Mr. Gilbert A. Garcia
Mrs. Lily C. Garfield
Mrs. Diane D. Gates
Mr. Wayne Gibbens
Mr. Jimmy I. Gibbs
Mr. Gary F. Gibson
Mr. Terry M. Giles
Mr. Thomas S. Glanville
Mr. George Y. Gonzalez
Dr. Marie Goradia
Mr. Steven L. Gordon
Mr. Richard W. Gray III
Mr. F. O’Neil Griffin
Mr. David M. Grimes II
Mrs. Rosalind Redfern Grover
Mr. Felo Guerra
Mr. Ben A. Guill
Mr. Robert G. Gwin
Mrs. Maureen Hackett
Mrs. Janelle Hail
Mrs. Katherine C. Hatcher
Mrs. Lawrence H. Hayward*
Ms. Adrea D. Heebe
Mrs. Becky Bradfield Heiser
Mrs. Gloria Hicks
Mrs. Mindy Hildebrand
Miss Lyda Hill
Mr. Yerger Hill III
Mr. Jeffrey C. Hines
Mr. Forrest E. Hoglund
Mr. D. Alter Holand
Mr. John A. Holland
Mrs. Desiree Lyon Howe
Mr. Woody L. Hunt
Mrs. Barbara R. Hurwitz
Mr. Charles E. Hurwitz
The Honorable Kay Bailey Hutchison
Mrs. Judith Jaynes
The Honorable Brenda L. Johnson
Ms. Luci B. Johnson
Mr. Tom Johnson
Mrs. Glenda R. Kane
Mrs. Danielle Kavanagh
Mr. T. Mark Kelly
Mrs. Nancy G. Kinder
Dr. Henry A. Kissinger
Mr. Wyck A. Knox, Jr.
Mr. David H. Koch
Mr. Gregory A. Kozmetsky
Dr. Demos T. Kyrazis
Mrs. Julie Kyte
Ms. Neda Ladjevardian
Mr. Eric S. Lane
Mrs. Elyse Lanier
Mr. Pierre F. Lapeyre, Jr.
Mr. Stephen A. Lasher
Mrs. Helen H. Laughery
Mr. C. Berdon Lawrence
Dr. Charles A. LeMaistre**
Ms. Marty V. Leonard
Mrs. Mary V. Lester
Mr. Max S. Levi
Mr. Michael R. Levy
Mr. Michael C. Linn
Mrs. Nancy B. Loeffler
Ms. Janice Longoria
Mr. Harry J. Longwell
Mr. Angel Losada
Mr. Jeff B. Love
Ms. Mary Ralph Lowe
Mrs. Marlene A. Malek
Mr. Jed Mancherian
Mr. Rodney H. Margolis
Mr. Kade L. Matthews
Mrs. Karen R. Matthews
Mr. L. Lowry Mays
Mrs. Linda Mays McCaul
Mrs. Mary Anne McCloud
Mr. Red McCombs
Mr. Andrew D. McCullough, Jr.
Mrs. Stacie McDavid
Mr. Michael D. McKinnon
Mr. R. Drayton McLane, Jr.
Mr. Michael J. Medrano
Mrs. Sonciera Messiah-Jiles
Mr. Allen A. Meyer
Mr. Howard M. Meyers
Mr. Steven L. Miller
Mrs. Kit Moncrief
Mr. W. A. “Tex” Moncrief, Jr.
Mrs. Denise D. Monteleone
Mr. William C. Montgomery
Dr. Laura G. Murillo
Ms. Martha W. Murphy
Mr. Henry G. Musselman
Mr. Joseph Neubauer
Mr. W. Robert Nichols III
Mr. Dennis E. Nixon
Mr. George E. Norcross III
Mr. Marvin Odum
Mrs. Kay M. Onstead
Mrs. Pamela K. Onstead
Mr. Paul F. Oreffice
Mr. Patrick C. Oxford
Ms. Ebru Ozdemir
Ms. Ana Palacio
Mrs. Vicky M. Pappas
Mrs. Roseann Park
Mrs. Melinda Hill Perrin
Mrs. Jan R. Pickens
Mr. T. Boone Pickens
Mr. Ralph Ponce de Leon
Dr. Leslie Rainbolt-Forbes
Mr. Jack P Randall
Mrs. Ashley Scott Rankin
Mrs. Sheila Reese
Mr. Reynaldo Reza
Dr. Robert C. Robbins
Ms. Regina J. Rogers
Mr. William E. Rosenthal
Dr. Alexander Rovt
Mr. Scott E. Rozzell
Mr. Thomas V. Rushing
Mrs. Helen Lho Ryu
Mr. Andrew E. Sabin
Mr. Federico Sada
Mr. Michael S. Samis
Mr. A. R. “Tony” Sanchez, Jr.
Mr. Christopher Sarofim
Joan Weingarten Schnitzer
Mr. John C. Schweitzer
Mr. Milton L. Scott
Dr. Thomas Setz
Mrs. Nancy M. Seigler
Mrs. Peggy Sewell
Mr. Marc J. Shapiro
Mr. John H. Shields II
Mrs. Jan A. Levit Silver
Mr. Doyle Simons
Mr. Herbert D. Simons
Mr. Donald R. Sinclair
Mr. Lester H. Smith
Mr. Walter J. Smith
Mr. Glenn B. Stearns
Mrs. Ida Louise Clement Steen
Mr. Gary W. Stein
Mrs. Lenise Stephenson
Mr. H. Leighton Steward
Mr. Charles W. Stiefel
Mrs. Gayle B. Stoffel
Rabbi Alvin M. Sugarman
Mr. Sam L. Susser
Mr. Charles W. Tate
Mr. Mac Tichenor, Jr.
Mrs. Sue S. Timken
Mr. Robert B. Tudor III
Mr. Tony Vallone
Mr. S. Wil VanLoh, Jr.
Mr. Steven H. Wasserman
Mr. William M. Webster IV
Mr. Herbert D. Weitzman
The Honorable Mark White
Mrs. Margaret Alkek Williams
Mrs. Michel H. Williams
Mrs. Sheridan Williams
Mr. John H. Wilson III
Mr. Melvyn L. Wolff
Mr. Don M. Woo
The Honorable Joseph Zappala
Mr. Eric S. Zorn

* New members  ** Deceased
MD Anderson gratefully acknowledges the following individuals, foundations, organizations and others who made commitments of $1,000 or more from Sept. 1, 2015, to Aug. 31, 2016.

Ronald DePinho, M.D., MD Anderson’s fourth full-time president, officially announced the creation of the Beau Biden Chair for Brain Cancer Research at the 75th anniversary gala. W.K. Alfred Yung, M.D., who served as Biden’s doctor, presented a commemorative memento to Dr. Jill Biden and Vice President Joe Biden.

5 Sisters Inc.
38th Street Pharmacy, Inc.

A

A & A Cattle Company
A. E. Machine Works, Inc.
A G Equipment Company
Carol and Steve Aaron
Mrs. Karen S. Abbott
Abbiglen Inc.
Dr. and Mrs. Christian R. Abee
Macy and Carlos Abello
Mr. Richard C. Abello
Ms. Barb Abernethy
Dorothy and Mickey Ables
Mr. Benjamin P. Abney
Mr. Peter Abeyes
Dr. Susan C. Abraham
Mr. and Mrs. Gary M. Abramson
Ms. Kathleen Abshire
Abundant Living Faith Center Church, Inc.
Acelity Corporation
Achillion Pharmaceuticals, Inc.
Mr. and Mrs. Robert G. Ackerley
Mr. and Mrs. Irwin B. Ackerman
Mr. Michael Ackerman
Mr. and Mrs. Richard Acosta
Acosta Management, Inc.
Dr. Kenneth S. Adam and Ms. Gayle Goodman
Mr. and Mrs. Albert T. Adams
Estate of Alvin F. Adams
Mr. and Mrs. Brian D. Adams
Mr. and Mrs. James E. Adams
Mr. Kevin D. Adams
ADB Airfield Solutions
Mrs. Patricia N. Adcock
Mr. Terence E. Adderley
Addi’s Faith Foundation
Mr. and Mrs. Kevin L. Addis
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Mr. and Mrs. Gerhard P. Adenacker
Adenoid Cystic Carcinoma Research Foundation
Ms. Mildred C. Adicks
Mrs. Rose Adkison
Mr. and Mrs. Jim S. Adler
Advance Medical, Inc.
Affiliated Solutions LLC
Altag
Mrs. Sushila Agrawal and Dr. Durga D. Agrawal
Mr. Dominic Ahearn
Mr. and Mrs. David Alquist
Mr. and Mrs. Aivinash C. Ahuja
Ms. Dana Alchier
Mr. Daniel G. Aiken
AlM at Melanoma Foundation
Mr. Jamal Akhtar
Mr. Barry Albano
The Albany Foundation
Albemarle Foundation
Mr. and Mrs. Mark W. Albers
Dr. and Mrs. Todd J. Albert
The Leo and Anne Albert Institute for Bladder Cancer Care and Research
Mrs. Joyce Albrecht
Ms. Patrice Alessandra
Charles Alexander and LaVerne Alexander
Joan and Stanford Alexander
Mr. and Mrs. John D. Alexander, Jr.
Jerri and Jim Alexander Endowment for Cancer Research
Mr. Steven R. Alfen

Ms. Kim Alfonso
Mr. and Mrs. Vic Alfonso
Albert and Margaret Alkek Foundation
Kristin and Gregory Allemann
Mr. and Mrs. Curtis L. Allen, Jr.
Dr. Harold A. Allen and Bertha Allen
Mr. Jack V. Allen, Jr.
Mr. and Mrs. Joe B. Allen
Mr. Joseph Allen
Mrs. Judy L. Allen
Mr. and Mrs. Lemuel Allen, Jr.
Mr. and Mrs. Marion T. Allen
Mr. Meredith B. Allen
Mrs. Nancy C. Allen
Nick and Barbara Allen
Mr. Robby R. Allen
Dr. and Mrs. Robert Allen
Mr. and Mrs. William A. Allen
Allen Enterprises, Inc.
Rita Allen Foundation
Mrs. Catherine C. Alley
Alliance Financial Group
The Alliance for Clinical Trials in Oncology
Mr. and Mrs. Pierce M. Aliffin
Almeda Holdings
Mr. and Mrs. Joseph Aloni
Mr. Arthur J. Alper
Mr. and Mrs. Jim Alsup
Mr. and Mrs. Fahad Al-Tamimi
Attec/Styslinger Foundation
Atman Goldstein Foundation
Mr. and Mrs. Anthony Atmann
Mr. Carlos Alvarez
Amarillo Area Foundation
American Academy of Neurology Institute
American Alloy Steel, Inc. and A. J. Moore
American Association for Cancer Research
American Association of Neurosurgeons
American Board of OB/Gyn Educational Foundation
American Borate Company
American Brachytherapy Society
American Cancer Society
The American Endowment Foundation
American Legion Post 208
The American Lung Association National Headquarters
American Society of Colon and Rectal Surgeons
American Society of Health-System Pharmacists
American Society of Hematology
American Steel & Aluminum Company
American-Italian Cancer Foundation
The Arena Energy Foundation
Dr. Van Ardoin and Mrs. Cynthia Ardoin
Mr. and Mrs. Greg Arden
American Cancer Society
American Brachytherapy Society
American Cancer Society
The American Endowment Foundation
American Legion Post 208
The American Lung Association National Headquarters
American Society of Colon and Rectal Surgeons
American Society of Health-System Pharmacists
American Society of Hematology
American Steel & Aluminum Company
American-Italian Cancer Foundation
The Arena Energy Foundation
Dr. Van Ardoin and Mrs. Cynthia Ardoin
The Arena Energy Foundation
Mr. Bruce A. Argetsinger
ARIAED Pharmaceuticals, Inc.
Arkansas Community Foundation
Mr. and Mrs. Charles F. Armbrust
Mr. and Mrs. David S. Armbruster
Dan and Mary Armstrong
Mr. and Mrs. Lester Armstrong, III
Armour Trust
The Armstrong Foundation
A.O. and S. L. Austin Foundation
The Arthur and Dixie Alvarez Foundation
Mr. and Mrs. John S. Austin
Dr. and Mrs. Bruce A. Austin
Aveosf Foundation
Mr. and Mrs. Gary D. Austin
Mr. Howard T. Austin, Jr.
Mr. James E. Austin
Mr. and Mrs. James F. Austin
John Henry and Dora Austin
The Honorable and Mrs. John S. Austin
Karen and Charles Austin
Mr. and Mrs. Kenneth W. Austin
Mr. and Mrs. Marcus A. Austin
Mr. and Mrs. Mark Austin
Ms. Martha L. Austin
Mr. Robert R. Austin
Mr. Robert W. Austin
Sydney J. Austin
Mr. Thorvin Austin
Mr. William C. Austin
Mr. and Mrs. William L. Austin, Jr.
M. D. Anderson Foundation
Rose Marie & Jack R. Austin Foundation
Mrs. Adele W. Avdung
Mr. and Mrs. Gilbert H. Avdel
Mr. and Mrs. Barry G. Avdel
Mr. Glynn Avdel
Mr. Joseph J. Avdel
Mr. and Mrs. Richard L. Avdel
Andrews Distributing of North Texas, Ltd.
Glynn Andrews Family Foundation
Andrews Foundation
A. W. and Suan Angelo Foundation
Angel’s Spa Cancer Foundation
Kelley and Michael Annino
Anonymous
The Honorable and Mrs. Hushang Ansary
Mrs. Joyce A. Antes
Mr. and Mrs. Matthew Anthony
Ms. Samuel Ella Antion
Mr. Charles Anszer
Aon Foundation
Apache Corporation
Mr. Ronald H. Apel
Applastic Anemia & MDS International Foundation, Inc.
Ms. Roberta K. Apolant and Mr. David Duerr
Dr. and Mrs. Bruce S. Applebaum
Apple Corporation
Applied Petroleum Technologies
Arbella Charitable Foundation, Inc.
Mr. Harlan T. Arden
Mr. Scott W. Archer
James B. & Lois R. Archer Charitable Foundation
Ms. Elizabeth A. Ardito
Armstrong Institute of Health
Mrs. Bonnie Ardown
Mr. and Mrs. George E. Ardown
Mr. and Mrs. Greg Ardown
Dr. Van Ardown and Mrs. Cynthia Ardown
The Arena Energy Foundation
Mr. Bruce A. Argetsinger
ARIAED Pharmaceuticals, Inc.
Arkansas Community Foundation
Mr. and Mrs. Charles F. Armbrust
Mr. and Mrs. David S. Armbruster
Dan and Mary Armstrong
Mr. and Mrs. Lester Armstrong, III
Armour Trust
Baddour Family Foundation Inc.  
Mr. Alan P. Baden  
Mr. and Mrs. Robert M. Baer  
Mr. and Mrs. Randy Baer  
Mr. and Mrs. David Baggett  
Mrs. Barbara Conway Bailey  
Mr. George Bailey, Jr.  
Mrs. Margaret C. Bailey  
Mr. Robert Ballagence  
Mr. Thomas B. Baird  
Dr. Joseph S. Bak  
Mr. and Mrs. Alan A. Baker  
Mr. and Mrs. Andrew M. Baker  
Mr. and Mrs. S. Robert Baker, Jr.  
Mr. and Mrs. Bradford N. Baker  
Mr. and Mrs. B. Robert Baker, Jr.  
Mr. and Mrs. Alan A. Baker, III  
Estate of Lamar Robert Baker, Jr.  
Mr. Lewis T. Baker, Jr.  
Estate of Renza Moscatelli Baker  
Mr. Robert A. Baker  
Mr. and Mrs. Robert H. Baker  
Baker Botts L.L.P.  
Baker Hughes Foundation  
Bakers Sign & Manufacturing Inc.  
Mrs. Jodi Bakes  
Mrs. Deborah A. Bakewell  
Mr. Vincent C. Baldassari  
Jerry and Emily Lou Baldridge  
Mr. Steven L. Balfie  
Mr. and Mrs. Robert C. Balfour III  
Mr. and Mrs. George L. Ball  
Mr. John G. Ball  
Mr. Bruce K. Ballard  
Ms. Cynthia Ballis  
Ms. Francys A. Ballenger  
Estate of James R. Ballinger  
Mr. and Mrs. Joseph Balusk  
Mr. and Mrs. P. Banavalkar  
Bancorp Investments, Inc.  
Mr. Mark Bandy  
Bank of America Corporation  
Employees of Bank of America Corporation  
Mr. Mark Bandy  
Dr. and Mrs. Andrew Aviloo  
AV Foundation  
Avery Foundation for Women  
Mr. Kenneth R. Awad  
Mr. and Mrs. Robert R. Ave  
Mr. Allen L. Aycox  
Estate of Donna M. Ayers  
Dr. and Mrs. Robert C. Ayers, Jr.  
Lawson Ay  
Dr. and Mrs. Jamil Azzam  
Charlotte and Jamil Azzam Foundation

Endowed Distinguished University Chairs

**HARRY CAROTHERS WIESS DISTINGUISHED UNIVERSITY CHAIR FOR CANCER RESEARCH**  
Robert C. Bast Jr., M.D.  

**OLGA KEITH AND HARRY CAROTHERS WIESS DISTINGUISHED UNIVERSITY CHAIR IN CANCER RESEARCH**  
Ethan Dmitrovsky, M.D.  

**THE ROBERT A. WELCH DISTINGUISHED UNIVERSITY CHAIR IN CHEMISTRY**  
Andrew Futreal, Ph.D.  

**FREDERICK F. BECKER DISTINGUISHED UNIVERSITY CHAIR FOR CANCER RESEARCH**  
Stanley R. Hamilton, M.D.  

**SAMSUNG DISTINGUISHED UNIVERSITY CHAIR IN CANCER MEDICINE**  
Hagop Kantarjian, M.D.  

**SHEIKH KHALIFA BIN ZAYED AL NAHYAN DISTINGUISHED UNIVERSITY CHAIR IN CANCER RESEARCH**  
Anirban Maitra, M.B.B.S.  

**OLGA KEITH WIESS DISTINGUISHED UNIVERSITY CHAIR FOR CANCER RESEARCH**  
Gordon B. Mills, M.D., Ph.D.  

**THE JOHN BROOKS WILLIAMS AND ELIZABETH WILLIAMS DISTINGUISHED UNIVERSITY CHAIR IN CANCER MEDICINE**  
Randal S. Weber, M.D.  

**SHEIKH ZAYED BIN SULTAN AL NAHYAN DISTINGUISHED UNIVERSITY CHAIR OF MEDICAL ONCOLOGY**  
Robert A. Wolff, M.D.  

As of Sept. 1, 2016
Endowed Distinguished Chairs

VIVIAN L. SMITH Distinguished Chair in Immunology
James P. Allison, Ph.D.

JOHN CHARLES CAIN Distinguished Chair in Cancer Prevention
Powel H. Brown, M.D., Ph.D.

HUBERT L. AND OLIVE STRINGER Distinguished Chair in Oncology in Honor of Sue Gribble Stringer
Thomas A. Buchholz, M.D.

PAMELA AND WAYNE GARRISON Distinguished Chair in Cancer Research
Junjie Chen, Ph.D.

JANE AND JOHN JUSTIN Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey
Jorge E. Cortes, M.D.

NATHAN W. LASSITER Distinguished Chair in Urology
Bogdan A. Czerniak, M.D., Ph.D.

W. A. “TEx” AND DEBORAH MONCRIEF, JR. Distinguished Chair in Urology
Colin R. N. Dinney, M.D.

WAUN KI HONG Distinguished Chair in Translational Oncology
Elizabeth A. Grimm, Ph.D.

GILBERT H. FLETCHER MEMORIAL Distinguished Chair
Stephen Hahn, M.D.

EVELYN AND SOL RUBENSTEIN Distinguished Chair for the Cancer Prevention Department
Samir Hanash, M.D., Ph.D.

BOONE PICKENS Distinguished Chair for Early Prevention of Cancer
Ernest Hawk, M.D.

LEVIT FAMILY Distinguished Chair in Diagnostic Imaging in Honor of Dr. Sidney Wallace
Marshall E. Hicks, M.D.

RUTH LEGGETT JONES Distinguished Chair
Miin-Chie Hung, Ph.D.

OLLA S. STRIBLING Distinguished Chair for Cancer Research
Raghu K. Kalluri, M.D., Ph.D.

MARY V. AND JOHN A. REILLY Distinguished Chair in Pediatric Oncology
Eugenie S. Kleiman, M.D.

W. T. AND LOUISE JARRETT MORAN Distinguished Chair in Thoracic Oncology
Shulin Li, Ph.D.

ROY M. AND PHYLLIS GOUGH HUNTINGFORD Distinguished Chair in Urologic Oncology
Christopher J. Logothetis, M.D.

LOCKTON Distinguished Chair in Pancreatic Cancer Research
Craig Logsdon, Ph.D.

J. TAYLOR WHARTON, M.D., Distinguished Chair in Gynecologic Oncology
Karen H. Lu, M.D.

JOHN S. DUNN Distinguished Chair in Diagnostic Imaging
William A. Murphy, Jr., M.D.

GERALD DEWEY DODD, JR. Distinguished Chair in Diagnostic Imaging
David Piwnica-Worms, M.D., Ph.D.

SENATOR A. M. AKIN, JR. Distinguished Chair
Helen M. Piwnica-Worms, M.D., Ph.D.

BARNTS FAMILY Distinguished Chair for Cancer Research
William K. Plunkett, Jr., Ph.D.

BUD JOHNSON CLINICAL Distinguished Chair
Jack A. Roth, M.D.

ANNE C. BROOKS AND ANTHONY D. BULLOCK III Distinguished Chair in Neurosurgery
Raymond Savaya, M.D.

CHARLES A. LEMAISTRE Distinguished Chair in Thoracic Oncology, Given by W. A. “Tex” and Deborah Moncrief, Jr.
Stephen G. Swisher, M.D.

THE ROBERT A. WELCH Distinguished Chair in Chemistry
John A. Tainer, Ph.D.

JOAN AND STANFORD ALEXANDER Distinguished Chair for Prostate Cancer Research
Timothy Thompson, Ph.D.

ROBERT D. MORETON Distinguished Chair in Diagnostic Radiology, Given by W. A. “Tex” and Deborah Moncrief, Jr.
Wei Tse Yang, M.D.

ELLEN F. KNISELY Distinguished Chair in Colon Cancer Research
James Yao, M.D.

HUBERT L. AND OLIVE STRINGER Distinguished Chair in Basic Science in Honor of Sally Stringer
Dihua Yu, M.D., Ph.D.

As of Sept. 1, 2016
Endowed Chairs

PAUL AND MARY HAAS CHAIR IN GENETICS IN HONOR OF AMANDA MARIE WHITTLE
Michael Andreifeff, M.D., Ph.D.

COLIN POWELL CHAIR FOR CANCER RESEARCH
Michelle Barton, Ph.D.

BEN F. LOVE CHAIR IN CANCER RESEARCH
Richard R. Behringer, Ph.D.

FRANK T. MCGRAW MEMORIAL CHAIR IN THE TREATMENT OF CANCER
Eduardo Bruera, M.D.

CHARLES B. BARKER CHAIR IN SURGERY
Charles E. Butler, M.D.

ROBERT C. HICKEY CHAIR IN CLINICAL CARE
Richard E. Champlin, M.D.

ANN RIFE COX CHAIR IN GYNECOLOGY
Robert L. Coleman, M.D.

MARY BETH PAWELEK CHAIR IN NEUROSURGERY IN HONOR OF DR. AND MRS. SAMUEL DICKENS BUGG AND MR. AND MRS. ALBERT F. PAWELEK
Franco DeMonte, M.D.

J. RALPH MEADOWS CHAIR IN CARCINOGENESIS RESEARCH AT SCIENCE PARK-RESEARCH DIVISION
Sharon Y. Dent, Ph.D.

WILLIAM C. LIFETKDE, JR. CHAIR IN CANCER RESEARCH
Lee M. Ellis, M.D.

REBECCA MEYER BROWN AND JOSEPH MELLINGER BROWN CHAIR IN BASIC SCIENCE RESEARCH
Varsha V. Gandhi, Ph.D.

DR. KENNETH B. MCCREDIE CHAIR IN CLINICAL LEUKEMIA RESEARCH
Guillermo Garcia-Manero, M.D.

CHARLES AND DANEEN STEFEL CHAIR IN CANCER RESEARCH IN HONOR OF MERRILL KIES, M.D., DAVID ROSENTHAL, M.D., AND RANDAL WEBER, M.D.
Ehab Y. Hanna, M.D.

BERNARD W. BIEDENHAR CHAIR IN CANCER RESEARCH
John D. Hazle, Ph.D.

DAVID BRUTON JR. CHAIR
John V. Heymach, M.D., Ph.D.

DALLAS/FORT WORTH LIVING LEGEND CHAIR FOR CANCER RESEARCH
Geoffrey S. Ibbott, Ph.D.

DALLAS/FORT WORTH LIVING LEGEND CHAIR FOR CANCER RESEARCH II
V. Craig Jordan, Ph.D.

JOHN G. AND MARIE STELLA KENEDY MEMORIAL FOUNDATION CHAIR
J. Jack Lee, Ph.D.

IRVING AND NADINE MANSFIELD AND ROBERT DAVID LEVITT CANCER RESEARCH CHAIR
Jeffrey E. Lee, M.D.

MATTIE ALLEN FAIR RESEARCH CHAIR
Guillermina Lozano, Ph.D.

NELLE B. CONNALLY CHAIR IN BREAST CANCER
Funda Meric-Bernstam, M.D.

FRANK T. MCGRAW MEMORIAL CHAIR IN THE STUDY OF CANCER
Bruce Minsky, M.D.

LARRY AND PAT MCNEIL CHAIR IN RADIATION ONCOLOGY HONORING DR. JAMES D. COX
Radhe Mohan, Ph.D.

FERENC AND PHYLIS GYORKEY CHAIR FOR RESEARCH AND EDUCATION IN PATHOLOGY
Víctor G. Prieto, M.D., Ph.D.

HOWARD FOSTER SMITH AND LEE DENNIS SMITH CHAIR FOR CANCER RESEARCH IN THE FIELD OF HEMATOLOGY
Elizabeth J. Shpall, M.D.

FRANK T. MCGRAW MEMORIAL CHAIR IN CANCER RESEARCH
Anil Sood, M.D.

SUE AND RADCLIFFE KILLAM CHAIR
Louise C. Strong, M.D.

CHRISTOPHER AND SUSAN DAMICO CHAIR IN VIRAL ASSOCIATED MALIGNANCIES
Erich M. Sturgis, M.D.

MOSHE TALPAZ ENDEDOWD CHAIR IN IMMUNOLOGY
Shao-Cong Sun, Ph.D.

DALLAS/FORT WORTH LIVING LEGEND CHAIR FOR CANCER RESEARCH III
David Twarday, M.D.

M. G. AND LILLIE A. JOHNSON CHAIR FOR CANCER TREATMENT AND RESEARCH
Ara A. Vaporiçyan, M.D.

JOSE M. TRUJILLO CHAIR IN LABORATORY MEDICINE
Elizabeth A. Waqar, M.D.

HUBERT L. STRINGER CHAIR IN CANCER RESEARCH
John N. Weinstein, M.D., Ph.D.

ANDERSON CLINICAL FACULTY CHAIR FOR CANCER TREATMENT AND RESEARCH
Ignacio Wistuba, M.D.

BETTY B. MARSUS CHAIR IN CANCER PREVENTION
Xifeng Wu, M.D., Ph.D.

As of Sept. 1, 2016

Mr. Richard Clark
The Honorable Ron and Joanna Clark
Mr. and Mrs. Charles F. Clarkson III
Mr. and Mrs. David A. Clay

Clays for Cara
Mr. and Mrs. John D. Clayton
Mr. and Mrs. Joseph A. Cleary, Jr.
Dr. and Mrs. John B. Clemmons

The Cleveland Foundation
Mr. and Mrs. Richard L. Clifford
Mr. James R. Clifton
The Clifton Foundation
Mr. and Mrs. Gerald P. Clinch
Mr. and Mrs. James F. Cingman, Jr.
CILL Global Research Foundation
Clorox Company Foundation
Mr. and Mrs. Omer Cloutier
ClubCorp, Inc.
Coach Sherrill’s Kickoff Team Scholarship
Coastal Bend Community Foundation
Coastal Del Inc.
Coastal Spray Company
Coastal Transport Co., Inc.
Mr. and Mrs. Tim L. Cobb
Dr. and Mrs. Benton Cocanougher
Mr. and Mrs. David A. Cockrell
Mr. and Mrs. Ernest H. Cockrell
Cockrell Family Fund
The Cockrell Foundation
Cockrell Interests LLC
Mr. and Mrs. Anthony C. Coen, Jr.
Mr. Bruce R. Cofer
Mary and Edward Coffey
Mr. Michael Coffey
Mr. Perry Cohen
Barton and Phyllis Cohen
Irwin and Gail Cohen
Mr. and Mrs. James H. Cohen
Mr. Melvin Cohen
Mr. and Mrs. Richard A. Cohen
Mr. and Mrs. Bernard L. Cohn
Mr. and Mrs. Bertram J. Cohn
Mr. Morton Allan Cohn
Mr. and Mrs. Joseph Colaruotolo
Mr. and Mrs. Archie L. Colburn
Mr. Shane Colburn
Mr. and Mrs. Carl W. Cole
Estate of Marguerite Elizabeth Cole
Mr. and Mrs. Paul L. Cole
Mr. and Mrs. Robert Cole
Mrs. Rose M. Cole
Sue and Jim Cole
Ben and Rose Cole Charitable PRIA Foundation
Mr. and Mrs. Chase Coleman III
Mr. and Mrs. Peter Coleman
The Chase and Stephanie Coleman Foundation
Collaborative Epiphenypedyna Research Network
Mr. and Mrs. Charles F. Collard
Mrs. Ruth Anne Colley
Mrs. Wendy and Pat Collini
Ms. Carol J. Collins
Mr. and Mrs. Philip N. Collins
Mr. and Mrs. T. Jay Collins
Mr. and Mrs. Ted Collins, Jr.
Mr. William A. Collins III
Colin Cancer Coalition
Dr. and Mrs. Charles J. Colvin
Mrs. Michelle Comel and Mr. William L. Schoen
Cominsky Foundation
Commonwealth Foundation for Cancer Research
Communities Foundation of Texas
Communities of Coastal Georgia Foundation
Community Charity Advancement, Inc. dba Breast Cancer Research & Support Fund
The Community Foundation for Greater Atlanta
The Community Foundation for Northeast Florida
Community Foundation for Southeast Michigan
The Community Foundation for the National Capital Region
The Community Foundation of Abilene
Community Foundation of Acadia
Community Foundation of Greater Memphis
The Community Foundation of Louisville, Inc.
Community Foundation of North Texas
Community Foundation of South Georgia, Inc.
Concierge Services of Atlanta, Inc.
Concordia Foundation
Mr. and Mrs. Robert Condon
C-One LLC
Conejos Group Corporation
The Honorable and Mrs. Peter R. Coneway
The Coneway Family Foundation
Mr. Lewis P. Conner
Ms. Teresa Conner
Mr. and Mrs. E. A. Conley
Mr. and Mrs. John B. Connelly III
Mr. John B. Connelly IV
Mr. and Mrs. Mark M. Connelly
Ms. Nell Frances Connelly
Mr. Kevin J. Conneally
Mr. and Mrs. Jeffrey A. Connelly
Mr. and Mrs. Jim Conner
Mr. Robert Connolly
Mr. and Mrs. Robert C. Connor
Conocophillips
Conquer Cancer Foundation of the American Society of Clinical Oncology
Mr. Gregory N. Conrad
Mr. and Mrs. Oliver A. Corrads
Dr. and Mrs. Francis P. Conroy
Dr. and Mrs. Scott Conroy
The Consule General of the United Arab Emirates
Continental NHS Products
Convenience Marketing Services, Inc.
Mr. Brian Cook
Mr. and Mrs. Brian C. Cook
Mr. and Mrs. John R. Cook
Mr. and Mrs. Robert M. Cook
Mr. and Mrs. Si E. Cook
Dr. and Mrs. Thomas Edwin Cook
Mr. and Mrs. Noel Coon
Mr. and Mrs. Clifton W. Coonrod
Ms. Cheryl A. Cooper
Mr. and Mrs. Glenn D. Cooper
Cooper Oil & Gas, Inc.
Mr. and Mrs. Jerry E. Copeland
Lynn Copeland
Coastelastas, Inc.
Mr. and Mrs. Vic Corley
Loretta R. Cormier
Dr. Yvonne C. Cormier and Mr. Rufus Cormier, Jr.
Mr. and Mrs. Ron Corn
Mr. Allen Cornell
CorpTax, Inc.
Carol and Thomas Corn
Mr. and Mrs. Charles A. Correll
Corrigan Family Holdings
Corrigan Properties, Inc.
Cos Bar at Woodlands, Inc.
Ms. Carol J. Collins
Drs. Wendy and Pat Collini
Mr. and Mrs. T. Jay Collins
Mr. and Mrs. Ted Collins, Jr.
Mr. William A. Collins III

Mr. and Mrs. Donald R. Cotten
Cheryl Cotner
Ms. Carol J. Collins
Ms. Cheryl A. Cooper
Mr. and Mrs. Noel Coon
Mr. and Mrs. Robert M. Cook
Mr. and Mrs. Si E. Cook
Dr. and Mrs. Thomas Edwin Cook
Mr. and Mrs. Noel Coon
Mr. and Mrs. Clifton W. Coonrod
Ms. Cheryl A. Cooper
Mr. and Mrs. Glenn D. Cooper
Mr. and Mrs. Thomas Edwin Cook
Mr. and Mrs. Noel Coon
Mr. and Mrs. Clifton W. Coonrod
Ms. Cheryl A. Cooper
Mr. and Mrs. Glenn D. Cooper
Mr. and Mrs. Clifton W. Coonrod
Ms. Cheryl A. Cooper
Mr. and Mrs. Glenn D. Cooper

Mr. and Mrs. David A. Clay

Mr. and Mrs. David A. Clay
Endowed Distinguished Professors

BIRDIE J. AND LYDIA J. RESOPT DISTINGUISHED PROFESSORSHIP IN GASTROINTESTINAL ONCOLOGY
Robert Bresalier, M.D.

EDWARD ROTAN DISTINGUISHED PROFESSORSHIP
Aman Buzdar, M.D.

ANNIE LAURIE HOWARD RESEARCH DISTINGUISHED PROFESSORSHIP
Paul M. Cinciripini, Ph.D.

RICHARD E. HAYNES DISTINGUISHED PROFESSORSHIP FOR CLINICAL CANCER PREVENTION
Lorenzo Cohen, Ph.D.

GLORIA LUPTON TENNISON DISTINGUISHED PROFESSORSHIP IN LUNG CANCER RESEARCH
Ritsuko Komaki Cox, M.D.

CLIFTON D. HOWE DISTINGUISHED PROFESSORSHIP IN PULMONARY MEDICINE
Burton F. Dickey, M.D.

TEXAS 4000 DISTINGUISHED PROFESSORSHIP
Kim-Anh Do, Ph.D.

SOPHIE C. STEVES DISTINGUISHED PROFESSORSHIP IN CANCER RESEARCH
Cathy Eng, M.D.

HELEN SHAFER FLY DISTINGUISHED PROFESSORSHIP OF ANESTHESIOLOGY, IN HONOR OF BERTHA DAVIS-CLARK, M.D.
Thomas W. Feeley, M.D.

ABELL-HANGER FOUNDATION DISTINGUISHED PROFESSORSHIP
Bonnie S. Glisson, M.D.

THE HAMILL FOUNDATION DISTINGUISHED PROFESSORSHIP IN HONOR OF DR. RICHARD G. MARTIN, SR.
Kelly K. Hunt, M.D.

P. H. AND FAY E. ROBINSON DISTINGUISHED PROFESSORSHIP IN CANCER RESEARCH
Henry Mark Kuerer, M.D., Ph.D.

RUBY E. RUTHERFORD DISTINGUISHED PROFESSORSHIP
Zhimin Lu, M.D., Ph.D.

CHARLES M. MCBRIDE DISTINGUISHED PROFESSORSHIP IN SURGICAL ONCOLOGY
Merrick I. Ross, M.D.

EDGAR LEWIS CURTIS, SAVILLA ELIZABETH CURTIS AND ELEANOR LEWIS CURTIS DISTINGUISHED PROFESSORSHIP IN PEDIATRIC CANCER RESEARCH
Cindy L. Schwartz, M.D.

NAGUIB A. SAMAAN DISTINGUISHED PROFESSORSHIP IN ENDOCRINOLOGY
Steven I. Sherrman, M.D.

BARNTS FAMILY DISTINGUISHED PROFESSORSHIP IN CANCER RESEARCH
Maria E. Suarez-Almazor, M.D., Ph.D.

NYLENE ECKLES DISTINGUISHED PROFESSORSHIP IN BREAST CANCER RESEARCH
Naoto T. Ueno, M.D., Ph.D.

GRADY F. SAUNDERS, PH.D. DISTINGUISHED PROFESSORSHIP FOR MOLECULAR BIOLOGY
Richard D. Wood, Ph.D.

DEL AND DENNIS MCCARTHY DISTINGUISHED PROFESSORSHIP IN GASTROINTESTINAL CANCER RESEARCH
Jeffrey Morris, Ph.D.

HUBERT L. AND OLIVE STRINGER DISTINGUISHED PROFESSORSHIP IN CANCER RESEARCH
Jeffrey N. Myers, M.D., Ph.D.

N. G. AND HELEN T. HAWKINS DISTINGUISHED PROFESSORSHIP FOR CANCER RESEARCH
Hui-Lin Pan, M.D., Ph.D.

JAY AND LORI EISENBERG DISTINGUISHED PROFESSORSHIP
Vali Papadimitrioupolou, M.D.

ROBERT R. HERRING DISTINGUISHED PROFESSORSHIP IN CLINICAL RESEARCH
Shreyaskumar R. Patel, M.D.

KATHERINE RUSSELL DIXIE DISTINGUISHED PROFESSORSHIP IN PEDIATRICS
Alexander V. Prokhorov, M.D., Ph.D.

GERALD P. BODEY, SR. DISTINGUISHED PROFESSORSHIP IN INFECTIOUS DISEASE
Issam Raad, M.D.

DR. JOHN R. STROEHLEIN DISTINGUISHED PROFESSORSHIP IN GASTROENTEROLOGY
G. S. Raju, M.D.

CHARLES M. MCBRIDE DISTINGUISHED PROFESSORSHIP IN SURGICAL ONCOLOGY
Merrick I. Ross, M.D.

EDGAR LEWIS CURTIS, SAVILLA ELIZABETH CURTIS AND ELEANOR LEWIS CURTIS DISTINGUISHED PROFESSORSHIP IN PEDIATRIC CANCER RESEARCH
Cindy L. Schwartz, M.D.

NAGUIB A. SAMAAN DISTINGUISHED PROFESSORSHIP IN ENDOCRINOLOGY
Steven I. Sherrman, M.D.

BARNTS FAMILY DISTINGUISHED PROFESSORSHIP IN CANCER RESEARCH
Maria E. Suarez-Almazor, M.D., Ph.D.

NYLENE ECKLES DISTINGUISHED PROFESSORSHIP IN BREAST CANCER RESEARCH
Naoto T. Ueno, M.D., Ph.D.

GRADY F. SAUNDERS, PH.D. DISTINGUISHED PROFESSORSHIP FOR MOLECULAR BIOLOGY
Richard D. Wood, Ph.D.

As of Sept. 1, 2016

Mrs. Gail L. Dupre
Mr. and Mrs. Rob Dupree
Dr. and Mrs. Leonel D. Durbin
Mr. Robert R. Durden
Ms. Denise D. Durel
Mr. Richard S. Durham
Mr. and Mrs. Kenneth W. Dusek
Ms. Dede Dunson
Dwight Andrus Insurance
Mr. Kevin W. Dywyer
Mrs. Lois W. Dyk
Mr. and Mrs. Gregory B. Dykes
Mr. and Mrs. John Dzubinski

Mr. James B. Ellis II and Mrs. Margaret R. Brady
Mr. Ernest Ellision II
The Ellison Medical Foundation
Mr. John E. Elissor
Mr. Kyle Ellisor
The Ellwood Foundation
Mr. Ahmed El-Mahdyaw
Mr. and Mrs. Gerry M. Elphingstone, Jr.
Barry R. and Karen B. Elson and Family
Mr. Matthew B. Ely
Mr. and Mrs. Mads Emanuelse
Suter and Gayle Embry
Dr. and Mrs. Michael W. Emerson
Emerson Process Management Valve Automation
Mr. Leonard E. Erne
Emily's Power for a Cure Foundation
Mr. John Emmite
EngCanCares (USA) Foundation
Encore 3.0 CD - Southcoastern
Energy Transfer Partners LP
EnergyQuest II, LLC
Mr. George B. Eng
Engineered Air Balance Co., Inc.
Mr. and Mrs. John M. Engler
Mrs. Shirley B. Engler
Mr. and Mrs. Michael T. English
Mrs. Ann Enloe
ENT of Georgia, LLC
Employees of Entergy
EOG Resources, Inc.
EPIC
Elizabeth and Mark Epley
Mr. Richard B. Eppler
Epsilon
Susan and Bobby Epstein
Mr. and Mrs. Wayne Epstein
Equafax, Inc.
Equine Medical Associates, PA
Erinheim-Chester Disease Global Alliance
Mr. and Mrs. Earl P. Erdmann
Mrs. Cynthia Erickson
Mr. and Mrs. Sheldon R. Erikson
Dr. and Mrs. Fred Ermanian III
Emest H. Cannon & Associates
Ernst & Young, LLP
Mr. and Mrs. John Erskine
Mr. and Mrs. John W. Erwin
The Honorable and Mrs. Mark W. Erwin
Mr. Raul T. Espino
Mr. and Mrs. Wilmot J. Estes
Mr. and Mrs. Billy G. Euell, Jr.
Mrs. Ann A. Eutsler
Mr. and Mrs. Arthur Russell Evans
Parne and Roy Gene Evans
Susie and Don Evans
Dr. Tracy Bialy Evans
Mr. and Mrs. Russell L. Everett
Mr. and Mrs. James H. Everest
Mr. and Mrs. Carl B. Everett III
Mr. Eric Everett
Exxon Mobil Corporation
Linda and Simon Eyles Foundation
Mrs. Elies V. Eybrook

Mr. Carel Vernon Dunaway
Kathy Raby Dunaway
Mr. Donald G. Dunbar, Jr.
Bob and Patty Duncan and Family
Mr. and Mrs. Charles W. Duncan, Jr.
M. and Mrs. Dan L. Duncan
Mr. Donald R. Duncan

Mr. and Mrs. John H. Duncan, Jr.
Mr. and Mrs. John H. Duncan, Sr.
Mr. Robert Duncan
Mr. Robert L. Duncan
Mr. and Mrs. William G. Duncan
Dan L Duncan Family
The Duncan Genesis Foundation

Linda and Archie Durham
Mr. and Mrs. Robert A. Dunkel
The Honorable and Mrs.CASWELL J. Dunlap
Mr. Gary Dunlap
Mr. and Mrs. Andrew Dunn
Mr. and Mrs. John S. Dunn, Jr.
John S. Dunn Foundation

E
Endowed Professorships

DOCTOR R. LEE CLARK PROFESSORSHIP
Christian R. Abebe, O.V.M.

HELEN BUCHANAN AND STANLEY JOSEPH SEGER RESEARCH PROFESSORSHIP
Salahadin Abdi, M.D., Ph.D.

RANSOM HORNE, JR. PROFESSORSHIP FOR CANCER RESEARCH
Keith Baggerly, Ph.D.

THE KENNETH D. MULLER PROFESSORSHIP IN TUMOR GENETICS
Mark Bedford, Ph.D.

ASHBEL SMITH PROFESSORSHIP
Diane Bodurka, M.D.

ASHBEL SMITH PROFESSORSHIP
Paul J. Chiao, Ph.D.

MCCULLOUGH PROFESSORSHIP FOR CANCER RESEARCH
Charles S. Cleeland, Ph.D.

H-E-B PROFESSORSHIP IN CANCER RESEARCH
Patrick M. Dougherty, Ph.D.

BLANCHE BENDER PROFESSORSHIP IN CANCER RESEARCH
Madeleine Duvic, M.D.

KENNETH D. MULLER PROFESSORSHIP IN MELANOMA RESEARCH
Adel K. El-Naggar, M.D., Ph.D.

KATHRYN O’CONNOR RESEARCH PROFESSORSHIP
Ziding Feng, Ph.D.

DR. JOHN M. SKIBBER PROFESSORSHIP FOR SURGICAL ONCOLOGY
Jeffrey Gershenson, M.D.

ASHBEL SMITH PROFESSORSHIP
Peng Huang, M.D., Ph.D.

HUBERT L. AND OLIVE STRINGER PROFESSORSHIP IN MEDICAL ONCOLOGY
Nancy D. Perrier, M.D.

JANIECE AND STEPHEN A. LASHER PROFESSORSHIP
Farhad Ravandi-Kashani, M.D.

A CONVERSATION WITH A LIVING LEGEND PROFESSORSHIP
Yu Shen, Ph.D.

ANISE J. SORRELL PROFESSORSHIP
Peter F. Thall, Ph.D.

MATTIE ALLEN FAIR PROFESSORSHIP IN CANCER RESEARCH
Elizabeth L. Travis, Ph.D.

DALLAS/FORT WORTH LIVING LEGEND PROFESSORSHIP
Stephen E. Ullrich, Ph.D.

BEZIE MCGOLDRICK PROFESSORSHIP IN CLINICAL CANCER RESEARCH
Jean-Nicolas Vauthrey, M.D.

DOUGLAS E. JOHNSON, M.D. PROFESSORSHIP
Christopher G. Wood, M.D.

As of Sept. 1, 2016

Mr. and Mrs. John W. Gibson
Mr. Rex H. Gibson
Mr. and Mrs. John M. Gilley
Mr. and Mrs. McHenry Griffin, Jr.
Mr. and Mrs. Charles J. Giglio
Mr. and Mrs. Daniel M. Gilbane
Mr. Adam Gilbert
Mr. and Mrs. Doug Gilbert-Smith
Terry M. Giles and Kalli S. O’Malley
Mrs. Catherine Egan Gilet
Ms. Mary Gayle Gill
Gill Family Partnership LTD.
Mr. and Mrs. Richard F. Gillette
Mr. and Mrs. Bobby Gilham
Mr. Jack Gillis
The Gibson Longenbaugh Foundation
Ms. Jamie L. Gilmore and Mr. Erik Glasscock
Mr. and Mrs. John R. Giordano
Ms. Patricia Giordano
Mr. and Mrs. John F. Gisselbeck
Mr. and Mrs. Stan Gitlin
Mr. and Mrs. Robert T. Givens
Mr. and Mrs. Henry A. Gladstone
Mr. and Mrs. Thomas S. Glavine
Mr. and Mrs. Douglas B. Glass
Mr. Grayson Glass
Mr. and Mrs. Judy M. Glass
Ms. Rayna Glass
Mrs. Judith Glenn
Mr. and Mrs. Lanny G. Glickert
Mr. and Mrs. Donald Glickman
GLN Investments LLC
Dr. and Mrs. Gary A. Glover
GlycoMimetics, Inc.
Dr. John R. Gochnour and Mrs. Paula Ruth Gochnour
Mr. and Mrs. Bill Goddard
The Charles B. Goddard Foundation Trust
Godfather’s Pizza
Mr. Gary Godwin
Dr. and Mrs. Helmut Goepfert
Mrs. Joyce L. Goerke
Mr. and Mrs. Glenn Goertz
Mrs. Frances A. Goetz
Mr. and Mrs. Charles F. Goff
Mr. and Mrs. John C. Goff
Mr. and Mrs. Walter S. Gowing III
Mrs. Carol S. Gold
Ms. Kim Gold
Mr. and Mrs. Lawrence J. Gold
Lance Goldberg
Mr. Neil A. Goldberg
Mr. and Mrs. Robert L. Goldberg
Mr. Barry Golden
Mrs. Eileen L. Golden
Linda and Ray Golden
Barbara Segal Goldfield
Golding Barge Line, Inc.
Goldman, Sachs & Co.
Goldman Sachs Philanthropy Fund
Mr. and Mrs. Frank A. Goldsmith
Golfers Against Cancer, Inc.
Mr. and Mrs. Julio C. Gomez
Julio and Ana Gomez Foundation
Mr. Jorge Gonzales, Jr.
Mr. and Mrs. Kevin G. Gonzales
Mr. and Mrs. Adrian G. Gonzalez
Ms. Jeanie C. Gonzalez
Ms. Mayra Gonzalez
Ms. Sylvia Gonzalez
Mrs. Nancy C. Good
Good Friday Golf Tournament
Ms. Anne L. Goodman
Scott K. Goodman
Mr. and Mrs. Jimmy Goodson
Mr. and Mrs. Kenneth E. Goodson
Mr. and Mrs. Peter Goodwin
Philip and Kay Goodwin
Mr. and Mrs. William H. Goodwin, Jr.
Mr. William J. Goodwin
The Donald G. Goodwin Family Foundation, Inc.
Ms. Dorothy Goodkyonzt
Google, Inc.
Employees of Google
Vijay and Marie Goradia Charitable Foundation
Mr. and Mrs. Daniel P. Gordon
Mr. and Mrs. Sheldon Gordon
Mrs. Caroline Cole Gordy
Mr. and Mrs. Michael G. Goris
Goritz Foundation Ltd.
Mr. Nick Gosda and Mrs. Rhonda Gosda
Mr. George K. Gosko
Dr. Sandra L. Goss and Mr. Bill N. Goss
Jules D. Gosseaux Foundation, Inc.
Ms. Cathy C. Gottesfeld
Mr. and Mrs. Morris S. Gottesman
Dr. Robert G. Gottlieb
Daron and Carolyn Gowen
Mr. J. Robert Grace, Jr.
Mr. and Mrs. Nancy Grace
Mr. and Mrs. Martin Grady
Grady-White Boats, Inc.
Mr. and Mrs. Skip Graeber
Graeber Foundation
Ms. Mary Ann Graf
Mr. Larry O. Graff
Mr. Craig Graham
Mrs. Donna A. Graham
Mr. and Mrs. Robert H. Graham
Dr. and Mrs. William L. Graham
Phil and Wendy Gramm
Claire and Jeff Granberry
Mr. and Mrs. William R. Granberry
Grand Prix Charities of Houston
Grand Trunk Western Railroad Company
Merle and William Graner
Mrs. Betty L. Grant
Mary A. & Thomas F. Grasselli Endowment Foundation
Mr. and Mrs. Andrew E. Graves
Mr. and Mrs. Robert R. Graves
Mr. and Mrs. Horace A. Gray
Dr. and Mrs. Kenneth N. Gray
Mr. Richard W. Gray III
The Greater Cincinnati Foundation
Greater Horizons
Greater Houston Community Foundation
The Greater Kansas City Community Foundation
The Greater Miami Jewish Federation
Mr. and Mrs. William E. Greehey
Greehey Family Foundation
Mr. and Mrs. Charles Edward Green
Ms. Haley Green
Mr. Joe R. Green
Mr. Mark Green
Mr. and Mrs. Norman N. Green
Sherie and Robert Green
Mr. and Mrs. William H. Green, III
Mr. Dean Greenberg
Mr. and Mrs. Raymond Greenberg
Mr. Theodore S. Greenberg
Mr. and Mrs. Irving J. Greenblum
Mr. and Mrs. Jim Green
Mr. and Mrs. Michael S. Greene
The GreenTree Fund
Mr. and Mrs. Wayne A. Greenwalt
Mr. and Mrs. James F. Greer
Mr. James H. Greer
The Greening Pen Company
Ann Gregory
Mrs. Charlotte Gregory
Mr. and Mrs. Gray Gregory
Ms. Terri White Gregory
Mr. and Mrs. Clifford H. Greisen
Mr. Brett Greimilian
Mr. and Mrs. Gaynor G. Greimilian
Mr. and Mrs. Edward Greimihan
Mr. John Gretil
Mr. and Mrs. Campbell A. Griffin, Jr.
Mr. and Mrs. F. O’Neil Griffin
Mr. and Mrs. Guy W. Griffin
Linda and John Griffin
Ms. Merlene Lou Griffin
Ms. Christine R. Griffln
Billy Royce Griggs
Mr. and Mrs. Kenneth E. Grimes
Mr. and Mrs. Jimmy Grimes
Mr. and Mrs. Richard L. Groebel
Mr. and Mrs. W. David Grindle
Mr. and Mrs. Robert H. Grinnell
Mr. and Mrs. W. David Grindle
Mr. Tavis Grinnestad and Ms. Marilee Wood
Mr. Richard L. Groebel
Advance Team

The following people comprise a volunteer leadership board focused on advancing MD Anderson’s mission to eliminate cancer through community-based initiatives centered on basic science research, education and cancer prevention.

Mrs. Kasey Asarch
Mrs. Ashil R. Blumenfeld
Mr. William R. Bobbora
Mr. Brian Camney
Ms. Carolyn Chachere
Ms. Nell F. Connally
Ms. Carolyn Chachere
Mr. Brian Carney
Mrs. Ashli R. Blumenfeld

Leukemia & Lymphoma Society
Leukemia Research Foundation
Leukemia Texas, Inc.
Mr. and Mrs. J. Waymon Levell
Mr. Daniel Leventhal
Mr. John Lever
Charles and Margaret Levin Family Foundation
Mrs. Jerome Levine
Mrs. Lee Levit
Milton and Lee Levit Family
Mr. and Mrs. Dan Levetan
Mr. and Mrs. Irvin L. Levowitz
Mr. and Mrs. David Levier
Ms. Carol R. Levy
Judith M. and Irwin L. Levy
Mr. Michael R. Levy
Mr. Ralph L. Levy
Mr. Shimon Levy
The Meyer Levy Charitable Foundation/Rachel Levy Goldberg, Mara Elizabeth Levy, Tobin Janel Levit & Michael R. Levy
Mr. and Mrs. Chris W. Lewis
Mr. and Mrs. Griffith T. Lewis
Harnet Yoshida Lewis and I. Norman Lewis
Mr. and Mrs. Jack Lewis
Mr. Jerome Lewis
Mr. and Mrs. Jerome F. Lewis
Mr. and Mrs. Michael A. Lewis
Mr. and Mrs. Robert F. Lewis
Mr. Rodney Lewis
Mr. Rupert S. Lewis
Lewis Energy Group
Richard Spencer Lewis Memorial Foundation
Lexington Livestock Commission
Mr. David W. Ley
Ley Development Company, LLC
Ms. Angela Li
Yinqian Li
Employees of Liberty Mutual
Mr. Brian L. Libman
Mr. and Mrs. Robert M. Lichten
Mr. and Mrs. Cary Lichtenstein
Mr. and Mrs. Fran G. Lichtenstein
Frank Gordon Lichtenstein Foundation
Mr. and Mrs. Don B. Lichten
Mr. and Mrs. Martin J. Liddle
Ms. Emily Liddle
Mr. and Mrs. Kenneth J. Lien
Mr. Jeffrey A. Liggert
Mr. and Mrs. Don Lightfoot
Julie Lightfoot, Discovery Toys
Mr. Vincent M. Lightfoot
Captain Thomas N. Lightsey, Jr.
Tom & Betty Lightsey Family Trust
Lila Construction Company
Mr. Byung K. Lim
Mr. and Mrs. Brent L. Lowery
Mr. and Mrs. Paul B. Loyd, Jr.
The Loyd Charitable Foundation
LPL Financial Services
LSI Industries Inc.
Mr. Guanqiu Lu
Mr. and Mrs. Sheldon Lubin
The Lubrizol Foundation
Mr. and Mrs. Mark C. Lucas
Mrs. Seymour Luckoff
Ms. Elizabeth Luera
Ms. Janet M. Luu
Luminata Foundation
The Luminiscence Foundation, Inc.
Lunch Money, Inc.
Mr. Wallace L. Lundgren, Sr.
Lung Cancer Research Foundation
LUNGeVity Foundation
Ms. Jean R. Lutman
Mr. and Mrs. Ted W. Lusher
Mr. and Mrs. Homer L. Luther, Jr.
Luther King Capital Management
Mr. Bill Luybes
LVM Holdings LP
Mr. and Mrs. Robert W. Lydick
Mrs. Rosemary K. Lykos
Ms. Patricia S. Lye
Mr. and Mrs. Jeffrey L. Lyman
Lymphma Research Foundation
Mr. Francis L. Lynch
Deborah A Lyon
LyondellBasell Industries
Mr. Allan R. Lyons
Mr. David F. Lyons
Toni and David Lyons Charitable Foundation

M2 The Agency, Inc.
Mr. Tamotsu Mabuchi
Mr. and Mrs. C. Robert Mace
Ms. Vanilla Macias-Rodriguez
Mr. and Mrs. John Mack
Mr. Andrew MacKechnie
Mr. Nick MacKenzie
Mr. Bruce G. Macklin
Mr. and Mrs. John Philip Madden
Mr. and Mrs. Robert R. Madden
Mr. and Mrs. Steven H. Madden
Mr. Melvin H. Madewell
Mr. John W. Magigan
Mr. and Mrs. Richard L. Madison
Mr. and Mrs. Andrew Maebius
Mr. and Mrs. Steve F. Marfige
Mr. and Mrs. Hubert E. Magee, Jr.
Mr. Mark Magee
Mr. Frank C. Maguire, Jr.
Mr. Jim Mahler
Mr. and Mrs. Jeffrey S. Mahlmann
Mr. Brian A. Mahoney
Mr. Glen Maitrank Jr.
Mr. Edward F. Malanda
Mr. Edward J. Malek
Marlene A. and Frederic V. Malek
Mr. and Mrs. Kevin Maley
Malibu Floors
Mr. and Mrs. Jean Malo
Bob and Diane Malone
Mr. and Mrs. S. Mandell
Mr. and Mrs. Moez S. Mangali
Ms. Zein B. Mangali
Mangen Family Charitable Foundation
The Harry T. Mangurian, Jr. Foundation, Inc.
Mr. and Mrs. Harendra M. Mangodi
Mr. and Mrs. Robert M. Manley
Ms. Elizabeth Mann
Nabors Corporate Services, Inc.
Nabors Industries Ltd.
Ms. Sandy Nachman
Naegeli Transportation, Inc.
Ms. Flolyn Naegelin
Mr. and Mrs. Firozali M. Naji
Dr. Roy V. Nakamoto
Ms. Fatima Naqvi
Mr. Govind Narasimhan
National Pancreas Foundation
National Christian Foundation Houston
National Breast Cancer Foundation, Inc.
Mr. Govind Narasimhan
Ms. Fatima Naqvi
Dr. Roy Y. Nakamoto
Ms. Flolyn Naegelin
Nabors Corporate Services, Inc.
Nabors Industries Ltd.
Mr. and Mrs. Huey Morris
Mr. and Mrs. Matthew Morris
Mr. Paul L. Morris
Mr. and Mrs. Thomas C. Morris, III
Dr. and Mrs. W. T. Morris, Jr.
Morris/McCany
Ms. Carla B. Morrison
Mr. and Mrs. Chet W. Morrison
Mr. and Mrs. David G. Morrison
Mr. Kellie Jean Morrison
Mr. Tom A. Morrison IV
Morrison and Morrison, Inc.
Ms. Penny Morris
Mr. Lyle Morrow
Mr. and Mrs. David S. Morse
Jeff and Jana Morton
Morton Family Foundation
Mr. and Mrs. Charles D. Moseley, Jr.
Paula and Jon Mosle
Bill and Janis Mosley
Dr. Mark Mosley and Mrs. Kristan Mosley
Mr. Lewis Moss
Mr. and Mrs. William P. Moss
Ms. Amy Mosser
Mr. Wiley L. Mossy
The Jane P and Willey L. Mossy Jr. Foundation
Mr. Ben Motion
Ms. Kimberly Mount
Mountain Area Health Education Center, Inc.
Mr. Wayne W. Mousseau
Beverly and Jerry Mouser
Mr. Robert W. Mouton
Mr. Jim Moylan, Sr.
Mr. and Mrs. Robert C. Mueller
Mr. and Mrs. Steven L. Mueller
Mr. and Mrs. Steve Mukavitz
Lisa and Greg Mullen
Mr. and Mrs. Timothy T. Mullen
Mr. Michael I. Muller
Muller Honda
Mr. Terence Mullery
Ms. Suzanne Mulligan
Mr. and Mrs. Don R. Mullins
Mr. and Mrs. Joe C. Mullins, Jr.
Mr. and Mrs. David G. Mulock
Multiple Myeloma Research Foundation
Miniam and Jim Mulva
Susan and Pat Mulvey
Mr. and Mrs. William T. Mumford
Ms. Betty J. Munnell
Mr. Henry Munoz
Mr. Bill Munro
Munro's Dry Cleaning Company
Mr. and Mrs. Kenneth A. Munson
Mr. and Mrs. Nick Munson
Mr. and Mrs. George W. Murfee
Murfee Engineering Company, Inc.
Mrs. Louise T. Murfey
Murfey Foundation
Mt. George Murckan
Ms. Reba Murphy
Ms. Christine L. Murphy
Mr. David Murphy
Ms. Erica M. Murphy
Ms. Kashette Murphy
Mr. Larry Murphy
Dr. M. John Murphy
Ms. Martha W. Murphy and Mr. John W. "Jack" Leahy, Jr.
Mr. and Mrs. Richard J. Murphy
Murphy Oil Corporation
Mr. James D. Murray
Mr. and Mrs. Michael W. Murray
Mrs. Sally C. Murray
Mr. Stephen B. Murray
Murray Law Firm
Mr. Tony Muscarello
Mr. and Mrs. Jeff Musgrove
Mr. and Mrs. Henry G. Musselein
Mr. Eerner T. Musshorn
Mr. and Mrs. Gray H. Muzzy
Mr. Donald C. Myers
Dr. Georgia Myers and Mr. S. C. Myers
Mr. and Mrs. Jeremy B. Myers
Maxine Myers
Mr. and Mrs. Mike A. Myers
Arthur B. & Marion V. Myers Trust Fund
Myriad Genetics, Inc.
Nabors Corporate Services, Inc.
Nabors Industries Ltd.
Mr. and Mrs. Huey Morris
Mr. and Mrs. Matthew Morris
Mr. Paul L. Morris
Mr. and Mrs. Thomas C. Morris, III
Dr. and Mrs. W. T. Morris, Jr.
Morris/McCany
Ms. Carla B. Morrison
Mr. and Mrs. Chet W. Morrison
Mr. and Mrs. David G. Morrison
Mr. Kellie Jean Morrison
Mr. Tom A. Morrison IV
Morrison and Morrison, Inc.
Ms. Penny Morris
Mr. Lyle Morrow
Mr. and Mrs. David S. Morse
Jeff and Jana Morton
Morton Family Foundation
Mr. and Mrs. Charles D. Moseley, Jr.
Paula and Jon Mosle
Bill and Janis Mosley
Dr. Mark Mosley and Mrs. Kristan Mosley
Mr. Lewis Moss
Mr. and Mrs. William P. Moss
Ms. Amy Mosser
Mr. Wiley L. Mossy
The Jane P and Willey L. Mossy Jr. Foundation
Mr. Ben Motion
Ms. Kimberly Mount
Mountain Area Health Education Center, Inc.
Mr. Wayne W. Mousseau
Beverly and Jerry Mouser
Mr. Robert W. Mouton
Mr. Jim Moylan, Sr.
Mr. and Mrs. Robert C. Mueller
Mr. and Mrs. Steven L. Mueller
Mr. and Mrs. Steve Mukavitz
Lisa and Greg Mullen
Mr. and Mrs. Timothy T. Mullen
Mr. Michael I. Muller
Muller Honda
Mr. Terence Mullery
Ms. Suzanne Mulligan
Mr. and Mrs. Don R. Mullins
Mr. and Mrs. Joe C. Mullins, Jr.
Mr. and Mrs. David G. Mulock
Multiple Myeloma Research Foundation
Miniam and Jim Mulva
Susan and Pat Mulvey
Mr. and Mrs. William T. Mumford
Ms. Betty J. Munnell
Mr. Henry Munoz
Mr. Bill Munro
Munro's Dry Cleaning Company
Mr. and Mrs. Kenneth A. Munson
Mr. and Mrs. Nick Munson
Mr. and Mrs. George W. Murfee
Murfee Engineering Company, Inc.
Mrs. Louise T. Murfey
Murfey Foundation
Mt. George Murckan
Ms. Reba Murphy
Ms. Christine L. Murphy
Mr. David Murphy
Ms. Erica M. Murphy
Ms. Kashette Murphy
Mr. Larry Murphy
Dr. M. John Murphy
Ms. Martha W. Murphy and Mr. John W. "Jack" Leahy, Jr.
Mr. and Mrs. Richard J. Murphy
Murphy Oil Corporation
Mr. James D. Murray
Mr. and Mrs. Michael W. Murray
Mrs. Sally C. Murray
Mr. Stephen B. Murray
Murray Law Firm
Mr. Tony Muscarello
Mr. and Mrs. Jeff Musgrove
Mr. and Mrs. Henry G. Musselein
Mr. Eerner T. Musshorn
Mr. and Mrs. Gray H. Muzzy
Mr. Donald C. Myers
Dr. Georgia Myers and Mr. S. C. Myers
Mr. and Mrs. Jeremy B. Myers
Maxine Myers
Mr. and Mrs. Mike A. Myers
Arthur B. & Marion V. Myers Trust Fund
Myriad Genetics, Inc.
Monroe Dunaway Anderson Society


Established in 1995, the Monroe Dunaway Anderson Society recognizes individuals and families who have selected the programs at MD Anderson to benefit from a planned gift such as a bequest, life insurance policy or other similar vehicle. Listed here are new members of the society who recently named the institution in their estate plans.

Mr. Alvin F. Adams
Ms. Kimberly M. Alfonzo
Mr. M. Stephen Beard
Mr. Ray J. Belski
Mr. Richard Bennett
Mr. Hugh C. Berry, Jr.
Mr. Alec K. Bond
Mr. Frank J. Bonitati
Mr. Bruce A. Broadbent
Ms. Ena Burlingham
Ms. Hultis O. Carlson
Mr. and Mrs. Candy Castle
Mr. Irwin M. Cohen
Mr. Donald P. Dampf
Mrs. Mary Victoria Damsgaard
Mrs. Clemence Alice Deane
Mr. Hall J Debusk
Mr. Raymond H. Eaves
Myra Eilenberg Trust
Mr. Donald F. Fisher
Mrs. Helen H. Fourmy
Mrs. Marguerette Frederick
Mr. William A. Frumovitz
The Honorable Bruce S. Gelb
Mr. Robert M. Hanley
Mr. Paul B. Hirschi
Mr. Randall Howard
Mrs. Adeline D. Hudson
Mr. Herbert L. Ingram
Mr. Jerry Irwin
Dr. Marilyn E. Johnson
Ms. Mary B. Kite
Ms. Lucy Lane
Mr. Bruce E. Latimer
Mr. Charles Lemoine

Mr. Val L. Lofgren
Mr. John E. Manzione
Mr. Robert J. Mathews
Ms. Janice C May
Ms. Nancy J Meyers
Ms. Laura McNemar
Mr. Kenneth K. Mercer
Mr. Carlton Moffett
Ms. Joan Morgenstern
Ms. Rosa Pennick
Ms. Joyce L. Phillips
Ms. Linda L. Pirtle
Mrs. Kathy D. Plaeger
Mrs. Gretchen Pressburg
Ms. Paralee Price
Major General Jack W. Ramsaur II
Ms. Mary F. Rich
Mr. William J. Roberson, Jr.
Ms. Martha Rolinson
Mr. Donald Cameron Ross
Mr. Andrew E. Sabin
Mr. Michael J. Schimberg
Ms. Lucy L. Sharp
Marvin Silverman Trust
Sheila Silverman Trust
Harry J. Skefes
Mr. Allen L. Smith
Mr. Terry Speed
Mrs. Lily Stark
Ms. Mickey Stern
Dr. Robert S. Toth
Ms. Verna J. Turpin
Ms. Lori D. Valentci
Mr. Jerry M. Waldschmidt
Ms. Doris E. Zagon
Andrew Sabin Family Foundation
Mr. and Mrs. Scott Charles Saenger
Ms. Theron D. Sage
Sage Patient Advocates
Sagis, PLLC
Ms. Moni S. Saggio
Mrs. Frances M. Saladin
Mr. Luis Salas
Mr. and Mrs. Franklin G. Salazar
Mr. Louis Salasal
Salerno Baptist Church
Mr. and Mrs. Alan J. Sales
Ms. Margaret Saliba
Sally K. Ride Elementary School
Mr. and Mrs. Philip Salazar
Mr. and Mrs. Rodney Salvaggio
Mr. Victor E. Salvinio
Mr. and Mrs. Michael S. Samis
Dr. and Mrs. Barry I. Samuels
Mrs. Betty Claire Samuels
Mrs. Marie R. Samuels
Mr. and Mrs. Michael Samulin
San Antonio Area Foundation
Mr. and Mrs. Adalio T. Sanchez
Mrs. Caroline B. Sanders
Mr. and Mrs. Harold H. Sanders
Dr. Sherri Lynn Sanders
Mr. and Mrs. Ronald P. Sandmeyer, Jr.
Mr. and Mrs. Patrick B. Sands
Mrs. Cindy Sanford
Sanoft-Aventis U.S. Charitable Trust
Mr. Luis Carlos Sarmiento
Mrs. Luz Angela Sarmiento and Mr. Antonio Ardid
Mr. and Mrs. Christopher Sarofim
Mr. Faye Z. Sarofim
Mr. and Mrs. John Sarraf
Mr. and Mrs. Laurence R. Saslaw
Mr. and Mrs. Trebes Sasser
Mr. and Mrs. Tom Sauer
The Saudi Arabian Cultural Mission
Judy and Henry Sauer
Mr. and Mrs. Hugh H. Saum III
Mr. and Mrs. Dan C. Savage
Mrs. Una Savaie
Mr. and Mrs. Wayne Sayatovic
Mr. Dennis Sbacs
SBBS Law PLLC
Mr. John F. Scarborough
Ivy and Joe Scarpinato
Mr. and Mrs. Stephen Schaar
Mr. and Mrs. Donald J. Schade
Mr. and Mrs. Jamie Schade
Leah R. & Alfred E. Schafer Charitable Foundation
Mr. and Mrs. Christopher Schaffer
Mr. Jerry R. Scheer
Mr. and Mrs. Steven E. Scheer
Mr. and Mrs. Rud E. Scheidt, Jr.
David and Amy Scheihagen
Mr. and Mrs. Brad A. Scherer
Mr. and Mrs. William R. Scherer, Jr.
Mr. and Mrs. Robert Schueer
Bob and Patricia Schieber
J. Thomas and Susanne Schieffer
Mr. and Mrs. Bobbie E. Schiel
Schiel B-R-C-B-B-L Foundation Inc.
Dennis and Dorothy Schiffler
Mr. and Mrs. Herbert E. Schilling II
Estate of Michael J. Schimmel
Mr. Donald T. Schlahtman
Dr. and Mrs. Russell H. Schlahtman II
Mr. and Mrs. Thomas A. Schlegle, Jr.
Ms. Carla K. Schlemmer
Mr. and Mrs. Pierre M. Schluumberg
Schluumberg Technology Corporation
Dr. and Mrs. Walter R. Schmeal
Ms. Susanne M. Schmelz
Mr. Alexander Schmidt
Ms. Leslie A. Schmidt
Mr. and Mrs. Paul B. Schmidt
Mr. and Mrs. Richard W. Schmidt
Dr. Schmitt
Mr. and Mrs. Mark Schmitz
Mr. and Mrs. Henry T. Schneckeley
Mr. and Mrs. Charles W. Schneider
The Honorable Harvey Schneider and Mrs. Marilyn Lee Schneider
Mr. and Mrs. Jay R. Schneider
Mr. and Mrs. Michael Schneider
Mr. and Mrs. Robert W. Schneider
Trey and Debi Schneider
Schneider Electric USA, Inc.
Schneider Family Fund of the Jewish Communal Fund
Mr. and Mrs. David Schnell
Joan Weingarten Schnitzer
Cynthia Schoeller
Ms. Pamela B. Schoen
Mr. Carl Schoener
Dr. Myron Scholes
Susan and David Scholes
Mr. and Mrs. Jack W. Scholl
Dr. and Mrs. Don F. Schomer
Mr. Kurt E. Schon
The Schoen Charitable Foundation
Mr. and Mrs. John D. Schofield
Mr. and Mrs. Richard D. Schreiber
Mrs. Sandra S. Schremp
Mr. Andrew C. Schroeder
Mr. and Mrs. Fred Schroeder
Mr. LeRoy H. Schulz, Jr.
Mr. and Mrs. Leo R. Schuster, Jr.
Joan & Leo Schuster Charitable Trust
Schaub Charitable Fund
Mr. Roger W. Schwandtner
Ms. Catherine M. Schwartz
Mr. and Mrs. Joseph M. Schwartz
Ms. Marjene J. Schwarz
Mr. and Mrs. John F. Schwarz
Alan and Marilyn Schwedel
Mr. John C. Schweitzer
Ms. Carole R. Scifani
Mr. Marc S. Scifani
Scleroderma Foundation
Dr. Annette Scott
Mr. and Mrs. Bill Scott
Dr. David W. Scott
Mr. and Mrs. Dwight Scott
Mr. and Mrs. Gerald L. Scott
Mr. and Mrs. James W. Scott
Neal and Sally Scott
Mr. Thomas D. Scott
The Thomas H. and Mayme P Scott Foundation, Inc.
Scott Universal Foundation, Inc.
Mr. and Mrs. Nick Scotto
Scipps Howard Foundation
Kim and Jeff Scrivener
Mr. and Mrs. Philip L. Scudder
Scurlock Foundation
Mrs. Saralyn C. Sears
Mr. and Mrs. William A. Sears
Ms. Sue H. Secker
Securit Metal Products Co.
Seekers Foundation
Mr. and Mrs. Elliot M. Segal
SEI Energy, LLC
Mr. and Mrs. Philip W. Seidenberger
Arnold and Janice Seidule
Mr. and Mrs. Michael J. Seiler
Mr. Terry Seitz
Mr. and Mrs. Peyton M. B. Self III
Self Foundation
Dr. Veronica Selinko-Curran and Mr. Michael F. Curran
Mr. and Mrs. Jerome Seila
Ms. Lauren Sella
Karen Abrahamson Selzer and John Scott
Podsednik
Seneca Resources Corp.
Mrs. Lindi Kooze Senez
David Senez Jr. Foundation
Sensient Technologies Foundation Inc.
Seperatic Hospital Fund
September
Serene LLC
Dr. and Mrs. Antonio C. Serra IV
Mr. and Mrs. Vernon A. Sevier, Jr.
Mr. and Mrs. Collin Sewell
Peggy and Carl Sewell
Sewell Village Cadillac
Mr. and Mrs. Nasser Shadparvar
Mr. and Mrs. Mel A. Shaftel
Shah Smith & Associates, Inc.
Mr. and Mrs. Lamar Shane, Jr.
Mrs. Abie Shanks
Mr. Jeff Shannon
Ms. Kerry A. Shannon and Mr. Steve Byrne
Dr. and Mrs. Tzu-Fann Shao
Marc and Jenny Shapiro
Mr. Steven J. Shapiro
Steve and Trish Shapiro Family Foundation
Mr. and Mrs. Rich Shappard
Mr. and Mrs. Mehrdad Shariari
Ms. Catherine A. Sharkey
Mary and Patrick Sharkey
Estate of Lucy Lane Sharp
Mr. and Mrs. Richard C. Sharp
Mr. and Mrs. James A. Shaunessy
Mr. and Mrs. Paul J. Shaunessy
Mr. Scott Shaver
Beth and David Shaw
Mr. Donald Shaw
Mr. and Mrs. Kelton Shaw
John and Dorothy Shea
Mr. David B. Shealy
Mr. and Mrs. Scott Sheean
Ms. Karen K. Shebab
Mr. and Mrs. Charles E. Sheedy
The Shedy Foundation
Mrs. Nancy H. Sheehan
Mr. and Mrs. Myron M. Sheinfeld
Shell Oil Company
Employees of Shell Oil Company
Shell Oil Company Foundation
Mrs. Beatrice M. Shelly
James E. Shelly Family Trust
Mr. Charles B. Shelton III
Mr. James D. Shelton
Mr. Robert J. Shelton
Sherling Concepts
Mr. and Mrs. Joseph J. Themenski
Mr. Sam Shemper
Shep F. Corneaux, CPA, MBA & Associates
Mr. and Mrs. Stanley O. Sherer
Mr. and Mrs. Lewis M. Sherer
Mr. and Mrs. Donald C. Sherman
Mr. and Mrs. George V. Sherman, Jr.
Mr. and Mrs. Jeff Sherrick
Mr. and Mrs. Richard Sherry
Mr. and Mrs. Austin Sherwood
Mr. Joseph A. Shevski
Mrs. Francis A. Shields
Mr. and Mrs. John H. Shields III
Ms. Shirleyan
Ms. Sogand Shojda
Mr. and Mrs. Derek W. Shoobridge
Mr. and Mrs. Timothy P. Shock
Shooting for a Cure
Ms. Jennifer L. Shufelt
Ms. Patricia Shure
Mr. Paul J. Sides, Jr.
Mr. and Mrs. Anna Siewerth
Mr. and Mrs. John J. Sie Foundation
Munefi S. Siebert Foundation
Bobb and Gary Siegel
Bobb and Gary Siegel Family Foundation of the
Jewish Community Foundation of New Mexico
Sigma Phi Epsilon Fraternity - Texas Delta
Signature Real Estate Services, Inc.
Mr. Leonard L. Signeski
Mr. Robert E. Sites
Ms. Sue C. Sites
Mr. and Mrs. Ronald Silber
Silicon Valley Community Foundation
Mr. Ebed M. Silv
Dr. and Mrs. Bernard Silver
Silver Eagle Distributors
Marvin Silverman Trust
Sheila Silverman Trust
Mr. and Mrs. Larry Silverstein
Mr. and Mrs. Randy Smt
Ms. Suzy Smay
Ms. Shannon H. Simke
Mrs. Annette C. Simmons
Ellen C. L. Simmons and Family
Mr. and Mrs. James A. Shaunessy
Mr. Scott Shaver
Beth and David Shaw
Mr. Donald Shaw
Mr. and Mrs. Kelton Shaw
John and Dorothy Shea
Mr. David B. Shealy
Mr. and Mrs. Scott Sheean
Ms. Karen K. Shebab
Mr. and Mrs. Charles E. Sheedy
The Shedy Foundation
Mrs. Nancy H. Sheehan
Mr. and Mrs. Myron M. Sheinfeld
Shell Oil Company
Employees of Shell Oil Company
Shell Oil Company Foundation
Mrs. Beatrice M. Shelly
James E. Shelly Family Trust
Mr. Charles B. Shelton III
Mr. James D. Shelton
Mr. Robert J. Shelton
Sherling Concepts
Mr. and Mrs. Joseph J. Themenski
Mr. Sam Shemper
Shep F. Corneaux, CPA, MBA & Associates
Mr. and Mrs. Stanley O. Sherer
Mr. and Mrs. Lewis M. Sherer
Mr. and Mrs. Donald C. Sherman
Mr. and Mrs. George V. Sherman, Jr.
Mr. and Mrs. Jeff Sherrick
Mr. and Mrs. Richard Sherry
Mr. and Mrs. Austin Sherwood
Mr. Joseph A. Shevski
Mrs. Francis A. Shields
Mr. and Mrs. John H. Shields III
Ms. Shirleyan
Ms. Sogand Shojda
Mr. and Mrs. Derek W. Shoobridge
Mr. and Mrs. Timothy P. Shock
Shooting for a Cure
Ms. Jennifer L. Shufelt
Ms. Patricia Shure
Mr. Paul J. Sides, Jr.
Mr. and Mrs. Anna Siewerth
Mr. and Mrs. John J. Sie Foundation
Munefi S. Siebert Foundation
Bobb and Gary Siegel
Bobb and Gary Siegel Family Foundation of the
Jewish Community Foundation of New Mexico
Sigma Phi Epsilon Fraternity - Texas Delta
Signature Real Estate Services, Inc.
Mr. Leonard L. Signeski
Mr. Robert E. Sites
Ms. Sue C. Sites
Mr. and Mrs. Ronald Silber
Silicon Valley Community Foundation
Mr. Ebed M. Silv
Dr. and Mrs. Bernard Silver
Silver Eagle Distributors
Marvin Silverman Trust
Sheila Silverman Trust
Mr. and Mrs. Larry Silverstein
Mr. and Mrs. Randy Smt
Ms. Suzy Smay
Ms. Shannon H. Simke
Mrs. Annette C. Simmons
Ellen C. L. Simmons and Family
Since its inception in 1989, The Anderson Assembly has recognized those whose support and financial contributions have enabled MD Anderson’s continued growth and progress. Listed here are members who have committed $1 million or more through cash gifts, documented cash pledges, irrevocable planned gifts and/or charitable remainder trusts to support MD Anderson programs.

Mr. and Mrs. Jerry Abbott
Addi’s Faith Foundation
Dr. Miniam & Sheldon G. Adelson Medical Research Foundation
Mr. and Mrs. Avinash C. Ahuja
Mr. and Mrs. Mark W. Albers
Joan and Stanford Alexander
Mr. and Mrs. Albert B. Alkek
American Brain Tumor Association
American Cancer Society
Amgen, Inc.
Homer Ammann Trust
Andarko Petroleum Corporation
Estate of June Carol Anderson
M. D. Anderson Foundation
Mrs. Rita Anderson
Mr. and Mrs. Barry G. Andrews
Apache Corporation
James B. & Lois R. Archer Charitable Foundation
Laura and John Arnold Foundation
AstraZeneca LP
Avon Foundation for Women
Mr. and Mrs. James A. Baker, III
Mr. and Mrs. Perry R. Bass
Paul Beck
Robert A. and Renee E. Beller Foundation
Estate of Gwinn C. Blair
Mr. and Mrs. Jack S. Blanton, Sr.
Dr. Eric Bodin and Pat Hewlett Bodin
The Bosarge Family Office
Breast Cancer Research Foundation
Bristol-Myers Squibb Company
Bristol-Myers Squibb Oncology
The Broach Foundation for Brain Cancer Research
Mrs. Elaine Brooks
Mr. and Mrs. Henry T. Brooks
Mr. Kyle C. Brooks
Mr. and Mrs. Howard Sinor, Jr.
SIR Foundation
Mr. and Mrs. Eric C. Siggo
Mr. and Mrs. Steve Simon
Mr. and Mrs. John J. Selzer
Ms. E. R. Sisson
SIUT North America, Inc.
Mr. Bill Spurrier
SK Foundation
Mr. Mark Skaggs
Mr. and Mrs. Millard L. Skaggs
Mr. and Mrs. Michael B. Skalka
Mr. and Mrs. Harry J. Skelos
Mr. and Mrs. Damir S. Skerli
Mr. and Mrs. James W. Skidmore
Ms. Lillian Susan Skiles
Ms. Marilise C. Skinner
Mr. and Mrs. Richard H. Skinner
Dr. Jared L. Sklar
Mr. and Mrs. Cory Slaughter
Mr. and Mrs. Denya R. Slater, Jr.
Mr. and Mrs. Gene Sledge
Mr. and Mrs. Jack W. Slagle
Mr. and Mrs. Steven Sletten
Mr. and Mrs. William T. Slick, Jr.
Alan B. Stiffka Foundation
Mr. and Mrs. Michael L. Slive
Mr. and Mrs. Melvin Sloan
Mr. and Mrs. Albert H. Small
Small Army For A Cause, Inc.
Don and Lori Smart
Mr. and Mrs. Frank M. Smeal
Ms. Alice U. Smith
Mr. and Mrs. Barry J. Smith
Mr. Bruce C. Smith
Mr. and Mrs. Bruce H. Smith
Mr. and Mrs. Bubba Smith
Mrs. Catherine C. Smith
Mr. Charles Aubrey Smith, Jr.
Mr. and Mrs. Darrell Smith
Mr. and Mrs. David H. Smith
Mr. Edwin Bomer Smith
Mr. and Mrs. Forrest M. Smith
Mr. Franklin R. Smith
Gaylyn and Larry Smith
Mr. and Mrs. Harvey W. Smith, Jr.
J. Chance Smith
Dr. and Mrs. James A. Smith
Mr. Jon Q. Smith
Mrs. Jimmie Miller Smith
Mr. Karl Russell Smith, Jr.
Mr. Kenneth James Smith
Mr. and Mrs. L. R. Smith
Mr. Larry Smith
Larry J. and Marsha Smith
Mr. Lawrence L. Smith
Mr. Louis E. Smith
Mrs. Lynn Smith
Mr. and Mrs. Mark D. Smith
Mr. and Mrs. Michael A. Smith
Onnie Leah Smith
Mr. and Mrs. Paul H. Smith
Mr. Randlow Smith
Mr. Robert G. Smith, Jr.
Mr. and Mrs. Robert L. Smith
Mrs. Shirley Ann Smith
Mr. Stephen F. Smith
Mr. and Mrs. Steven M. Smith
Mr. Stuart H. Smith
Mr. Terence J. Smith
Mr. and Mrs. W. Brett Smith
Ryan Smith ACC Cancer Research Foundation
Clara B. & W. Aubrey Smith Charitable Foundation
Vivian L. Smith Foundation
The William A. and Madeline Welder Smith Foundation
Mr. Gerrit J. Smitskamp
Mr. and Mrs. Mark S. Smock
Mr. Paul N. Smolen
Mrs. Barbara Harab Smolowitz
Mr. and Mrs. James T. Smythe
J & Smythe Family, LLC
Mr. and Mrs. Malcolm Sneed III
Mr. and Mrs. Thomas M. Snell
Mr. James Stephen Snider
Mr. and Mrs. Currin Snipes
Mr. and Mrs. J. Dudley Snyder
Mrs. Joan M. Snyder
Mr. John C. Snyder
Ms. Rosanna Snyder
Mr. and Mrs. Roy Snyder
Ms. Ruth Snyder
G. Whitney Snyder Charitable Fund
Mr. Robert Sobczak
Mr. and Mrs. Robert E. Socia
Social and Environmental Entrepreneurs, Inc.
Mr. and Mrs. Robert E. Socia
G. Whitney Snyder Charitable Fund
Mr. and Mrs. Roy Snyder
Ms. Rosanna Snyder
Mr. John C. Snyder
Estate of Lillian C. Koehler
Mr. and Mrs. David H. Koch
Estate of Lillian C. Koehler
Susan G. Komen Breast Cancer Foundation
Saranne and Livingston Kosberg
The State of Kuwait
Mr. and Mrs. William Kyte
Estate of Emma Lou Lancaster
Estate of Nathan W. Lassiter
Helen H. Laughery
Mrs. Theodore N. Law
Mr. and Mrs. C. Berdon Lawrence
Sun Lee, CRNA
Mr. and Mrs. Howard Lester
Leukemia & Lymphoma Society
Mr. and Mrs. Milton Levit and Family
Rochelle and Max Levit
Mr. and Mrs. Jack Lewis, Jr.
Mr. and Mrs. Thomas C. Liebman
LIVESTRONG
Mr. and Mrs. John T. Lockton, III
The Gillson Longenbaugh Foundation
The Longwell Family Foundation/Norma and Harry Longwell
Mr. and Mrs. Ben F. Love
Mr. Jho Low/Jynwel Charitable Foundation Limited
LUNGevity Foundation
The Lustgarten Foundation
Lymphoma Research Foundation
LyondellBasell Industries
The Harry T. Mangurian, Jr. Foundation, Inc.
Jed Manocherian
Marathon Oil Corporation
The G. Harold and Leila Y. Mathers Charitable Foundation
M. D. Matthews Foundation
The Mayer Family
Maynard Family Foundation
Lovry and Peggy Mays
Del and Dennis McCarthy
Red and Charline McCombs
John P McGovern Foundation
The Robert and Janice McNair Foundation
Mr. and Mrs. Charles D. McVean
J. Ralph and Lillian H. Meadovs
Melanoma Research Alliance
Mr. and Mrs. LeRoy Melcher
Mr. and Mrs. Allen A. Meyer
Estate of Anne W. McGraw Midgley
Mr. and Mrs. George P. Mitchell
Estate of A. Clifton Mock
W. A. “Tex” and Deborah Moncrief, Jr.
Monteleone Family Foundation
Estate of Mary E. Montrose
Jean H. and Jerry J. Moore
Estate of Louise J. Moran
Estate of Frances Morse
The Honorable and Mrs. Robert A. Mosbacher, Sr.
Ralph E. and Virginia Mullin
Multiple Myeloma Research Foundation
Mr. and Mrs. James J. Mulva
Estate of Wanda L. Munry
Ms. Sara Brown Musselman
National Breast Cancer Foundation, Inc.
National Foundation for Cancer Research
The Robert R. and Kay M. Onstead Foundation
The John M. O’Quinn Foundation
The Ovarian Cancer Research Fund
Elsa U. Pardee Foundation
Ray Park and Family
The Parker Foundation
Pennzoil-Quaker State Company
Phillips 66
Mr. T. Boone Pickens
Mr. Hanns Pielenz
Mr. Gene Rainbolt
Jack and Beverly Randall
The Randall Foundation
Bernard and Audre Rapoport
Ms. Judi A. Rees
The Reynolds and Reynolds Company
RGK Foundation
Sid W. Richardson Foundation
Rising Tide Foundation
Corbin J. Robertson and Wilhelmina C. Robertson Smith
Mr. and Mrs. James C. Roe
Ben, Julie, and Regina Rogers
Mr. T. Gary Rogers
Dr. Marnie Rose Foundation
Estate of David Rosenstone
Rotary Club of Houston Foundation, Inc.
The Jerry and Maury Rubenstein Foundation
Damon Runyon Cancer Research Foundation
Mr. Andrew E. Sabin
Dr. Raymond and Beverly Sackler
Mr. and Mrs. Federico Sada
Samsung Electronics America, Inc.
The A. R. “Tony” and Maria J. Sanchez Family Foundation
SBC Foundation
Schecter Family Foundation
Scherling-Plough Corporation
Estate of Gene Schulze
Estate of Dr. Sam Schwartzberg
Mr. Solon Scott, III
Mr. Thomas D. Scott
Scurlock Foundation
Peggy and Carl Sewell
Estate of Jeanne F. Shelby
Shell Oil Company Foundation
Cecil P. and Anna C. Simpson
Clara B. and W. Aubrey Smith Charitable Foundation
Estate of Mowry Smith, Jr.
R. E. “Bob” and Vivian L. Smith
The William A. and Madeline Welder Smith Foundation
Mrs. Terry Sonnevil
Ron and Ytcha Stading
Mr. and Mrs. Charles W. Stiefel
The Sunderland Foundation
The Weingarten Schnitzer Family
Ms. Donna Arp Weitzman and Mr. Herbert D. Weitzman
The Robert A. Welch Foundation
Neva and Wesley West Foundation
E. L. Wiegand Foundation
Harry Carothers and Olga Keith Wiss
J. Brooks Williams
Mr. and Mrs. John Eddie Williams, Jr.
Mrs. Margaret Aikek Williams
Mr. and Mrs. Melvyn L. Wolff
The Wortham Foundation, Inc.
Karen Buchwald Wright
WWWW Foundation, Inc. (QuadW)
Mr. and Mrs. Oscar S. Wyatt, Jr.
The Anne and Henry Zarrow Foundation
Sunoco LP
Mr. and Mrs. David M. Talla
Ms. Electa C. Taylor
Dr. and Mrs. John C. W. Taylor
T.L.L. Temple Foundation
Tenneco Inc.
Texas 4000 For Cancer
Texas Federation of Business and Professional Women’s Clubs, Inc.
William G. and Dorothy K. Theisinger
Mr. and Mrs. Jon L. Thompson
Timken Foundation of Canton
Tony’s Prostate Cancer Research/Tony Masraff
Mrs. Shirley W. Toomim
Mr. and Mrs. Morton L. Topfer
Triumph Over Kid Cancer Foundation
Estate of Harold L. Tull
Beverly and John Turner
Herbert H. and Katharine Moore Unsworth
The V Foundation For Cancer Research
Vale-Ashe Foundation
Mr. and Mrs. J. Virgil Waggoner
Ms. Lindsay Lavine Webster
Mr. William M. Webster IV
The Weingarten Schnitzer Family
Ms. Donna Arp Weitzman and Mr. Herbert D. Weitzman
The Robert A. Welch Foundation
Neva and Wesley West Foundation
E. L. Wiegand Foundation
Harry Carothers and Olga Keith Wiss
J. Brooks Williams
Mr. and Mrs. John Eddie Williams, Jr.
Mrs. Margaret Aikek Williams
Mr. and Mrs. Melvyn L. Wolff
The Wortham Foundation, Inc.
Karen Buchwald Wright
WWWW Foundation, Inc. (QuadW)
Mr. and Mrs. Oscar S. Wyatt, Jr.
The Anne and Henry Zarrow Foundation
This historical listing reflects the original names of individuals, foundations and corporations as they were brought into The Anderson Assembly.
Fiscal Year 2016 financial and statistical data
## Sources of revenue

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross patient revenue (includes inpatient, outpatient and professional services)</td>
<td>$6,144,132,636</td>
<td>$6,582,112,827</td>
<td>$6,994,996,215</td>
<td>$7,567,179,285</td>
<td>$7,571,426,899</td>
</tr>
<tr>
<td>Deductions from gross patient revenue&lt;sup&gt;1&lt;/sup&gt;</td>
<td>3,185,346,342</td>
<td>3,403,247,816</td>
<td>3,859,313,782</td>
<td>3,935,319,324</td>
<td>4,044,324,615</td>
</tr>
<tr>
<td><strong>Net patient revenue</strong></td>
<td><strong>$2,958,786,294</strong></td>
<td><strong>$3,178,865,011</strong></td>
<td><strong>$3,335,682,434</strong></td>
<td><strong>$3,631,859,960</strong></td>
<td><strong>$3,527,102,284</strong></td>
</tr>
<tr>
<td>Restricted grants and contracts, philanthropy</td>
<td>$426,455,579</td>
<td>$505,144,559</td>
<td>$421,761,275</td>
<td>$402,702,183</td>
<td>$466,883,217</td>
</tr>
<tr>
<td>State-appropriated general revenue</td>
<td>170,383,019</td>
<td>154,562,093</td>
<td>185,393,182</td>
<td>187,350,746</td>
<td>201,848,484</td>
</tr>
<tr>
<td>Auxiliary income&lt;sup&gt;2&lt;/sup&gt;</td>
<td>36,957,473</td>
<td>40,674,618</td>
<td>41,502,690</td>
<td>44,808,473</td>
<td>42,462,462</td>
</tr>
<tr>
<td>Other income&lt;sup&gt;3&lt;/sup&gt;</td>
<td>56,151,131</td>
<td>75,564,178</td>
<td>99,702,455</td>
<td>107,422,200</td>
<td>112,515,085</td>
</tr>
<tr>
<td>Investment and other non-operating income</td>
<td>87,098,290</td>
<td>180,428,432</td>
<td>328,881,907</td>
<td>121,624,475</td>
<td>129,632,830</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td><strong>$3,735,831,786</strong></td>
<td><strong>$4,135,238,891</strong></td>
<td><strong>$4,412,923,943</strong></td>
<td><strong>$4,495,768,037</strong></td>
<td><strong>$4,480,444,361</strong></td>
</tr>
</tbody>
</table>

<sup>1</sup> Amounts discounted from established rates as a result of agreements with third-party payors, including Medicare, Medicaid and insurance companies. Also includes deductions associated with indigent care and bad debt.

<sup>2</sup> Funds received from parking fees, valet services, dining facilities, hotel charges, gift shop sales and vending-machine sales

<sup>3</sup> Includes tuition and student fees, Children’s Art Project sales, management fees and other sources

### Sources of revenue (in millions)

- **$3,527.1** Net Patient Revenue | **78.7%**
- **$466.9** Restricted Grants and Contracts, Philanthropy | **10.4%**
- **$201.8** State Appropriated General Revenue | **4.5%**
- **$42.4** Auxiliary Income | **0.9%**
- **$129.6** Investment and Other Non-Operating Income | **2.5%**
- **$112.5** Other Income | **2.9%**

---

<sup>1</sup> Amounts discounted from established rates as a result of agreements with third-party payors, including Medicare, Medicaid and insurance companies. Also includes deductions associated with indigent care and bad debt.

<sup>2</sup> Funds received from parking fees, valet services, dining facilities, hotel charges, gift shop sales and vending-machine sales

<sup>3</sup> Includes tuition and student fees, Children’s Art Project sales, management fees and other sources
### Uses of revenue

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Instruction, academic support and public service</td>
<td>164,580,132</td>
<td>209,633,502</td>
<td>195,958,981</td>
<td>225,871,577</td>
<td>234,488,229</td>
</tr>
<tr>
<td>Patient care</td>
<td>1,880,230,560</td>
<td>2,013,554,826</td>
<td>2,065,617,566</td>
<td>2,369,972,993</td>
<td>2,642,145,329</td>
</tr>
<tr>
<td>Facilities and depreciation</td>
<td>460,445,328</td>
<td>471,335,938</td>
<td>486,793,306</td>
<td>508,973,014</td>
<td>550,277,895</td>
</tr>
<tr>
<td>Institutional support, auxiliary and other*</td>
<td>280,844,123</td>
<td>305,390,616</td>
<td>312,865,408</td>
<td>155,828,553</td>
<td>158,060,132</td>
</tr>
<tr>
<td>Allocation to capital plan (For future projects to replace and improve facilities and technology)</td>
<td>402,895,083</td>
<td>546,059,455</td>
<td>729,743,895</td>
<td>566,878,529</td>
<td>207,532,714</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td>$3,735,831,786</td>
<td>$4,135,238,891</td>
<td>$4,412,923,943</td>
<td>$4,495,768,037</td>
<td>$4,480,444,361</td>
</tr>
</tbody>
</table>

### Uses of revenue (in millions)

- **Patient Care**: $2,642.1 (59.0%)
- **Facilities and Depreciation**: $550.3 (12.3%)
- **Institutional Support, Auxiliary and Other***: $158.1 (3.5%)
- **Research**: $687.9 (15.4%)
- **Allocation to Capital Plan**: $207.5 (4.6%)
- **Instruction, Academic Support and Public Service**: $234.5 (5.2%)

### Gross revenue by payor classification (in millions)

- **Medicaid**: $211.0 (2.8%)
- **Medicare**: $2,800.4 (37.0%)
- **Other (International/Self Pay/Other)**: $327.5 (4.3%)
- **Indigent**: $52.9 (0.7%)
- **Managed Care**: $4,179.6 (55.2%)

---

* Includes support for parking, food and gift shop services, as well as general institutional support (e.g. information technology, human resources, administration, development activities, etc.)
## Clinical profile

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital admissions</td>
<td>26,726</td>
<td>27,905</td>
<td>27,761</td>
<td>28,167</td>
<td>27,391</td>
</tr>
<tr>
<td>Patient days</td>
<td>191,735</td>
<td>202,553</td>
<td>202,636</td>
<td>202,483</td>
<td>198,080</td>
</tr>
<tr>
<td>Average daily census</td>
<td>536</td>
<td>569</td>
<td>571</td>
<td>574</td>
<td>561</td>
</tr>
<tr>
<td>Average length of stay</td>
<td>7.2</td>
<td>7.3</td>
<td>7.3</td>
<td>7.2</td>
<td>7.2</td>
</tr>
<tr>
<td>Average number of inpatient beds</td>
<td>616</td>
<td>635</td>
<td>654</td>
<td>665</td>
<td>661</td>
</tr>
<tr>
<td>Outpatient clinic visits, treatments, procedures</td>
<td>1,281,489</td>
<td>1,338,706</td>
<td>1,363,008</td>
<td>1,440,684</td>
<td>1,404,329</td>
</tr>
<tr>
<td>Pathology/laboratory medicine procedures</td>
<td>11,619,591</td>
<td>11,718,405</td>
<td>12,005,766</td>
<td>12,334,917</td>
<td>12,073,679</td>
</tr>
<tr>
<td>Diagnostic imaging procedures</td>
<td>497,660</td>
<td>501,887</td>
<td>523,297</td>
<td>530,590</td>
<td>524,044</td>
</tr>
<tr>
<td>Surgery hours</td>
<td>66,241</td>
<td>70,221</td>
<td>69,506</td>
<td>69,987</td>
<td>67,936</td>
</tr>
<tr>
<td>Total active clinical protocols</td>
<td>1,078</td>
<td>1,065</td>
<td>1,101</td>
<td>1,197</td>
<td>1,202</td>
</tr>
</tbody>
</table>

### Workforce

- **21,119** total employees
- **1,711** faculty
- **953** onsite trained volunteers
- **2,146** offsite myCancerConnection trained survivor volunteers

MD Anderson provided more than **$287.3 million** in uncompensated care to Texans with cancer in FY16.

*This figure includes unreimbursed costs of care for patients who either have no insurance or are underinsured, or whose care was not fully covered by government-sponsored health programs.*
Total philanthropic gift support by type

<table>
<thead>
<tr>
<th>Cash gifts</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporations</td>
<td>$11,248,710</td>
</tr>
<tr>
<td>Foundations</td>
<td>33,921,440</td>
</tr>
<tr>
<td>Individuals</td>
<td>61,162,580</td>
</tr>
<tr>
<td>Organizations</td>
<td>3,716,324</td>
</tr>
<tr>
<td>Trusts and estates</td>
<td>7,838,449</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>$117,887,503</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pledge gifts</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporations</td>
<td>$13,586,781</td>
</tr>
<tr>
<td>Foundations</td>
<td>42,853,552</td>
</tr>
<tr>
<td>Individuals</td>
<td>45,965,177</td>
</tr>
<tr>
<td>Organizations</td>
<td>18,605,370</td>
</tr>
<tr>
<td>Trusts and estates</td>
<td>54,896,801</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>$175,907,681</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gifts-in-kind</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporations</td>
<td>$216,271</td>
</tr>
<tr>
<td>Foundations</td>
<td>1,771</td>
</tr>
<tr>
<td>Individuals</td>
<td>18,396</td>
</tr>
<tr>
<td>Organizations</td>
<td>6</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>$236,444</strong></td>
</tr>
</tbody>
</table>

**TOTAL** | **$294,031,628**

---

Total philanthropic gift support by purpose (in millions)

- **$267.6** | Research² | **91.0%**
- **$11.8**  | Education/prevention/patient assistance | **4.0%**
- **$14.7**  | Annual/unrestricted/undesignated¹ | **5.0%**

¹ These dollars fund institutional peer-reviewed research.
² Donor-targeted gifts to research conducted in all mission areas.
## Sources of research expenditures

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>External funding for research</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Federal grants, contracts</td>
<td>$196,753,104</td>
<td>$182,970,502</td>
<td>$158,986,303</td>
<td>$161,170,908</td>
<td>$155,043,499</td>
</tr>
<tr>
<td>Private industry grants, contracts</td>
<td>$68,413,794</td>
<td>$65,579,036</td>
<td>$75,307,463</td>
<td>$81,076,353</td>
<td>$89,454,454</td>
</tr>
<tr>
<td>Philanthropy, foundations</td>
<td>$100,794,491</td>
<td>$101,642,898</td>
<td>$147,016,586</td>
<td>$172,412,727</td>
<td>$166,374,314</td>
</tr>
<tr>
<td><strong>Total external funding</strong></td>
<td>$365,961,389</td>
<td>$350,192,436</td>
<td>$381,310,352</td>
<td>$414,659,988</td>
<td>$410,872,268</td>
</tr>
<tr>
<td><strong>State funding allocated for research</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>State-appropriated general revenue</td>
<td>$11,618,126</td>
<td>$11,776,785</td>
<td>$13,636,669</td>
<td>$13,658,113</td>
<td>$14,991,640</td>
</tr>
<tr>
<td>Tobacco settlement receipts</td>
<td>$8,854,774</td>
<td>$5,837,249</td>
<td>$11,175,016</td>
<td>$10,227,690</td>
<td>$12,188,092</td>
</tr>
<tr>
<td>CPRIT</td>
<td>19,546,278</td>
<td>24,262,525</td>
<td>25,072,890</td>
<td>32,049,453</td>
<td>40,227,040</td>
</tr>
<tr>
<td><strong>Total state funding</strong></td>
<td>$40,019,178</td>
<td>$41,876,559</td>
<td>$49,884,575</td>
<td>$55,935,256</td>
<td>$67,406,772</td>
</tr>
<tr>
<td><strong>Internal funding allocated for research</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital operating margins</td>
<td>$215,527,886</td>
<td>$182,770,342</td>
<td>$202,607,346</td>
<td>$198,607,568</td>
<td>$193,071,901</td>
</tr>
<tr>
<td>Institutional grants*</td>
<td>$26,032,444</td>
<td>$95,730,271</td>
<td>$102,391,157</td>
<td>$111,374,655</td>
<td>$115,938,206</td>
</tr>
<tr>
<td><strong>Total internal funding</strong></td>
<td>$241,560,330</td>
<td>$278,500,613</td>
<td>$304,998,503</td>
<td>$309,982,223</td>
<td>$309,010,107</td>
</tr>
<tr>
<td><strong>TOTAL RESEARCH EXPENDITURES</strong></td>
<td><strong>$647,540,897</strong></td>
<td><strong>$670,569,608</strong></td>
<td><strong>$736,193,430</strong></td>
<td><strong>$780,577,467</strong></td>
<td><strong>$787,289,147</strong></td>
</tr>
</tbody>
</table>

### Education profile

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical residents, fellows</td>
<td>1,187</td>
<td>1,231</td>
<td>1,276</td>
<td>1,507</td>
<td>1,693</td>
</tr>
<tr>
<td>Research trainees</td>
<td>1,714</td>
<td>1,743</td>
<td>1,853</td>
<td>1,890</td>
<td>1,847</td>
</tr>
<tr>
<td>Observers, visitors, special programs</td>
<td>431</td>
<td>507</td>
<td>452</td>
<td>752</td>
<td>838</td>
</tr>
<tr>
<td>Nursing trainees</td>
<td>2,531</td>
<td>1,306*</td>
<td>1,238</td>
<td>1,352</td>
<td>1,499</td>
</tr>
<tr>
<td>Student programs participants</td>
<td>1,317</td>
<td>1,396</td>
<td>1,204</td>
<td>817</td>
<td>810</td>
</tr>
<tr>
<td>School of Health Professions students</td>
<td>316</td>
<td>291</td>
<td>318</td>
<td>303</td>
<td>317</td>
</tr>
<tr>
<td><strong>TOTAL TRAINEES</strong></td>
<td><strong>7,496</strong></td>
<td><strong>6,474</strong></td>
<td><strong>6,341</strong></td>
<td><strong>6,621</strong></td>
<td><strong>7,004</strong></td>
</tr>
</tbody>
</table>

*Total includes academic credit clinical placement only. Previous data included outreach and CPRIT education programs.
In honor of Charles Aubrey “Mickey” LeMaistre, M.D.

Feb. 10, 1924 – Jan. 28, 2017

Charles LaMaistre, M.D., was the second full-time president of The University of Texas MD Anderson Cancer Center, serving for 18 years, from 1978-1996. Before taking the reins from R. Lee Clark, M.D., LeMaistre spent seven years as chancellor of The University of Texas System.

A pioneering figure in cancer prevention, LeMaistre served on the first U.S. Surgeon General’s Advisory Committee on Smoking and Health, which in 1964 issued its landmark report identifying cigarettes as a major health hazard.

Under his leadership, MD Anderson’s prevention program became an international model of research and service initiatives that advanced the science and application of cancer prevention and population sciences. He also pioneered multidisciplinary care. “Mickey’s passing causes us to pause and remember his tremendous contributions to the growth and scope of MD Anderson,” says John Mendelsohn, M.D., MD Anderson’s third full-time president and director of the Khalifa Institute for Personalized Cancer Therapy. “MD Anderson experienced happy and productive years under Mickey’s leadership, and I was fortunate to have the privilege of building upon his legacy when I succeeded him as president in 1996.”

THE UNIVERSITY OF TEXAS SYSTEM BOARD OF REGENTS

Paul L. Foster, El Paso
   Chairman
R. Steven Hicks, Austin
   Vice chairman
Jeffery D. Hildebrand, Houston
   Vice chairman
Ernest Aliseda, McAllen
David J. Beck, Houston
Kevin Paul Eltife, Tyler
Janiece M. Longoria, Houston
Sara Martinez Tucker, Dallas
James Conrad Weaver, San Antonio
Varun P. Joseph, McKinney
   Student regent
Francie A. Frederick
   General counsel to the Board of Regents

THE UNIVERSITY OF TEXAS SYSTEM ADMINISTRATION

William H. McRaven
   Chancellor
Raymond S. Greenberg, M.D., Ph.D
   Executive vice chancellor for Health Affairs

LOCATIONS

MD Anderson has Houston-area locations in the Texas Medical Center, Bay Area, Katy, Sugar Land, The Woodlands, Bellaire and West Houston (diagnostic imaging), Memorial City (surgery) and The Woman’s Hospital of Texas (gynecologic oncology). MD Anderson physicians also provide cancer care to Harris County’s underserved patients at Lyndon B. Johnson Hospital. In addition, there are two research campuses in Bastrop County, Texas. The institution also has developed a network of national and international locations.

MD ANDERSON CANCER NETWORK®
   www.mdanderson.org/cancernetwork

PARTNER MEMBERS
   • Banner MD Anderson Cancer Center (Gilbert, Arizona)
   • MD Anderson Cancer Center at Cooper (Camden, New Jersey)
   • Summit Medical Group MD Anderson Cancer Center (Berkeley Heights, New Jersey)
   • Baptist MD Anderson Cancer Center (Jacksonville, Florida)
   • Scripps MD Anderson Cancer Center (San Diego, Calif.)

CERTIFIED MEMBERS
   • 15 health systems and hospitals in 12 states

ASSOCIATE MEMBERS
   • Hospital Israelita Albert Einstein (São Paulo)
   • MD Anderson Cancer Center Madrid
   • Vehbi Koç Foundation American Hospital (Istanbul)

AFFILIATE MEMBERS
   • MD Anderson Radiation Treatment Center at American Hospital (Istanbul)
   • Presbyterian MD Anderson Radiation Treatment Center (Albuquerque, New Mexico)

EDITOR
   Andy Olin, program director, Public Relations

DESIGNER
   Michael Clarke

---

Conquest is published by the MD Anderson Cancer Center Board of Visitors on behalf of MD Anderson.

All correspondence should be addressed to the Public Relations Office – Unit 700, MD Anderson Cancer Center, 6900 Fannin St., Houston, Texas 77030-3800, 713-792-3457.

Email: ConquestMagazine@mdanderson.org.

Articles and photos may be reprinted with permission.

For information on supporting programs at MD Anderson, please contact Patrick Mulvey, vice president, Development, 713-792-3450, or visit the myGiving website at www.mdanderson.org/WinterConquest.

For information on patient services at MD Anderson, call askMDAnderson at 877-632-6789, or log on to www.mdanderson.org/ask.

© 2016 The University of Texas MD Anderson Cancer Center

Not printed at state expense. Printed with soy-based ink.